Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases by Fischer, S. & Zechmeister-Koss, I.
 Vasoprotectives 
Efficacy and safety of 
capillary stabilising agents 
for venous insufficiency or 
haemorrhoidal diseases 
 
 
Final Report 
 
LBI-HTAProject Report No./Projektbericht Nr.: 79 
ISSN: 1992-0488 
ISSN-online: 1992-0496 
 Vasoprotectives 
Efficacy and safety of 
capillary stabilising agents 
for venous insufficiency or 
haemorrhoidal diseases 
 
 
Final Report 
 
Vienna, December 2014 
 Project Team/Projektteam 
Project Management/Projektleitung: Dr. rer. soc.oec. Ingrid Zechmeister-Koss 
Authors/AutorInnen: Dipl. Ges-oec. Stefan Fischer 
Dr. rer. soc.oec. Ingrid Zechmeister-Koss 
 
Additional contribution/Projektbeteiligung:  Dr. Anna Glechner (Danube University Krems, performedmeta-analysis) 
Systematic Literature Search/Systematische Literatursuche:  Tarquin Mittermayr, BA 
Hand Search/Handsuche:  Stefan Fischer 
External Review/Externe Begutachtung: Priv.-Doz. Dr. med. univ. Thomas Gary  
(Klinische Abteilung für Angiologie, Meduni Graz) 
 Dipl.-Ing. Erich Kvas (Hermesoft, Graz) 
Internal Review/Interne Begutachtung: Priv.-Doz. Dr. phil. Claudia Wild 
 
 
Correspondence/Korrespondenz: Stefan Fischer: stefan.fischer@hta.lbg.ac.at 
 
 
This report should be referenced as follows/Dieser Bericht soll folgendermaßen zitiert werden: 
Fischer S, Zechmeister-Koss I: Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency 
or haemorrhoidal diseases. LBI-HTA Project Report No.: 79, 2014, Vienna: Ludwig Boltzmann Institute for Health 
Technology Assessment. 
 
Conflict of Interest/Interessenskonflikt  
All authors declare no conflict of interest in sense of the Uniform Requirements of Manuscripts Statement of Medical 
Journal Editors (www.icmje.org)/Alle beteiligten AutorInnen erklären, dass keine Interessenskonflikte im Sinne der 
Uniform Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org) bestehen. 
 
IMPRESSUM 
Media Owner and Publisher/Medieninhaber und Herausgeber: 
Ludwig Boltzmann Gesellschaft GmbH 
Nußdorferstr. 64, 6 Stock, A-1090 Wien 
http://www.lbg.ac.at/de/themen/impressum 
Responsible for Content/Für den Inhalt verantwortlich: 
Ludwig Boltzmann Institut/e for/für Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Wien 
http://hta.lbg.ac.at/ 
Die HTA-Projektberichte erscheinen unregelmäßig und dienen der Veröffentlichung der Forschungsergebnisse 
des Ludwig Boltzmann Instituts für Health Technology Assessment. 
Die HTA-Projektberichte erscheinen in geringer Auflage im Druck und werden über den Dokumentenserver 
„http://eprints.hta.lbg.ac.at„ der Öffentlichkeit zur Verfügung gestellt: 
LBI-HTA Projektbericht Nr.: 79 
ISSN:1992-0488 
ISSN-online:1992-0496 
© 2014 LBI-HTA – All rights reserved/Alle Rechte vorbehalten 
 LBI-HTA | 2014 3 
Content 
 Summary ........................................................................................................................................................ 9 
 Zusammenfassung ...................................................................................................................................... 13 
1 Background .................................................................................................................................................. 21 
1.1 Targeted diseases ........................................................................................................................................ 21 
1.1.1 Diseases of the veins ............................................................................................................................... 21 
1.1.2 Venous insufficiency (chronic) ............................................................................................................. 22 
1.1.3 Haemorrhoids ......................................................................................................................................... 24 
1.2 Vasoprotectives: Capillary stabilising agents ........................................................................................... 26 
1.2.1 Bioflavonoids ........................................................................................................................................... 28 
1.2.2 Other capillary stabilising agents ......................................................................................................... 29 
2 Methods ....................................................................................................................................................... 31 
2.1 Research questions ..................................................................................................................................... 31 
2.2 Inclusion criteria ........................................................................................................................................ 31 
2.3 Exclusion criteria ........................................................................................................................................ 32 
2.4 Literature search ......................................................................................................................................... 33 
2.5 Literature selection .................................................................................................................................... 34 
2.6 Data extraction and analysis ...................................................................................................................... 34 
2.7 Patient-relevant outcomes.......................................................................................................................... 36 
2.7.1 Chronic venous insufficiency ................................................................................................................ 36 
2.7.2 Haemorrhoidal disease .......................................................................................................................... 37 
2.7.3 Clinical relevance of outcome indicators ............................................................................................. 38 
3 Results .......................................................................................................................................................... 41 
3.1 Chronic venous insufficiency .................................................................................................................... 41 
3.1.1 Oxerutin-containing agents ................................................................................................................... 41 
3.1.2 Flavonoid fraction-containing agents .................................................................................................. 63 
3.1.3 20 mg aescin-containing agents ............................................................................................................ 84 
3.1.4 50 mg aescin-containing agents ............................................................................................................ 86 
3.1.5 Calcium dobesilate-containing agents ................................................................................................. 96 
3.1.6 Comparison between capillary stabilising agents............................................................................. 115 
3.2 Treatment of haemorrhoidal diseases ..................................................................................................... 127 
3.2.1 Oxerutin-containing agents ................................................................................................................. 127 
3.2.2 Flavonoid fraction-containing agents ................................................................................................ 132 
3.2.3 20 mg aescin-containing agents .......................................................................................................... 156 
3.2.4 50 mg aescin-containing agents .......................................................................................................... 156 
3.2.5 Calcium dobesilate-containing agents ............................................................................................... 156 
3.2.6 Comparison between capillary stabilising agents............................................................................. 156 
4 Summary and discussion .......................................................................................................................... 163 
4.1 Strength of evidence and clinical relevance of outcomes ...................................................................... 163 
4.2 Summary of evidence ............................................................................................................................... 165 
4.3 Limitations ................................................................................................................................................ 169 
5 Conclusion ................................................................................................................................................. 171 
6 Literature ................................................................................................................................................... 173 
7 Appendix ................................................................................................................................................... 177 
 
 
 
Vasoprotectives 
4 LBI-HTA | 2014 
Figures 
Figure 1.2-1: Development of prescriptions of and costs for capillary stabilising agents in Austria 
Reference: From data sent by the Main Association of Austrian Social Security Institutions ....... 27 
Figure 2.5-1: Summary of the process used to identify and select studies for the review  
(PRISMA Flow Diagram) ................................................................................................................. 34 
Figure 3.1-1: Leg volume change (in ml) after 1 month for oxerutin-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) .............................................. 52 
Figure 3.1-2: Leg volume change (in ml) after 2 months for oxerutin-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) .............................................. 52 
Figure 3.1-3: Leg volume change (in ml) after 3 months for oxerutin-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) .............................................. 53 
Figure 3.1-4: Symptom change (score 0-10) after 1 month for oxerutin-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) .............................................. 54 
Figure 3.1-5: Risk of bias of RCTs for treatment of CVI with oxerutin-containing agents ............................... 55 
Figure 3.1-6: Risk of bias of non-randomised controlled studies for treatment of CVI with 
oxerutin-containing agents ............................................................................................................... 56 
Figure 3.1-7: Ulcer healing rate (dichotomous) after 2 months for flavonoid fraction-containing 
agents + compression stockings vs. compression stockings alone ................................................ 74 
Figure 3.1-8: Adverse events (dichotomous) for flavonoid fraction-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) .............................................. 75 
Figure 3.1-9: Risk of bias of meta-analysis for treatment of CVI with flavonoid fraction-containing agents ..... 77 
Figure 3.1-10: Risk of bias of RCTs for treatment of CVI with flavonoid fraction-containing agents ............... 77 
Figure 3.1-11: Risk of bias of (un)controlled studies fortreatment of CVI with flavonoid  
fraction-containing agents ................................................................................................................ 78 
Figure 3.1-12: Risk of bias of non-randomised controlled studies for 20 mg aescin-containing 
agents for treatment of CVI .............................................................................................................. 85 
Figure 3.1-13: Leg volume change (in ml) after 0.5-4 months for 50 mg aescin-containing  
agents versus placebo ........................................................................................................................ 89 
Figure 3.1-14: Ankle circumference (in mm) change after 0.5-1 month for 50 mg aescin-containing 
agents versus placebo ........................................................................................................................ 90 
Figure 3.1-15: Calf circumference (in mm) change after 0.5-1 month for 50 mg aescin-containing 
agents versus placebo ........................................................................................................................ 90 
Figure 3.1-16: Risk of bias of systematic review for treatment of CVI with 50 mg aescin-containing agents ....... 91 
Figure 3.1-17: Pain (dichotomous) for calcium dobesilate-containing agents (+ compression 
stockings) vs. placebo (+ compression stockings) ........................................................................ 104 
Figure 3.1-18: Heaviness (dichotomous) for calcium dobesilate-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) ............................................ 105 
Figure 3.1-19: Paraesthesias (dichotomous) for calcium dobesilate-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) ............................................ 106 
Figure 3.1-20: General adverse events (dichotomous) for calcium dobesilate-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) ............................................ 107 
Figure 3.1-21: Treatment-related adverse events (dichotomous) for calcium dobesilate-containing 
agents (+ compression stockings) vs. placebo (+ compression stockings) ................................ 108 
Figure 3.1-22: Risk of bias of systematic review for treatment of CVI with calcium  
dobesilate-containing agents .......................................................................................................... 109 
Figure 3.1-23: Risk of bias of RCTs for treatment of CVI with calcium dobesilate-containing agents ............ 109 
Figure 3.1-24: Risk of bias of (un)controlled studies for treatment of CVI with calcium  
dobesilate-containing agents .......................................................................................................... 110 
Content 
LBI-HTA | 2014 5 
Figure 3.1-25: Risk of bias of systematic review for treatment of CVI comparing capillary 
stabilising agents ............................................................................................................................. 122 
Figure 3.1-26: Risk of bias of RCTs for treatment of CVI comparing capillary stabilising agents ................... 122 
Figure 3.1-27: Risk of bias of non-RCT fortreatment of CVI comparing capillary stabilising agents ............. 123 
Figure 3.2-1: Risk of bias of RCTs for treatment of HD with oxerutin-containing agents ............................. 130 
Figure 3.2-2: General adverse events (dichotomous) for flavonoid fraction-containing agents vs. placebo ...... 145 
Figure 3.2-3: Risk of bias of RCTs for treatment of HD with flavonoid fraction-containing agents .............. 147 
Figure 3.2-4: Risk of bias of (un)controlled trials for treatment of HD with flavonoid  
fraction-containing agents .............................................................................................................. 147 
Figure 3.2-5: Risk of bias of RCTs for treatment of HD comparing capillary stabilising agents ................... 159 
 
 
Tables 
Table 1.1-1: Classification of venous insufficiency according to Widmer ......................................................... 23 
Table 1.1-2: CEAP classification of venous diseases/insufficiency .................................................................... 23 
Table 1.1-3: Treatment options for venous diseases ............................................................................................ 24 
Table 1.1-4: Classification of haemorrhoidal diseases according to Banov et al. .............................................. 25 
Table 1.1-5: Classification of haemorrhoidal diseases according to Goligher et al........................................... 25 
Table 1.2-1: Content and prices of bioflavonoids ................................................................................................ 28 
Table 1.2-2: Content and prices of other capillary stabilising agents ................................................................ 29 
Table 2.2-1: Inclusion criteria ............................................................................................................................... 31 
Table 3.1-1: Efficacy and safety-related outcomes of randomised controlled trials of  
oxerutin-containing agents vs. placebo and/or compression stockings for CVI .......................... 42 
Table 3.1-2: Safety-related outcomes of non-randomised trials of oxerutin-containing agents for CVI ......... 50 
Table 3.1-3: Evidence profile: Efficacy and safety of oxerutin-containing agents for treatment  
of CVI compared to placebo ............................................................................................................. 57 
Table 3.1-4: Evidence profile: Efficacy and safety of oxerutin-containing agents for treatment  
of CVI compared to compression stockings .................................................................................... 61 
Table 3.1-5: Evidence profile: Safety of oxerutin-containing agents for treatment of CVI 
compared to no treatment ................................................................................................................. 62 
Table 3.1-6: Efficacy and safety-related outcomes of a meta-analysis and randomised controlled trials of 
flavonoid fraction-containing agents vs. placebo or compression stockingsor surgery for CVI ..... 64 
Table 3.1-7: Safety-related outcomes of non-randomised trials of flavonoid fraction-containing 
agents for CVI .................................................................................................................................... 70 
Table 3.1-8: Evidence profile: Efficacy and safety of flavonoid fraction-containing agents  
for treatment of CVI compared to placebo ...................................................................................... 79 
Table 3.1-9: Evidence profile: Efficacy and safety of flavonoid fraction-containing agents  
+ compression stockings for treatment of CVI compared to compression stockings 
alone ................................................................................................................................................... 80 
Table 3.1-10: Evidence profile: Efficacy and safety of flavonoid fraction-containing agents  
+ surgery for treatment of CVI compared to surgery alone .......................................................... 82 
Table 3.1-11: Evidence profile: Safety of flavonoid fraction-containing agents for treatment of CVI 
(results from single-arm studies) ..................................................................................................... 83 
Table 3.1-12: Safety-related outcomes of non-randomised controlled trials of 20 mg aescin-containing 
agents vs. placebo for CVI ................................................................................................................ 84 
Vasoprotectives 
6 LBI-HTA | 2014 
Table 3.1-13: Evidence profile: Efficacy of 20 mg aescin-containing agents for treatment of CVI 
compared to placebo ......................................................................................................................... 86 
Table 3.1-14: Evidence profile: Safety of 20 mg aescin-containing agents for treatment of CVI 
compared to placebo ......................................................................................................................... 86 
Table 3.1-15: Efficacy and safety-related outcomes of a systematic review of 50 mg aescin-containing 
agents vs. placebo or compression stockings for CVI ..................................................................... 87 
Table 3.1-16: Evidence profile: Efficacy of 50 mg aescin-containing agents (+ compression stockings) 
for treatment of CVI compared to placebo or compression stockings alone ................................ 93 
Table 3.1-17: Evidence profile: Safety of 50 mg aescin-containing agents for treatment of CVI....................... 95 
Table 3.1-18: Efficacy and safety-related outcomes of a systematic review and randomised 
controlled trials of calcium dobesilate-containing agents vs. placebo for CVI ............................ 97 
Table 3.1-19: Safety-related outcomes of non-randomised trials for calcium dobesilate-containing 
agents for CVI .................................................................................................................................. 102 
Table 3.1-20: Evidence profile: Efficacy of calcium dobesilate-containing agents (+ compression 
stockings) for treatment of CVI compared to placebo (+ compression stockings) .................... 111 
Table 3.1-21: Evidence profile: Safety of calcium dobesilate-containing agents (+ compression 
stockings) for treatment of CVI (compared to placebo) ............................................................... 114 
Table 3.1-22: Efficacy and safety-related outcomes of a systematic review and randomised controlled 
trials of capillary stabilising agents versus other capillary stabilising agents for CVI .............. 116 
Table 3.1-23: Safety-related outcomes of controlled trials for capillary stabilising agents versus 
other capillary stabilising agents ................................................................................................... 119 
Table 3.1-24: Evidence profile: Efficacy of capillary stabilising agents versus other capillary 
stabilising agents for treatment of CVI ......................................................................................... 124 
Table 3.1-25: Evidence profile: Safety of capillary stabilising agents versus other capillary 
stabilising agents for treatment of CVI ......................................................................................... 126 
Table 3.2-1: Efficacy and safety-related outcomes of a randomised controlled trial of  
oxerutin-containing agents vs. placebo for HD ............................................................................ 127 
Table 3.2-2: Evidence profile: Efficacy and safety of oxerutin-containing agents for treatment of 
HD compared to placebo ................................................................................................................ 131 
Table 3.2-3: Efficacy and safety-related outcomes of randomised controlled trials of flavonoid fraction-
containing agents vs. placebo, no treatment, infrared photocoagulation, sclerotherapy, fibre 
supplements, rubber band ligation or anti-inflammatory medication for HD .......................... 133 
Table 3.2-4: Safety-related outcomes of non-randomised trials for flavonoid fraction-containing 
agents vs. placebo for treatment of HD ......................................................................................... 141 
Table 3.2-5: Evidence profile: Efficacy of flavonoid fraction-containing agents for treatment of HD ......... 149 
Table 3.2-6: Evidence profile: Safety of flavonoid fraction-containing agents for treatment of HD ............. 154 
Table 3.2-7: Efficacy and safety-related outcomes of a randomised controlled trial of capillary 
stabilising agents versus other capillary stabilising agents for HD ............................................ 157 
Table 3.2-8: Evidence profile: Efficacy and safety of capillary stabilising agents versus other 
capillary stabilising agents for treatment of HD .......................................................................... 161 
Table 4.2-1: Summary of the efficacy of capillary stabilising agents for treatment of CVI ........................... 167 
Table 4.2-2: Summary of the efficacy of capillary stabilising agents for treatment of HD ............................ 168 
 
 
 
Content 
LBI-HTA | 2014 7 
Abbreviations 
acc. .......................according 
ATC-Code ...........Anatomical Therapeutic Chemical/Defined Daily Dose Classification 
CEAP ..................classification for CVI based on clinical signs of venous disease (C), etiology (E), 
anatomy (A), and the underlying pathophysiology (P) 
CI .........................confidence intervall 
CVI ......................chronic venous insufficiency 
EKO.....................Code of Reimbursement (for pharmaceuticals, in German: Erstattungskodex) 
GRADE ...............Grading of Recommendations, Assessment, Development and Evaluation 
HCSE ..................horse chestnut seed extract 
HD .......................haemorrhoidal disease 
HVB .....................Hauptverband der Sozialversicherung  
(Main Association of Austrian Social Security Institutions) 
LBI-HTA ............Ludwig Boltzmann Institute for Health Technology Assessment 
MPFF ..................micronised purified flavonoid fraction 
n/a .......................data not available 
non-RCT .............non-randomised controlled trial 
N.S. ......................not statistically significant 
OTC .....................over-the-counter 
OR .......................odds ratio 
RCT .....................randomised controlled trial 
RR .......................relative risk 
S.S. .......................statistically significant 
vs. .........................versus 
 
 LBI-HTA | 2014 9 
Summary 
Background 
Chronic venous insufficiency (CVI) and haemorrhoidal diseases (HD) are very 
common, affecting about 20 to 40% of the Austrian population. Even if CVI 
and HD are not directly associated with mortality, both diseases severely af-
fect the quality of life. 
One frequently chosen approach to reduce symptoms is oral treatment with 
capillary stabilising agents. However, while roughly € 20 million are spent an-
nually on these drugs, their benefit has never been thoroughly evaluated so 
far. 
The aim of this systematic review was to assess the efficacy and safety of a 
treatment of CVI and HD with capillary stabilising agents that are listed in 
the Austrian Code of Reimbursement (EKO). 
 
Methods 
A total of 681 records were identified through a database search, a hand search 
and via additional industry requests. Studies were selected according to pre-
defined criteria. In the end, 56 studies met our inclusion criteria. 
The risk of bias and strength of evidence were assessed according to the Grad-
ing of Recommendations, Assessment, Development and Evaluation (GRADE) 
approach. 
Literature selection, data extraction and evidence assessment were done by 
two review authors (IZ, SF), independently from each other, whereby differ-
ences were discussed in order to achieve consensus. A third person was in-
volved in cases of uncertainty. 
 
Results 
Oxerutin-containing agents (Venoruton®) 
The studies on oxerutin-containing agents (Venoruton
®) have shown that com-
pression stockings reduced leg volume (obsolete surrogate parameter for oe-
dema) more than oxerutin-containing agents. Furthermore, if patients took 
oxerutin-containing agents in addition to wearing compression stockings, some 
experienced a slight improvement of some CVI signs (oedema) and symp-
toms (heaviness) compared to compression stockings in combination with pla-
cebo. However, improvement in symptoms is marginal and below clinical rel-
evance. In addition, oxerutin-containing agents reduced the severity of signs 
and symptoms of HD, yet whether this improvement is statistically significant 
is unknown. 
The studies have either an unclear or high risk of bias and the overall strength 
of evidence is low. 
 
venöse Insuffizienz und 
Hämorrhoiden häufige 
Krankheiten 
häufige Verschreibung 
kapillarstabilisierender 
Mittel  
Ziel: Wirksamkeit und 
Sicherheit kapillarstabil-
isierender Mittel 
nach Literatursuche 56 
Studien eingeschlossen 
Studienbewertung  
nach GRADE 
Auswahl und  
Extraktion Literatur 
Oxerutin + 
Kompressionsstrümpfe 
reduzierten Anzeichen 
und Symptome marginal 
Evidenzstärke gering 
Vasoprotectives 
10 LBI-HTA | 2014 
Flavonoid fraction-containing agents (Daflon® 500 mg tablets) 
Flavonoid fraction-containing agents (Daflon
®
) in addition to wearing com-
pression stockings slightly improved ulcer healing compared to wearing com-
pression stockings only and ulcer healing plus oedema compared to compres-
sion stockings combined with placebo. Yet, up to 50% of patients did not show 
improvements. Other signs and symptoms were either not measured or the 
benefit was below clinical relevance. Whether patients benefit from taking 
flavonoid fraction-containing agents after surgery compared to no treatment 
after surgery is unknown, due to incomplete data on outcome and statistical 
significance.  
Treating HD with flavonoid fraction-containing agents does not seem more 
effective than with anti-inflammatory medication, however data on between-
group differences are incomplete. Compared to office-based treatment (e.g., 
infrared photocoagulation or sclerotherapy), fewer patients who took flavo-
noid fraction-containing agents had bleedings during medication. Yet, after 
stopping medication, office-based treatments were eventually slightly more 
effective in terms of symptoms and recurrence rate. Compared to placebo, a 
treatment of HD with flavonoid fraction-containing agents slightly improved 
the signs and symptoms. However many data are incomplete and improve-
ment of symptoms (quality of life, pain etc.) is not clinically relevant. After 
surgery, flavonoid fraction-containing agents reduced the severity of pain and 
the recurrence rate slightly more than no treatment, yet pain reduction was 
not clinically relevant. We are unable to draw a conclusion on whether fla-
vonoid fraction-containing agents have an additional benefit when combined 
with fibre supplements, compared to no treatment (and fibre supplements). 
The studies have either an unclear or high risk of bias and the overall strength 
of evidence is moderate to low. 
 
20 mg aescin-containing agents (Reparil® 20 mg dragées) 
We could not identify any randomised controlled trials to assess the efficacy 
of agents containing 20 mg of aescin (Reparil
®
 20 mg dragées) for the treatment 
of CVI and HD. 
 
50 mg aescin-containing agents (Venosin retard® 50 mg capsules) 
A treatment with agents containing 50 mg of aescin (Venosin
®
 retard 50 mg cap-
sules), in addition to compression stockings, improved some signs (oedema) 
and symptoms (pain) of CVI, compared to compression stockings with pla-
cebo. However, we are unable to draw a conclusion regarding a treatment of 
HD with 50 mg aescin. 
The strength of evidence is low. 
 
Calcium dobesilate (Doxium® 500 mg capsules) 
When added to compression stockings, calcium dobesilate slightly improved 
some symptoms of CVI (pain, cramps, restless legs), compared to placebo (and 
compression therapy). For other symptoms (itching, swelling), this was not 
the case. We are unable to draw a conclusion on the efficacy of Doxium
®
 for 
HD, since the drug is not explicitly indicated for HD. 
The risk of bias in the studies is low and the strength of evidence is moder-
ate. 
Flavonoidfraktion hilft 
eventuell etwas um 
Anzeichen der CVI zu 
verbessern 
Behandlung 
Hämorrhoiden mit 
Flavonoidfraktion sowie 
Entzündunghemmer 
ähnlich (in)effektiv 
Evidenzstärke 
überwiegend gering 
Wirksamkeit von  
20 mg Aescin unbekannt 
50 mg Aescin + 
Kompressionsstrümpfe 
eventuell wirksam  
bei CVI 
Evidenzstärke gering 
Calciumdobesilat + 
Kompressionsstrümpfe 
eventuell wirksam  
bei CVI 
moderate Evidenzstärke 
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Comparison between capillary stabilising agents 
Oxerutin-containing agents for the treatment of CVI have shown similar re-
sults for oedema, pain, itching, heavy legs and swelling as 50 mg aescin con-
taining agents and slightly better (with unknown significance) improvements 
of general CVI symptoms than flavonoid fraction-containing agents. Moreo-
ver, there was no superiority of either calcium dobesilate- or flavonoid frac-
tion-containing agents in terms of reducing HD symptoms and the recurrence 
rate. We do not know whether one agent is generally superior to others. 
Furthermore, the strength of evidence is low. 
 
Comparison with further alternatives 
We could not identify any evidence where a CVI treatment with capillary sta-
bilising agents was compared with lifestyle changes, medical or surgical treat-
ment. In addition, there was no evidence available to assess capillary stabilis-
ing agents for a treatment of HD compared to lifestyle changes and surgical 
treatment options. 
 
Safety 
A treatment of CVI and HD with capillary stabilising agents does not seem 
to be associated with a high rate of serious adverse events or side effects.  
 
Discussion and conlusion 
Since the strength of the evidence of nearly all identified studies is low, we 
cannot draw a final conclusion on the efficacy of capillary stabilising agents 
for the treatment of CVI and HD. 
Major limitations of the studies are, firstly, the lack of transparency concern-
ing the study design (e.g., unclear allocation concealment) and, secondly, 
study designs that introduce a high risk of bias. Examples for the latter are 
the small number of patients with short durations of treatment or flexibly al-
lowing people to have additional interventions (e.g., wearing compression 
stockings for CVI treatment), which raises the question of whether any effect 
measured was due to the drug treatment or to the additional intervention. 
Moreover, some of the used outcome indicators (leg volume, symptoms meas-
ured on scales from 1-3) are obsolete according to today’s standards and, there-
fore, are a very weak outcome to draw a conclusion for efficacy as a whole. 
From the numerous patient-relevant signs and symptoms of CVI and HD pre-
sented in the studies, some single parameters showed better improvement in 
the groups that received capillary stabilising agents than in the control groups. 
In addition, some of the differences between the groups were statistically sig-
nificant. However, the clinical relevance of any improvement presented was 
marginal and, in most cases, even negligible. 
For Doxium
®
 500 mg capsules (for CVI only), Venoruton
®
 (for CVI only), Daflon
®
 
500 mg tablets (for CVI and HD) and Venosin retard
®
 50 mg capsules (for CVI 
only) the evidence shows a weak tendency for a benefit, yet the results are 
very uncertain. 
For Reparil
®
 20 mg dragées we could not identify any efficacy-assessing evi-
dence and, therefore, it is unclear whether the drug is more effective than 
other alternatives.  
nicht klar, welches 
Medikament am besten 
wirkt 
geringe Evidenzstärke 
kaum Studien im 
Vergleich mit anderen 
Behandlungsoptionen 
schwere 
Nebenwirkungen nicht 
zu erwarten 
insgesamt schwache 
Evidenz 
viele 
Studienlimitationen 
einige Endpunkte 
veraltet 
zwar Verbesserungen in 
Behandlungsgruppen, 
aber nicht klinisch 
relevant 
Doxium, Venoruton, 
Daflon + Venosin retard 
wirken eventuell 
kaum Evidenz zu Reparil 
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Future reimbursement of the drugs should be made conditional upon the gen-
eration of robust evidence concerning patients’ benefits. This needs to be pro-
vided by the manufacturers. Cooperation with public payers in terms of study 
design (particularly concerning the selection of outcome parameters) is rec-
ommended. 
 
stärkere Evidenz 
unabdingbar, um 
solidarische 
Finanzierung 
kapillarstabilisierender 
Mittel zu rechtfertigen 
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Zusammenfassung 
Hintergrund 
Vasoprotektoren sind Medikamente, die auf die Blutgefäße wirken. Zu ihnen 
zählen auch sogenannte kapillarstabilisierende Mittel, die hauptsächlich bei 
der Behandlung chronisch venöser Insuffizienz (CVI) sowie Hämorrhoiden 
eingesetzt werden. 
Kapillarstabilisierende Mittel werden in Österreich oft verschrieben, wobei der 
Nutzen weitgehend unklar ist. Daher soll der vorliegende Bericht die Wirk-
samkeit und Sicherheit kapillarstabilisierender Mittel, die im Erstattungs-
kodex (EKO) gelistet sind und von der Sozialversicherung erstattet werden, 
bei der Behandlung von CVI und Hämorrhoiden untersuchen. 
Die CVI kann vorrangig durch einen inadäquaten Venenabfluss entstehen, 
meist hervorgerufen durch einen geringen Blutfluss oder schwache Venen-
klappen, vorrangig in den Beinen. Es gibt kaum Daten zur Prävalenz der 
CVI in Österreich, es wird aber davon ausgegangen, dass jeder 5.-6. Mensch 
die Krankheit aufweist. Die Diagnose der CVI erfolgt über deren Symptome, 
wie Schmerzen, schwere Beine oder Juckreiz bis hin zu typischen Anzeichen 
wie Hautveränderungen, Ödeme und Geschwüre, mittels einer klinischen Un-
tersuchung und/oder Ultraschall. Die Behandlung der CVI sollte konserva-
tiv starten, gefolgt oder unterstützt von Medikamenten. Operative Maßnah-
men gelten als letzte Option. 
Hämorrhoiden sind vaskuläre Strukturen im Afterbereich, die im Sinne des 
Hämorrhoidalleidens vergrößert sind. Die genaue Ursache der Erkrankung 
ist nicht geklärt, möglicherweise ist ein erhöhter Druck im Rektum ausschlag-
gebend. Auch gibt es kaum Daten zur Prävalenz in Österreich. Schätzungen 
gehen von ca. 40 % Betroffenen aus. Die Symptome von Hämorrhoiden sind 
abhängig von der Lokalisation, meist gehen Hämorrhoiden mit Juckreiz und 
Schmerzen einher. Typische Anzeichen reichen von Prolaps, der auch Nässen 
kann, bis hin zu fäkaler Inkontinenz. Die Diagnose sollte über eine präzise 
Anamnese erfolgen. Die Behandlung von Hämorrhoiden setzt an der Symp-
tomverbesserung und Verhinderung der Verschlechterung des Krankheits-
grads an. In frühen Stadien sind Lebensstiländerungen (z. B. Diät) indiziert, 
gefolgt oder unterstützt von Medikamenten und lokalen ambulanten Maß-
nahmen (z. B. Sklerotherapie). In späteren Stadien wird oftmals ein operati-
ver Eingriff notwendig. 
Kapillarstabilisierende Mittel sind unterteilbar in Bioflavonoide und andere 
kapillarstabilisierende Mittel. Im Jahr 2013 gab die Sozialversicherung ca. 
19,4 Millionen Euro für folgende, im EKO gelistete, kapillarstabilisierende 
Mittel aus: 
 Venoruton® 300 mg Dragées 
 Venoruton® 500 mg Tabletten 
 Venoruton® 1000 mg Granulat 
 Daflon® 500 mg Tabletten 
 Reparil® 20 mg Dragées 
 Venosin retard® 50 mg Kapseln 
 Doxium® 500 mg Kapseln 
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Fragestellung und Methoden 
Die Forschungsfragen des Berichts wurden wie folgt definiert: 
 Sind die derzeit im Erstattungskodex gelisteten, kapillarstabilisieren-
den Mittel zur Behandlung von PatientInnen mit venöser Insuffizienz 
oder Hämorrhoiden wirksamer und sicherer bezüglich der definierten 
Outcomeparameter im Vergleich zu Alternativen (z. B. keine aktive 
Therapie, Placebo, etc.) 
 Bestehen innerhalb der kapillarstabilisierenden Mittel Unterschiede 
in der Wirksamkeit bzw. Sicherheit? 
Zur Identifikation relevanter Literatur wurden eine systematische Literatur-
suche in vier Datenbanken (Chochrane, Centre for Research and Dissemina-
tion, Embase und Medline) und eine zusätzliche Handsuche durchgeführt. 
Außerdem wurden auch alle österreichischen Vertriebspartner der Medika-
mente, bzw. die Hersteller, bezüglich weiterer Studien kontaktiert. 
Von insgesamt 681 Treffern wurden letztlich 56 Studien, die den Einschluss-
kriterien entsprachen, für eine Datenextraktion ausgewählt. Darunter waren 
zwei systematische Übersichtsarbeiten, eine Meta-Analyse, 40 randomisierte 
kontrollierte Studien (RCTs), sechs nicht randomisierte kontrollierte Studien 
und sieben einarmige Studien. Im Falle des Einschlusses von systematischen 
Übersichtsarbeiten, wurden nur Einzelstudien mit jüngerem Veröffentlichungs-
datum zitiert. 
Das Bias-Risiko sowie die Bewertung der Evidenzstärke wurden nach dem Gra-
ding of Recommendations, Assessment, Development and Evaluation (GRADE) 
Schema vorgenommen.  
Die Datenextraktion, die Bewertung des Bias Risikos und der Evidenzstärke 
wurde vom Erstautor vorgenommen und von der Zweitautorin kontrolliert. 
Als patientInnen-relevante Endpunkte zur Bewertung der Wirksamkeit und 
Sicherheit kapillarstabilisierender Mittel bei der Behandlung der CVI wurden 
Veränderung der Anzeichen der CVI (z. B. Hautveränderungen, Ödeme und 
Geschwüre) und der Symptome der CVI (z. B. Schmerzen, Krämpfe, ruhelose, 
schwere Beine, Juckreiz, Schwellungen, Parästhesie), die Lebensqualität so-
wie unerwünschte Ereignisse herangezogen. Bei der Behandlung von Hämor-
rhoiden waren die Endpunkte Veränderungen der Anzeichen (z. B. Prolaps, 
Nässen und Inkontinenz) und Symptome (Schmerzen, Blutungen und Juck-
reiz) sowie Lebensqualität, Rückfallrate und unerwünschte Ereignisse. 
Die Anzeichen und Symptome wurden oftmals mit Scores auf Skalen von 0-3 
oder 0-100 gemessen und Ödeme als Volumen oder Umfang angegeben. Die 
klinische Relevanz der Indikatoren wurde von ExpertInnen eingeschätzt. So 
wurde die Angabe von Beinvolumen als wenig relevant, Skalen von 0-3 oder 
0-100 als veraltet, eine Umfangreduktion erst von 10 mm und mehr, eine Score-
Veränderung von 5 und mehr sowie ein Gruppenunterschied bei Blutungen 
von 3 Tagen und mehr als klinisch relevant eingestuft. 
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Ergebnisse 
Oxerutin enthaltende Mittel (Venoruton®) 
Chronisch venöse Insuffizienz 
Für die Bewertung der Wirksamkeit und Sicherheit von Oxerutin enthalten-
den Mitteln zur Behandlung der CVI konnten 10 RCTs und 2 non-RCTs mit 
insgesamt 1.084 PatientInnen identifiziert werden.  
Die Vergleichsgruppen, insofern es welche gab, erhielten entweder Placebo, 
Kompressionsstrümpfe oder keine Behandlung (non-RCT).  
Die Scores für Ödeme wurden sowohl in den Oxerutin- als auch in den Pla-
cebo-Gruppen reduziert. Gemessen als Beinvolumen (ein veralteter Surrogat-
parameter), und als Knöchelumfang konnten Ödeme statistisch signifikant 
mehr in den Oxerutin-Gruppen reduziert werden, als mit Placebo. Beinge-
schwüre traten jedoch sowohl bei mit Oxerutin als auch mit Placebo behan-
delten PatientInnen erneut auf. Generelle und einzelne CVI-Symptome (z. B. 
Schmerzen, Krämpfe etc.) wurden in den Oxerutin Gruppen meist stärker re-
duziert als in den Placebo-Gruppen, der Unterschied ist jedoch marginal und 
ohne klinische Relevanz. Es gilt zu beachten, dass in einigen Studien die Pa-
tientInnen zusätzliche Kompressionsstrümpfe getragen haben. 
Für den Vergleich von Oxerutin mit Kompressionsstrümpfen wurde lediglich 
das Beinvolumen (Surrogatparameter für Ödeme) erhoben, das jedoch mit 
Kompressionsstrümpfen stärker reduziert wurde. 
Insgesamt gab es keine unerwünschten Ereignisse mit Oxerutin. 
Die Studien zeigten ein unklares oder hohes Verzerrungspotenzial und die 
Stärke der Evidenz wurde insgesamt als niedrig bis sehr niedrig eingestuft. 
Hämorrhoidalleiden 
Für die Bewertung der Wirksamkeit und Sicherheit von Oxerutin enthalten-
den Mitteln zur Behandlung von Hämorrhoiden konnte 1 RCT mit insgesamt 
97 PatientInnen identifiziert werden. Die Vergleichsgruppe erhielt Placebo. 
Die generellen Anzeichen und Symptome von Hämorrhoiden konnten in der 
Oxerutin-Gruppe tendenziell eher verbesserst werden, als in der Placebo-
Gruppe allerdings wurden keine Angaben zur statistischen Signifikanz des 
Unterschieds gemacht. 
Durch die Behandlung mit Oxerutin bedingte Nebenwirkungen wurden in 
ca. 6 % der PatientInnen festgestellt. 
Die Studie hat ein unklares Verzerrungspotenzial und die Stärke der Evidenz 
ist niedrig 
 
Flavonoidfraktion enthaltende Mittel (Daflon® 500 mg Tabletten) 
Chronisch venöse Insuffizienz 
Für die Bewertung der Wirksamkeit und Sicherheit von Flavonoidfraktion 
enthaltenden Mitteln zur Behandlung der CVI konnten 1 Meta-Analyse, 8 
RCTs, 1 non-RCT und 5 einarmige Studien mit insgesamt 13.613 PatientIn-
nen identifiziert werden.  
Die Vergleichsgruppen, insofern es welche gab, erhielten entweder Placebo 
oder keine medikamentöse Behandlung (dies war in 2 Studien der Fall, wo 
alle PatientInnen einer OP unterzogen wurden). 
10 RCTs und  
2 non-RCTs identifiziert 
Vergleichsgruppen 
Oxerutin tendenziell 
etwas besser als Placebo 
Kompressionsstrümpfe 
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besser als Placebo, aber 
unklar ob Unterschied 
signifikant 
6 % Nebenwirkungen 
geringe Evidenzstärke 
15 Studien identifiziert 
Vergleich: Placebo oder 
keine Behandlung 
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Hautveränderungen konnten bei mehr PatientInnen der Flavonoidfraktion-
Gruppen, als bei PatientInnen die Placebo erhielten, verbessert werden. Zu 
Ödemen, gemessen in ml, gab es widersprüchliche Ergebnisse in den Studien, 
jedoch stieg das Volumen in den Flavonoidfraktion-Gruppen, während der 
Knöchelumfang bei den Behandelten minimal (klinisch nicht relevant) sank 
und geringfügig bessere Ulcus-Heilungsraten beschrieben wurden. Zu keinem 
dieser Ergebnisse wurde angegeben, ob die Gruppenunterschiede signifikant 
sind. Generelle Symptome sowie Krämpfe im Speziellen konnten mit Flavo-
noidfraktion enthaltenden Mitteln in signifikant mehr PatientInnen verbes-
sert werden als mit Placebo – in bis zu 50 % der PatientInnen traten jedoch 
gar keine Verbesserung. Es gilt zu beachten, dass in einigen Studien die Pa-
tientInnen zusätzliche Kompressionsstrümpfe tragen konnten. 
Geschwüre wurden bei PatientInnen, die Flavonoidfraktion enthaltende Mittel 
mit zusätzlichen Kompressionsstrümpfen erhielten, statistisch signifikant häufi-
ger geheilt sowie reduziert als bei PatientInnen, die nur Kompressionsstrümpfe 
bekamen. Bei 30 bis 50 % der PatientInnen heilten sie trotz Behandlung nicht. 
Ebenso konnte das Symptom „schwere Beine“ in der Behandlungsgruppe et-
was verbessert werden, der Unterschied ist jedoch minimal und klinisch nicht 
relevant. 
Ödeme, Juckreiz, schwere Beine und die Lebensqualität konnten mit Flavo-
noidfraktion enthaltenen Mitteln und zusätzlicher Operation eher verbessert 
werden als nur mit einer Operation. Es fehlten jedoch fast überall vollständi-
ge Angaben zu den Ergebnissen, sowie Angaben zur statistischen Signifikanz 
der Unterschiede. 
Nebenwirkungen mit Flavonoidfraktion enthaltenden Mitteln traten in 0-8 % 
der PatientInnen auf.  
Die Studien weisen entweder ein unklares (fehlende Angaben) oder hohes 
Verzerrungspotenzial auf und die Stärke der Evidenz ist niedrig. 
Hämorrhoidalleiden 
Für die Bewertung der Wirksamkeit und Sicherheit von Flavonoidfraktion 
enthaltenden Mitteln zur Behandlung von Hämorrhoiden konnten 13 RCTs 
und 1 einarmige Studie mit insgesamt 2.031 PatientInnen identifiziert wer-
den. Die Vergleichsgruppen erhielten Placebo, keine Behandlung, ambulante 
Maßnahmen oder Entzündungshemmer. 
Sowohl generelle Anzeichen von Hämorrhoiden sowie Prolaps und „Nässen“ 
im Speziellen als auch generelle Symptome sowie Schmerzen und Juckreiz im 
Speziellen konnten mit Flavonoidfraktion enthaltenden Mitteln eher verbes-
sert werden, als mit Placebo. Jedoch ist die endgültige Beurteilung wegen oft 
fehlender Angaben zu den verwendeten Skalen eingeschränkt und die Ver-
änderungen bei manchen Indikatoren (Lebensqualität, generelle Anzeichen 
von Hämorrhoiden, Schmerzen) klinisch nicht relevant. Blutungen konnten 
meist mehr mit Flavonoidfraktion enthaltenden Mitteln reduziert werden als 
mit Placebo, jedoch waren die Änderungen nicht klinisch relevant. Die Rück-
fallrate war mit Placebo geringer. 
Nach einem operativen Eingriff konnten Schmerzen mit Flavonoidfraktion ent-
haltenden Mitteln geringfügig mehr (aber klinisch nicht relevant) reduziert 
werden, als ohne Behandlung. Die Rückfallrate war bei PatientInnen in der 
Behandlungsgruppe um 5 %-Punkte geringer, hingegen war die Anzahl der 
Tage, an denen Blutungen nach der OP auftraten, in beiden Studiengruppen 
ähnlich. 
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Schmerzen, Blutungen und auch Juckreiz konnten mit einer Behandlung 
durch Entzündunghemmer tendenziell mehr reduziert werden als bei einer Ga-
be von Flavonoidfraktion enthaltenden Mitteln, die Unterschiede sind jedoch 
nicht signifikant bzw. die Angaben zur statistischen Signifikanz fehlen. 
Im Vergleich mit ambulanten Maßnahmen, wie z. B. die Sklerotherapie, war 
eine Behandlung mit Flavonoidfraktion enthaltenden Mitteln bei der Verbes-
serung genereller Symptome und Rückfallraten gleichauf, allerdings wurden 
kaum Angaben zur Signifikanz der Gruppenunterschiede gemacht. Bei der 
Reduktion von Blutungen und der Verbesserung der Lebensqualität konnten 
langfristig bessere Ergebnisse mit ambulanten Maßnahmen erzielt werden. 
Es ist zu beachten, dass PatientInnen teilweise zusätzlich eine ballaststoff-
reiche Ernährung bekamen. 
Wenn alle PatientInnen zusätzlich eine ballaststoffreiche Ernährung beka-
men, gab es bei Blutungen und bei der Rückfallrate kaum einen Unterschied 
zwischen einer Behandlung der Hämorrhoiden mit Flavonoidfraktion enthal-
tenden Mitteln oder keiner Behandlung. 
Nebenwirkungen mit Flavonoidfraktion enthaltenden Mitteln traten in 0-8 % 
der PatientInnen auf.  
Die Studien weisen ein teils unklares, teils hohes Verzerrungspotenzial auf, 
die Stärke der Evidenz ist moderat bis niedrig 
 
20 mg Aescin enthaltende Mittel (Reparil® 20 mg Dragées) 
Chronisch venöse Insuffizienz 
Zur Bewertung der Wirksamkeit von 20 mg Aescin enthaltenden Mitteln zur 
Behandlung der CVI konnten keine Studien identifiziert werden. Lediglich 
zur Bewertung der Sicherheit konnte ein non-RCT identifiziert werden. 
Nebenwirkungen mit 20 mg Aescin enthaltenden Mitteln traten in ca. 1 % der 
PatientInnen auf.  
Hämorrhoidalleiden 
Es konnten keine Studien zur Bewertung der Wirksamkeit oder Sicherheit 
von 20 mg Aescin enthaltenden Mitteln bei Hämorrhoiden identifiziert wer-
den. 
 
50 mg Aescin enthaltende Mittel (Venosin retard® 50 mg Kapseln) 
Chronisch venöse Insuffizienz 
Für die Bewertung der Wirksamkeit und Sicherheit von 50 mg Aescin ent-
haltenden Mitteln zur Behandlung der CVI konnte 1 systematischer Review 
mit insgesamt 1.292 PatientInnen identifiziert werden.  
Die Vergleichsgruppen erhielten entweder Placebo und/oder Kompressions-
strümpfe. 
Im Vergleich zu Placebo konnten Ödeme und Schmerzen statistisch signifikant 
mehr mit 50 mg Aescin enthaltenden Mitteln reduziert werden. 
Mit zusätzlichen Kompressionsstrümpfen konnten Ödeme und CVI-Anzeichen 
mit 50 mg Aescin etwas mehr als ohne weitere Behandlung verbessert werden, 
die Unterschiede sind jedoch nicht signifikant. 
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Es traten keine Nebenwirkungen mit 50 mg Aescin enthaltenden Mitteln auf. 
Der verwendete Review weist ein geringes Verzerrungspotenzial auf, die da-
rin behandelten Studien hingegen ein hohes, weshalb die Stärke der Evidenz 
insgesamt als niedrig einzustufen ist.  
Hämorrhoidalleiden 
Es konnten keine Studien zur Bewertung der Wirksamkeit oder Sicherheit 
von 50 mg Aescin enthaltenden Mitteln bei Hämorrhoiden identifiziert wer-
den. 
 
Calciumdobesilat enthaltende Mittel (Doxium® 500 mg Kapseln) 
Chronisch venöse Insuffizienz 
Für die Bewertung der Wirksamkeit und Sicherheit von Calciumdobesilat ent-
haltenden Mitteln zur Behandlung der CVI konnten 1 systematischer Review, 
4 RCTs, 1 non-RCT sowie 2 Ein-Arm-Studien mit insgesamt 2.768 Patien-
tInnen identifiziert werden.  
Die Vergleichsgruppen des systematischen Reviews und der RCTs erhielten 
Placebo. Es gilt zu beachten, dass in einigen Studien die PatientInnen zu-
sätzliche Kompressionsstrümpfe tragen konnten. 
Ödeme konnten nicht in allen Studien zum Vorteil von Calciumdobesilat 
enthaltenden Mitteln im Vergleich zu Placebo reduziert werden. 
Einige Symptome der CVI (generelle, Schmerzen, Krämpfe und ruhelose Bei-
ne) konnten in den Calciumdobesilat erhaltenden Gruppen mehr reduziert 
werden, als in den Placebo-Gruppen. Für andere Symptome (z. B. Juckreiz 
oder Schwellungen) war dies nicht der Fall. 
Nebenwirkungen mit Calciumdobesilat enthaltenden Mitteln traten in ca. 0-
27 % der PatientInnen auf.  
Das Verzerrungspotenzial in den Studien ist überwiegend gering, die Stärke 
der Evidenz ist moderat. 
Hämorrhoidalleiden 
Es konnten keine Studien zur Bewertung der Wirksamkeit oder Sicherheit 
von Calciumdobesilat enthaltenden Mitteln bei Hämorrhoiden identifiziert 
werden. 
 
Vergleich zwischen kapillarstabilisierenden Mitteln 
Chronisch venöse Insuffizienz 
Für die Bewertung der Wirksamkeit und Sicherheit von kapillarstabilisieren-
den Mitteln im Vergleich konnten 1 systematischer Review, 2 RCTs und 1 
non-RCT identifiziert werden, die Oxerutin enthaltende mit 50 mg Aescin 
enthaltenden Mitteln oder Flavonoidfraktion enthaltende Mitteln verglichen.  
Bei den untersuchten Parametern (Ödeme, Schmerzen, Juckreiz, schwere Bei-
ne und Schwellungen) erzielten Oxerutin und 50 mg Aescin enthaltenden Mit-
tel ähnliche Ergebnisse. 
Nebenwirkungen traten bei 5-16 % der Oxerutin-PatientInnen und bei 3 % der 
50 mg Aescin-PatientInnen auf. 
keine Nebenwirkungen 
Evidenzstärke gering 
keine Evidenz 
8 Studien identifiziert 
Vergleich: Placebo 
Ödemreduktion mit 
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Generelle Symptome konnten mit Oxerutin enthaltenden Mitteln etwas mehr 
(Angaben zur statistischen Signifikanz fehlen) reduziert werden als mit Fla-
vonoidfraktion enthaltenden Mitteln. Nebenwirkungen traten bei keinem Me-
dikament auf. 
Die Stärke der Evidenz ist niedrig bis sehr niedrig. 
Hämorrhoidalleiden 
Für die Bewertung der Wirksamkeit und Sicherheit von kapillarstabilisieren-
den Mitteln im Vergleich zueinander für die Behandlung von Hämorrhoiden 
konnte 1 RCT identifiziert werden.  
Einige Symptome konnten mit Calciumdobesilat enthaltenden Mitteln zwar 
geringfügig mehr reduziert werden als mit Flavonoidfraktion enthaltenden 
Mitteln, die Unterschiede waren jedoch entweder nicht signifikant oder An-
gaben zur Signifikanz fehlten. Nebenwirkungen traten bei keinem Medika-
ment auf. Die Rückfallrate war mit beiden Medikamenten gleich. 
Zu Nebenwirkungen wurde nichts in dem RCT berichtet. 
Die Stärke der Evidenz ist niedrig. 
 
Diskussion  
Limitationen der Evidenz 
Insgesamt war die Stärke der Evidenz zu gering, um robuste Aussagen über 
die Wirksamkeit von kapillarstabilisierenden Mitteln zur Behandlung der 
CVI und von Hämorrhoiden zu treffen. 
Bezüglich Sicherheit ist davon auszugehen, dass eine Behandlung mit kapil-
larstabilisierenden Mitteln nicht mit zahlreichen oder schwerwiegenden 
Nebenwirkungen assoziiert ist. 
Generell waren die identifizierten Studien vorrangig älteren Publikationsda-
tums, daher ist es schwierig das Bias-Risiko und die Evidenzstärke mit heu-
tigen Kriterien zu bewerten. 
Problematisch ist, dass PatientInnen in einigen Interventionsgruppen nicht 
standardisiert weitere Interventionen (Kompressionsstrümpfe bei der CVI-
Behandlung, ballaststoffreiche Nahrung bei Hämorrhoiden) erhielten, daher 
ist es möglich, dass positive Effekte nicht durch die kapillarstabilisierenden 
Mittel, sondern durch die zusätzlichen Interventionen hervorgerufen wurden.  
Einige Parameter, mit denen Endpunkte gemessen wurden, sind veraltet; so 
werden heutzutage keine Messungen mehr auf Skalen von 0-3 oder 0-100 
durchgeführt. Außerdem war die klinische Relevanz einiger Endpunkte nicht 
gegeben, auch wenn die Studiengruppenunterschiede signifikant waren. 
Zusätzliche Probleme stellen die vorwiegend kleinen Fallzahlen in den Stu-
dien und auch die kurzen Studiendauern dar. Die wenigsten Studien hatten 
eine Nachbetrachtungszeit, nachdem die Medikamente abgesetzt wurden. 
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Limitationen des Reviews 
Die Schwächen der vorliegenden systematischen Übersichtsarbeit liegen in 
folgenden Punkten:  
Es wurden Surrogatparameter, wie Beinvolumen oder Knöchelumfang, ak-
zeptiert, um Ödeme zu messen, wenngleich sie wenig Aussagekraft zum pa-
tientInnenrelevanten Nutzen haben und teilweise veraltet sind. Außerdem 
wurden zur besseren Vergleichbarkeit die gemessenen Scores der Studien an 
eine Skala von 0 bis 10 angepasst. Die Daten basieren jedoch auf Skalen, de-
ren Validität umstritten ist (beispielsweise 0-3) und Primärerhebungen mit 
der akzeptierten Skala (0-10) würden möglicherweise zu anderen Ergebnissen 
führen.  
Einige Studien wurden nicht in die Synthese eingeschlossen, da die Dosis oder 
die Darreichungsform nicht im EKO gelistet ist. Insofern gelten die Ergeb-
nisse des vorliegenden Berichts ausschließlich für die sieben eingangs genann-
ten Produkte.  
Weiters erfolgte keine getrennte Betrachtung der einzelnen Dosen und Dar-
reichungsformen der Oxerutin enthaltenden Mittel. Jedoch war die Evidenz-
stärke der entsprechenden Studien relativ gering, insofern wäre eine indivi-
duelle Betrachtung wenig aussagekräftig gewesen. 
Außerdem war es auf Basis der vorhandenen Evidenz nicht möglich, das wirk-
samste kapillarstabilisierende Mittel für eine Behandlung der CVI oder von 
Hämorrhoiden zu ermitteln.  
 
Fazit 
Die endgültige Wirksamkeit oder Unwirksamkeit kapillarstabilisierender Mit-
tel für die Behandlung der CVI oder von Hämorrhoiden konnte nicht bewie-
sen werden. 
Die Evidenz zeigt tendenziell eine Wirksamkeit für Doxium
®
 500 mg Kapseln
 
(nur für CVI), Venoruton
®
 (nur für CVI), Daflon
®
 500 mg Tabletten (für CVI 
und Hämorrhoiden) und Venosin retard
®
 50 mg Kapseln (nur für CVI), auch 
wenn die Ergebnisse sehr ungewiss sind.  
Für Reparil
®
 20 mg Dragées konnten wir keine Evidenz identifizieren, um die 
Wirksamkeit bei CVI oder Hämorrhoiden zu bewerten.  
Es ist sicherlich fraglich, ob Studien aus den 1980er Jahren mit heutigen Kri-
terien bewertet werden können. Zugleich ist es aber auch höchst fragwürdig, 
weiterhin 20 Millionen Euro öffentlicher Gelder für kapillarstabilisierende 
Mittel pro Jahr auszugeben, wenn deren Wirksamkeit nicht deutlich belegt 
werden kann.  
Die künftige Kostenerstattung der Medikamente sollte an die Generierung 
robuster Evidenz zur Belegung der Wirksamkeit seitens der Hersteller ge-
knüpft werden. Es wird empfohlen, das Studiendesign (z. B. die Definition 
der Outcomeparameter) in Kooperation mit den öffentlichen Kostenträgern 
zu erstellen. 
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1 Background 
This report will focus on the drugs of the subcategory C05C “capillary stabi-
lising agents” that are listed in the Code of Reimbursement (Erstattungsko-
dex; EKO), of the Main Association of Austrian Social Security Institutions 
(Hauptverband der österreichischen Sozialversicherung; HVB). This document 
contains approved, eligible and secured medicinal products which are avail-
able in Austria [1]. 
Vasoprotectives are blood vessel-affecting drugs. They constitute a therapeu-
tic subgroup of the group “C-Cardiovascular System” in the Anatomical Ther-
apeutic Chemical/Defined Daily Dose Classification (ATC-Code) with the 
code “C05” [1, 2]. Capillary stabilising agents are mainly used for the treat-
ment of chronic venous insufficiency (CVI), especially reducing the associated 
symptoms, and haemorrhoidal diseases (HD).  
Capillary stabilising agents are often prescribed by physicians, yet their bene-
fit is uncertain. However, the main principle of the Austrian health care sys-
tem is that a medical treatment must be sufficient and appropriate, but should 
not exceed the needs [1]. Therefore, this report will provide a systematic anal-
ysis of the literature to prove the efficacy and safety of capillary stabilising 
agents for the treatment of CVI and haemorrhoidal diseases. 
In the following introductory sections, we will highlight some background 
information regarding the two targeted diseases (CVI and HD) and the vari-
ous capillary stabilising agents that are listed in the EKO. 
 
 
1.1 Targeted diseases 
This report will focus on two different diseases (see Chapter 1.2): venous in-
sufficiency (chronic) and haemorrhoidal diseases, which are further described 
below. 
 
1.1.1 Diseases of the veins 
The human circulatory system consists of three sets of vessels: arteries, lym-
phatics, and veins. Arteries deliver oxygen-rich blood from the heart to the 
tissues and lymphatic vessels bring this fluid back into circulation. Veins, on 
the other hand, deliver oxygen-depleted blood from the organs and tissues 
back to the heart and lungs, where it is re-oxygenated [3].  
In general, diseases of the veins can be divided into two major categories: 
blockage from a blood clot (thrombosis or embolism) and inadequate venous 
drainage (insufficiency). Haemorrhoids and (chronic) venous insufficiency are 
a subgroup of the latter; they must be distinguished, however, from other dis-
eases caused by inadequate venous drainage, such as varicose veins [3, 4].  
In the 10
th
 revision of the International Statistical Classification of Diseases 
and Related Health Problems (ICD-10), diseases of the veins are categorised 
within the group “I80-89 diseases of the veins, lymphatic vessels and lymph 
nodes”. This group is classified in ten subgroups [4]: 
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 I80 Phlebitis and thrombophlebitis 
 I81 Portal vein thrombosis 
 I82 Other venous embolism and thrombosis 
 I83 Varicose veins of lower extremities 
 I84 Haemorrhoids 
 I85 Oesophageal varices 
 I86 Varicose veins of other sites 
 I87 Other disorders of veins 
 I88 Nonspecific lymphadenitis 
 I89 Other noninfective disorders of lymphatic vessels and lymph nodes 
Whereas haemorrhoids are summarised in category “I84”, chronic venous 
insufficiency is categorised in the subcategory “I87.2 Venous insufficiency 
(chronic) (peripheral)”of “I87 Other disorders of veins” [4].  
 
1.1.2 Venous insufficiency (chronic) 
Venous insufficiency can be a consequence of an inadequate venous drain-
age. When the disease lasts over a long period of time, it is categorised as 
“chronic”. Chronic venous insufficiency (CVI) is also called chronic venous 
disease (CVD). Inadequate venous drainage, mostly in the legs, may occur as 
a result of obstructed blood flow between the limbs and the heart or due to the 
reflux of blood back into the veins, caused by malfunctioning valves [3, 5, 6]. 
Venous dysfunction can result from either a congenital or an acquired disor-
der [7]. 
No recent information about the prevalence of CVI in Austria is available. 
An Austrian study published in 1998 about the prevalence of venous diseas-
es (based on self-reporting) has shown that about 6% of the patients reported 
to be suffering from venous diseases, such as varicosis, phlebitis or venous 
thrombosis [8]. For estimating the prevalence of CVI in Germany, the Bonn 
Vein Study
1
 is often cited [8, 9]. The study concluded that every 6
th 
male and 
every 5
th 
female suffers from chronic venous insufficiency. In addition, CVI 
is more likely in women and older people. The data show that venous disor-
ders are highly prevalent, but that the severity of CVI has decreased over the 
past 20 years [9]. 
In early stages of chronic CVI, the disease can primarily be diagnosed by the 
presence of symptoms in the legs, such as pain, cramps (especially during the 
night), restless legs, itching (a tingling sensation of the skin) and heaviness 
(or heavy legs). The intensity of the symptoms can cause only a moderate dis-
comfort or even limitations in common daily activities. In further stages the 
presence of reticular or varicose veins, swellings of the legs (or a sensation of 
tension) and paraesthesia limit the common activities of patients. The swell-
ings are accentuated while standing and increase during the day. In later stag-
es, CVI will cause typical CVI-related signs like skin changes, particularly 
pigmentation (e.g., telangiectasia: small red points on the skin caused by per-
                                                             
1
 The Bonn Vein Study was conducted between 2000 and 2002 to investigate the pre-
valence and severity of chronic venous disorders in the German urban and rural resi-
dential population. A total of 3,072 persons, aged between 18 and 79 years, partici-
pated, whereas the overall response rate was 59%. 
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manently opened tiny blood vessels; and lipodermatosclerosis: hardening of 
the skin which may gain red or brown pigmentation), oedemas and ulcers or 
eczemas [5, 6, 8-10]. 
Diagnosis of CVI can be done by clinical examination (e.g., inspection, pal-
pation, etc.) and using ultrasound (duplex or intravascular). Patients should 
also be asked for symptoms and a complete history examination is recom-
mended [5, 6, 11]. In addition, CT and MR are used to diagnose CVI [11]. 
In German-speaking countries, CVI is usually classified according to Widmer 
[5, 8, 9], summarised in the following table. 
Table 1.1-1: Classification of venous insufficiency according to Widmer 
Classification Clinical signs 
Grade I telangiectasias beyond the inner ankle, ‘corona phlebectatica’ 
Grade II indurated edema, eczema, dermatoliposclerosis, hyperpigmentation 
Grade III active or healed ulcer 
Reference: [5] 
 
A different classification system is the CEAP classification that was devel-
oped for venous diseases by the American Venous Forum (AVF). The classi-
fication is based on clinical signs of venous disease (C), etiology (E), anatomy 
(A), and the underlying pathophysiology (P), and is widely used [5, 7, 9, 12]. 
The CEAP classification is shown in the following table.  
Table 1.1-2: CEAP classification of venous diseases/insufficiency 
Classification Clinical signs 
Clinical Co no visible or palpable signs of venous disease 
C1 teleangiectasias or reticular veins 
C2 varicose veins 
C3 swellings 
C4 
a. pigmentation and eczema 
b. lipodermatosclerosis and atrophie blanche 
C5 healed venous ulcer 
C6 active venous ulcer 
Etiologic Ec ongenital 
Ep primary 
Es secondary (post-thrombotic) 
En no venous cause identified 
Anatomic As superficial veins 
Ap perforator veins 
Ad deep veins 
An no venous location identified 
Pathophysiologic Pr reflux 
Po obstruction 
Pr,o reflux and obstruction 
Pn: no venous pathophysiology identifiable 
Reference: [12] 
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Treatment of venous insufficiency is aimed at improving the symptoms (e.g., 
pain, heaviness, restless legs, etc.) and signs (especially edema, trophic alter-
nations and ulcer), as well as avoiding the worsening of the CVI stage. Initial 
treatment should be conservative, starting with lifestyle changes (e.g., exercis-
ing or diet) or local treatment (e.g., compressions or wound cleansing, etc., 
in case of ulcers). Conservative treatment can be followed or supplemented 
by medication (e.g., capillary stabilising agents). If conservative or medical 
treatment is not feasible or is ineffective, specific surgical procedures can be 
considered (e.g., vein stripping, superficial vein surgery, sclerotherapy, inter-
ruption of perforator veins, etc.) [5, 6, 11]. The possible treatment options for 
CVI are summarised in the following table. 
Table 1.1-3: Treatment options for venous diseases 
Treatment Treatment option 
Lifestyle changes  Exercising (physical activity, elevate legs, etc.) 
 Diet 
Local  Compression therapy (stockings, bandages or compression pumps) 
 Dressings (hydrocolloids, foam dressings, etc.);  
often in combination with compression therapy 
 Wound cleansing 
 Debridement 
 Lymph drainage 
Medical  Phlebotonics, like capillary stabilising agents (flavonoid fractions, aescin, etc.) 
 Antibiotics (only if there is an infection) 
 Topical agents (antimicrobial agents, moisturisers or local anaesthetic creams) 
Surgical  Vein stripping 
 Superficial vein surgery 
 Sclerotherapy 
 Interruption of perforator veins 
 Ablation (radiofrequency or laser) 
References: [5, 6, 11] 
 
1.1.3 Haemorrhoids 
Haemorrhoids are vascular structures in the anus and lower rectum. They be-
come pathological (also known as piles) when they are swollen or inflamed. 
The disease is therefore called haemorrhoidal disease (HD). Haemorrhoids 
can be located inside the rectum (internal haemorrhoids), or they may develop 
under the skin around the anus (external haemorrhoids) [13-15]. 
The exact pathophysiology of haemorrhoids is not clear. Apparently, the veins 
around the anus tend to stretch under pressure and may bulge or swell. Swol-
len veins (haemorrhoids) can develop from an increase in pressure in the low-
er rectum. Factors that might cause increased pressure include [13-15]: 
 Straining during bowel movements 
 Sitting for long periods of time on the toilet 
 Chronic diarrhoea or constipation 
 Obesity 
 Pregnancy 
 Anal intercourse 
 Low-fibre diet 
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Exact data on the prevalence of HD is rare. However, haemorrhoids are a 
common disease, though more likely in older people. In an Austrian study
2
, 
about 39% of the study population suffered from haemorrhoids, whereby a 
considerable number of people did not complain about symptoms [13, 14]. 
In 2012, haemorrhoid surgery (haemorhoidectomy) was performed 3,942 times 
in Austria (in public hospitals) [16].  
The symptoms of haemorrhoids usually depend on the location, but mostly 
include pain or discomfort, bleeding (partially without any pain and especial-
ly during bowel movements) and itching (or prutitus) [13, 14, 17]. 
Typical signs of haemorrhoidal diseases are prolapses (a kind of lumps, which 
may be sensitive or painful), discharge (also called leakage). Furthermore, 
haemorrhoids (especially internal) can cause faecal incontinence [13, 14, 17]. 
The diagnosis of haemorrhoids should include a precise anamnesis and physi-
cal examination to exclude other diseases. Internal haemorrhoids, without a 
prolapse, can only be found by endoscopy [13-15].  
Complications associated with haemorrhoids are rare, but could contain  
[13-15]: 
 Chronic blood loss from haemorrhoids that may cause anaemia,  
resulting in fatigue and weakness. 
 Interruption of blood supply to an internal haemorrhoid that can 
cause extreme pain and lead to tissue death. 
There are two major classification systems for haemorrhoids (or haemorrhoi-
dal diseases): one is by Banov et al. and the other is by Goligher et al. [13-15]. 
Both systems classify the disease into four grades, whereby the description for 
every grade is slightly different. The two classification systems are described 
in the two tables below. 
Table 1.1-4: Classification of haemorrhoidal diseases according to Banov et al. 
Classification Clinical signs 
Grade I Prominent haemorrhoidal vessels, no prolapse 
Grade II Prolapse with straining, spontaneous reduction 
Grade III Prolapse with straining, requires manual reduction 
Grade IV Chronic prolapse, manual reduction is ineffective 
Reference: [17] 
Table 1.1-5: Classification of haemorrhoidal diseases according to Goligher et al. 
Classification Clinical signs 
Grade I Normal appearance; bleeding but no prolapse 
Grade II Bleeding and prolapse, spontaneous reduction 
Grade III Bleeding and prolapse, must be manually reduced 
Grade IV Bleeding and permanent prolapse 
Reference: [13] 
                                                             
2
 Between 2008 and 2009, 976 patients who attended the Austrian nationwide health 
care program for colorectal cancer screening (people of 50 years or older) at four 
medical institutions were screened for haemorrhoids. 
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The treatment of haemorrhoids aims at improving the symptoms and avoiding 
the worsening of the stage of the disease. Initial treatment should be conserva-
tive, starting with lifestyle changes (e.g., diet) and followed or supplemented 
by medication (e.g., capillary stabilising agents). Office-based procedures are 
reserved for patients with grades I, II, and III haemorrhoidal diseases and who 
have failed conservative and medical management. An office-based treatment 
is performed in outpatient facilities or physician’s offices and is less invasive 
than surgical interventions. A surgical treatment of haemorrhoids is indicat-
ed when patients are not responding to or feasible for office-based procedures, 
as well as for patients with large external haemorrhoids or grade III/IV com-
bined internal/external haemorrhoids. However, a surgical treatment can re-
sult in faecal incontinence [13, 15, 17]. 
The possible treatment options for haemorrhoids are summarised in the fol-
lowing table. 
Table 1.1-6: Treatment options for haemorrhoidal diseases 
Treatment Treatment option 
Lifestyle 
changes  
 Diet (grade I-III) 
 Warm baths 
 Toilet habit retraining 
Medical  Capillary stabilising agents (flavonoid fractions, aescin, etc.) 
 Topical agents (steroids, hydrocortisone, etc.) 
Office-based  Rubber band ligation 
 Sclerotherapy 
 Infrared-coagulation 
Surgical  Surgical excision 
 Stapled haemorrhoidopexy 
 Doppler guided ligation 
References: [13, 15, 17] 
 
 
1.2 Vasoprotectives:  
Capillary stabilising agents 
Capillary stabilising agents are mainly used to treat chronic venous insuffi-
ciency (particularly the symptoms) and haemorrhoids and can be given oral-
ly as tablets, dragées or granulate [1]. 
The capillary stabilising agents listed in the Austrian Code of Reimbursement 
(EKO) are divided into “bioflavonoids” and “other capillary stabilising agents”. 
The bioflavonoids are further divided into drugs containing only rutisode 
(Venoruton
®
) and a combination of diosmin (Daflon
®
) as a component. More-
over, the other capillary stabilising agents are divided into drugs containing 
aescin (Reparil
®
 and Venosin
®
 retard) and calcium dobesilate (Doxium
®
) [1].  
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There were around 2.4 million prescriptions of capillary stabilising agents 
per year in the outpatient sector from 2011 to 2013. The annual costs for the 
social health insurance amounted to between 19.2 and 19.4 million Euros in 
these years
3
. Both numbers were relatively constant over the past three years. 
The costs for prescribed capillary stabilising agents in 2013 is equivalent to 
0.06% of the Austrian health expenditures of 31,960 million Euros [18]. In 
addition, some of the agents are over-the-counter (OTC) drugs and therefore 
will in some cases be paid privately by patients. Hence, the total annual ex-
penditures on capillary stabilising agents in Austria will be higher than the 
figure stated above. 
The relatively constant course of the costs for and number of prescriptions of 
capillary stabilising agents in the years 2011 to 2013 are shown in Figure 1.2-1. 
 
Figure 1.2-1: Development of prescriptions of and costs for capillary stabilising agents in Austria 
Reference: From data sent by the Main Association of Austrian Social Security Institutions 
 
  
                                                             
3
 The information about the costs and prescriptions of capillary stabilising agents was 
provided by the Main Association of Austrian Social Security Institutions. 
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1.2.1 Bioflavonoids 
Rutoside: Oxerutin-containing agents (Venoruton®) 
The only rutoside-containing drug that is listed in the EKO is Venoruton
® 
[1]. 
The main content of Venoruton
®
 is O-(beta-hydroxyethyl)-rutoside (HR), also 
known as oxerutin [1, 19]. Furthermore, the drug is available in several dos-
age forms with different prices – reimbursed by the social insurance – which 
are summarised in Table 1.2-1. 
The treatment with Venoruton
®
 is indicated for oedema and symptoms asso-
ciated with CVI, like painful, tired, heavy, swollen legs with cramps and par-
aesthesia. It can be also used to treat the symptoms of haemorrhoids (pain, 
pruritus and bleeding) and their complications [19]. 
Venoruton
®
 is supposed to act on the capillary wall, increasing its resistance 
and normalising its permeability. It is an OTC drug, available in pharmacies, 
whereby the Austrian distributor of the drug is Novartis Consumer Health-
Gebro [19]. Moreover, O-(beta-hydroxyethyl)-rutosides are available in other 
countries under different product names like Paroven (Switzerland) or Relvène 
(France) [20, 21]. 
 
Diosmin, combination:  
Flavonoid fraction-containing agents (Daflon®) 
The only drug containing a combination of diosmin with another active com-
ponent listed in the EKO is Daflon
® 
500 mg tablets (a combination of diosmin 
and hesperidin) [1]. The main content is a micronised purified flavonoidic 
fraction of 500 mg, whereby the fraction contains 450 mg diosmin and 50 mg 
hesperidin (a flavonoid) [22] (see Table 1.2-1).  
Daflon
® 
is indicated for the treatment of symptoms related to CVI (heavy 
legs, pain, cramps, etc.) and symptoms related to haemorrhoidal diseases or 
acute haemorrhoidal attacks and their frequency, severity and duration [22].  
The drug aims at reducing venous distensibility and stasis, at normalising 
capillary permeability, and at increasing capillary resistance. Daflon
® 
is only 
available on prescription of a physician. The Austrian distributor of the drug 
is Servier Austria GmbH [22]. Moreover, Daflon
®
 is available in other coun-
tries under registered product names like Alvenor, Ardium, Arvenum, Capiven, 
Detralex, Elatec, Flebotropin, Variton or Venitol [23]. 
Table 1.2-1: Content and prices of bioflavonoids 
Product name Active agent 
Number of items 
per package 
Price 
Venoruton® 300 mg Dragées Oxerutin (300 mg) 50 Euro 8.55 
Venoruton® 500 mg Tablets Oxerutin (500 mg) 30 Euro 7.85 
Venoruton® 1000 mg Granulate Oxerutin (1000 mg) 16 Euro 7.85 
Daflon® 500 mg Tablets Flavonoid fraction (500 mg) 
= 450 mg diosmin + 50 mg hesperidin 
30 Euro 7.80 
References: [1, 22] 
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1.2.2 Other capillary stabilising agents 
20 mg/0.02 g aescin-containing agents (Reparil®) 
One of the aescin (or escin)-containing drugs that are listed in the Austrian 
Code of Reimbursement is Reparil
®
 20 mg dragées [1]. The main content of 
Reparil
®
 is a 20 mg dosage of aescin that is a mixture of saponins, found in 
the horse chestnut (Aesculus hippocastanum) [24, 25]. The drug is available 
in only one dosage form at a price of 4.40 Euro [1] (see Table 1.2-2). 
The treatment with Reparil
®
 is mainly indicated for venous diseases, like CVI, 
varicose veins or leg ulcers. Furthermore, Reparil
®
 can also be used for the 
treatment of traumatic swellings, tenosynovitis and painful lesions of the ver-
tebral column [24, 25]. The package insert gives no information that the drug 
is indicated for the treatment of HD. 
Reparil
®
 is supposed to reduce the capillary permeability and to therefore de-
crease the fluid outflow into the tissue. It is only available on prescription 
from a physician. The Austrian distributor of the drug is Madaus Ges.m.b.H. 
in Vienna [24, 25].  
 
50 mg/0.05 g aescin/0.3 g horse chestnut-containing agents 
(Venosin® retard) 
Another aescin (or escin)-containing drug listed in the Austrian Code of Re-
imbursement is Venosin
® 
retard 50 mg capsules [1]. The main content is a 50 
mg dosage of aescin, made from 240-290 mgs of horse chestnut seed extract 
(HCSE) [1, 26]. The drug is available only in one dosage form in two different 
packages sizes at a price of 3.55 and 8.30 Euro [1, 26] (see Table 1.2-2). 
Venosin
® 
retard is mainly indicated to treat the symptoms of CVI like heavy 
legs, pain, cramps or itching, but also varicose veins, or phlebitis [26]. The 
package insert gives no information that the drug is indicated for the treat-
ment of HD. 
The drug is targeting the reduction of venous distensibility and stasis plus 
the normalisation of capillary permeability and the increase of capillary re-
sistance. Venosin
®
 retard is an OTC drug, available in pharmacies. Astellas 
Pharma is distributing the drug in Austria [26].  
Table 1.2-2: Content and prices of other capillary stabilising agents 
Product name Active agent 
Number of items 
per package 
Price 
Reparil® 20 mg Dragées Aescin (20 mg) 60 Euro 4.40 
Venosin® retard 50 mg Capsules Aescin (50 mg) 
= 240-290 mg horse chestnut extract 
20 
60 
Euro 3.55 
Euro 8.30 
Doxium® 500 mg Capsules Calcium dobesilate (500 mg) 60 Euro 19.45 
References: [1, 26] 
 
 
Reparil® 20 mg ist ein 
von Sozialversicherung 
erstattetes Medikament 
mit Aescin als Wirkstoff 
zahlreiche 
Indikationsbereiche, 
hauptsächlich bei CVI 
verschreibungs-
pflichtiges Medikament 
Venosin® retard 50 mg 
ist ein von 
Sozialversicherung 
erstattetes Medikament 
mit Aescin als Wirkstoff 
Indiziert bei Behandlung 
von Symptomen der CVI 
rezeptfrei in  
Apotheken erhältlich 
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Calcium dobesilate-containing agents (Doxium®) 
The only drug containing calcium dobesilate, listed in the Austrian Code of 
Reimbursement, is Doxium
® 
500 mg capsules [1]. The main content is a 500 
mg dosage of calcium dobesilate [27] (see Table 1.2-2). 
The treatment with Doxium
®
 is indicated for CVI (particularly the symptoms) 
and the aftereffects, like edema and leg ulcers [27]. Furthermore, the drug 
can be used for the treatment of dysfunction in the microcirculation and a 
combination with compression therapy is recommended [27]. The package in-
sert gives no direct information that the drug is indicated for the treatment 
of HD. 
Doxium
®
 is supposed to reduce the capillary permeability and therefore to 
decrease the fluid outflow into the tissue. It is only available on prescription 
from a physician.The Austrian distributor of the drug is Ebewe Pharma (now 
a part of Sandoz, Novartis) [27].  
 
 
Doxium® ist  
einziges Medikament 
mit Calciumdobesilat 
Indikation: 
hauptsächlich 
Symptome CVI 
verschreibungspflichtiges 
Medikament 
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2 Methods 
2.1 Research questions 
We have sought to answer the following research questions:  
1. Are capillary stabilising agents, listed in the Austrian Code of Reimburse-
ment, more effective and safer for the treatment of patients with venous in-
sufficiency and haemorrhoids with regard to defined outcomes (see PICO 
scheme) compared to other alternatives (no treatment, placebo, etc.)? 
2. Are there any differences between the different capillary stabilising agents 
according to efficacy and safety? 
 
 
2.2 Inclusion criteria 
The inclusion criteria for relevant studies are summarised in the following 
table. Since the product names of the capillary stabilising agents listed in 
the Austrian Code of Reimbursement are different from those in other coun-
tries, we also searched for the active components of the individual drugs.  
Table 2.2-1: Inclusion criteria 
Population Patients with: 
 Venous insufficiency 
 Haemorrhoids 
Intervention, 
Setting 
Oral medication of capillary stabilising agents (ATC-Code C05C): 
 Oxerutin 0.3 (Venoruton 300 mg) 
 Oxerutin 0.5 (Venoruton 500 mg) 
 Oxerutin 1.0 (Venoruton 1000 mg) 
 Flavonoid fraction 0.5 (Daflon 500 mg) 
 Aescin 0.02 (Reparil 20 mg) 
 Aescin 0.05 (Venosin retard 50 mg) 
 Calcium dobesilate 0.5 (Doxium 500 mg) 
Control Venous insufficiency: 
 No intervention 
 Lifestyle changes (exercising, diet, elevate legs, etc.) 
 Medical treatment (placebo, other capillary stabilising agents mentioned under 
“intervention”, antibiotics, etc.) 
 Local treatment (compression therapy, etc.; additional wound dressings and 
debridement if applicable) 
 Surgical interventions (vein stripping, superficial vein surgery, sclero-therapy, 
interruption of perforator veins, etc.) 
 
Forschungsfragen: 
kapillarstabilisierende 
Mittel wirksam und 
sicher bei Behandlung 
CVI und Hämorrhoiden? 
Unterschiede zwischen 
Medikamenten? 
Einschlusskriterien 
gemäß  
PIKO-Fragestellung 
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Control 
(continuation) 
Haemorrhoids: 
 No intervention 
 Lifestyle changes (diet, etc.) 
 Medical treatment (placebo, other capillary stabilising agents mentioned under 
“intervention”, etc.) 
 Local/Office-based treatment (rubber band ligation, sclerotherapy,  
infrared-coagulation, etc.) 
 Surgical interventions (surgical excision, stapled haemorrhoidopexy,  
doppler-guided ligation, etc.) 
Outcomes Efficacy: 
 Venous insufficiency: 
 Change of CVI stage 
 Improvement of CVI signs (in general, trophic alternations, oedema, etc.) 
 Improvement of CVI symptoms (pain, swelling, itching, etc.) 
 Quality of life 
 Haemorrhoids: 
 Change of HD stage 
 Improvement of HD signs (in general, discharge, prolapse, etc.) 
 Improvement of HD symptoms (pain, bleeding, itching, etc.) 
 Quality of life 
 Recurrence rate 
Safety: 
 Complications/adverse events (gastrointestinal and neurovegetative disorders, 
allergic reactions, vomiting, nausea, headache, pain, dizziness, inflammation, 
tachycardia, etc.) 
Types of studies systematic reviews, meta-analyses, HTA reports, prospective controlled studies with ≥ 
10 patients (for efficacy and safety), prospective uncontrolled studies with ≥ 50 patients 
(for safety only) 
Publication period 1900-2014 
Language German/English 
Type of publication (un)published journal articles and research reports 
 
 
2.3 Exclusion criteria 
We excluded studies with the following populations and interventions plus 
the stated types of studies and publications: 
 Population: 
 Animals 
 Patients with post-thrombotic syndrome 
 Patients with primary varicose veins (not related to CVI) 
 Intervention: 
 Vasoprotectives with ATC-Code C05A “agents for treatment  
of haemorrhoids and anal fissures for topical use” and  
C05B “antivaricose therapy” 
 Combination therapies in one of two study groups 
 Capillary stabilising agents and related dosages/dosage forms that 
are not included in the Austrian Code of Reimbursement 
ausgeschlossene 
Populationen, 
Interventionen, Studien 
und Publikationen 
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 Types of studies: 
 Dose-response studies 
 Controlled studies with less than 10 patients 
 Uncontrolled studies with less than 50 patients 
 Retrospective studies 
 Case-reports 
 Case-series 
 Editorials, letters to the editor, comments, other correspondence 
etc.  
 Types of publications: 
 Abstracts, posters, comments, letters 
 Books 
 
 
2.4 Literature search 
The medical literature was searched to identify relevant studies and reviews 
for the period between 1900 and May 2014. Searches were conducted via the 
following databases: 
 Cochrane 
 Centre for Research and Dissemination (CRD)  
 Embase 
 Medline 
The detailed search strategy including the used search terms is described in 
the appendix. Furthermore, an additional hand search via Scopus and Google 
was conducted. 
Furthermore, we contacted the individual Austrian distributors of the sever-
al drugs for studies in August 2014. 
 
 
  
Literatursuche in  
vier Datenbanken 
detaillierte 
Suchstrategie im 
Anhang 
außerdem Anfrage 
Pharmaunternehmen 
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2.5 Literature selection 
A total of 681 records were identified through database, hand search and via 
additional industry requests. Two review authors (IZ, SF) included and ex-
cluded the literature, independently from each other, whereas differences 
were discussed between the authors. A PRISMA flowchart is shown in Fig-
ure 2.5-1, outlining the number of citations considered at each stage of the 
systematic review. 
 
Figure 2.5-1: Summary of the process used to identify and select studies for the review (PRISMA Flow Diagram) 
 
2.6 Data extraction and analysis 
One author extracted the data (SF) of the included studies and a second au-
thor controlled the extracted data (IZ). If the same data were duplicated in 
multiple articles, only results from the most comprehensive or most recent ar-
ticle were included. 
Literaturauswahl  
aus 681 Quellen 
Erstautor extrahierte 
Studiendaten, 
Zweitautor kontrollierte 
Records identified through 
database searching  
(n=505) 
Sc
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g 
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d 
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Id
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o
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 Additional records identified 
through other sources  
(n=176) 
Records after duplicates removed 
(only studies published between 1900 
and 2014 were considered) 
(n=681) 
Records screened  
(n=681) 
Records excluded 
(n=508) 
Full-text articles  
assessed for eligibility  
(n=173) 
Full-text articles excluded,  
with reasons  
(n=117) 
 Wrong endpoints (n=11) 
 Wrong intervention (n=27) 
 Wrong population (n=5) 
 Wrong comparator (n=0) 
 Wrong study size (n=2) 
 Duplicate results (n=7) 
 Abstract only (n=13) 
 Wrong study design (n =35) 
 Wrong language (n=15) 
 Article not available (n=2) 
Studies included in 
qualitative synthesis  
(n=56) 
System. Reviews (n=2) 
Meta-analyses (n=1) 
RCTs (n=40) 
Non-RCTs (n=6) 
Single-arm studies (n=7) 
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The extracted results of the identified studies are classified by indication (CVI 
and haemorrhoids) and by the individual agents (flavonoid fractions, oxeru-
tin, aescin, etc.). The studies in the extraction tables are sorted by publication 
date, starting with the oldest study. 
In case a high quality systematic review or meta-analysis was identified for a 
certain indication and/or intervention, and the reported outcomes matched 
our criteria, we included only those primary studies that were published af-
ter the review. 
If homogenous outcome data were available from more than two studies they 
were quantitatively analysed in a meta-analysis (Software: Comprehensive 
Meta-Analysis, version 2.2.050), using a random-effects model. The results 
from the meta-analyses are presented in forest-plots in the respective chap-
ters on the drug-related efficacy and safety. A sensitivity analysis was per-
formed if there were more than 5 studies per outcome (or three studies with 
minimum a moderate strength of evidence). 
For all studies the methodological quality was assessed using the criteria from 
the Cochrane risk of bias tool listed in the internal manual of the LBI-HTA 
[28], by two review authors (SF, IZ), independently from each other. A risk 
of bias summary is presented in several figures in the relevant chapters. The 
risk of bias analysis for each individual study is available on author’s request.  
The strength of evidence was assessed according to the Grading of Recom-
mendations, Assessment, Development and Evaluation (GRADE) approach 
for every defined outcome parameter by two review authors (SF, IZ), inde-
pendently from each other. Thereby, all relevant study results for each end-
point were summarised and assessed regarding to the strength of evidence. 
Differences were solved by discussion and consensus or by a third person. A 
detailed description of the used criteria for assessing the strength of evidence 
is stated in the internal manual of the LBI-HTA [28] or in the recommenda-
tions of GRADE, respectively [29].  
GRADE uses the following categories to assess the strength of evidence: 
 high: it is unlikely that new studies will have an important influence 
on the estimated effect 
 moderate: new studies will have a potential influence on the estimated 
effect 
 low: new studies will have a very likely influence on the estimated effect 
 very low: an evaluation of the effect is very uncertain 
In some studies, baseline measurements on outcome parameters were not pre-
sented, hence changes in outcomes over time could not be calculated. In the 
GRADE-tables only outcomes that could be presented as reductions or chang-
es from baseline were considered. Furthermore, outcomes measured on dif-
ferent scores were adapted to single scores of 0 to 10 to increase comparabil-
ity and consistency, i.e., scores of 0-2 were multiplied by 5, scores of 0-3 were 
multiplied by 3.33 and scores of 0-100 were divided by 10. 
Incidentally, the planned comparative effectiveness analysis (see research ques-
tion) was not applicable, since we could not identify studies for every agent 
and indication. Moreover, the quality of evidence did not allow any compar-
ative effectiveness analysis. 
 
 
Ergebnisse getrennt 
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GRADE-Kategorien 
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2.7 Patient-relevant outcomes 
2.7.1 Chronic venous insufficiency 
One of the aims of treating CVI is avoiding the worsening of the disease stage 
(see Chapter 1.1.2). Therefore, “change of the CVI stage” was chosen as one 
patient-relevant outcome. 
The disease will also cause typical CVI-related signs, especially in later stag-
es, like skin changes, particularly pigmentation (e.g., telangiectasia: small red 
points on the skin caused by permanently opened tiny blood vessels; and lipo-
dermatosclerosis: hardening of the skin which may gain red or brown pigmen-
tation); oedemas and ulcers (or eczemas). Therefore, the assessment of these 
signs was chosen as patient-relevant outcome. Incidentally, skin changes are 
summarised under the term “trophic alternations” and “oedema” could be 
measured as volume (in ml, l, cm³, etc.), circumference (in mm or cm at the 
calf, ankle or at the leg in general) or assessed on a scale. 
CVI can primarily be diagnosed by the presence of symptoms in the legs (see 
also Chapter 1.1.2), in early stages especially pain, cramps (mostly during the 
night), restless legs, itching (a tingling sensation of the skin), a feeling of heav-
iness (also called heavy legs). The intensity of the symptoms can cause discom-
fort and limitations in common daily activities. In further stages the presence 
of swellings of the legs (a sensation of tension) and paraesthesia are limiting 
common activities of patients. The swellings are accentuated while standing 
and increase during the day. Hence, the assessment of these symptoms was 
defined as patient-relevant. In addition, the assessment of general symptoms 
was selected, e.g., if studies did not report individual symptoms. 
Furthermore, the quality of life was chosen as an additional patient-relevant 
outcome. 
To assess the safety we selected adverse events in general and treatment-re-
lated adverse events. If possible, the adverse events were classified by major 
and minor adverse events.  
In summary, the patient-relevant outcomes to assess efficacy and safety of sta-
bilising agents for the treatment of CVI
4
 are: 
Efficacy
5
: 
 Change of the CVI stage 
 CVI signs: 
 general 
 trophic alternations (telangieactasia, reticular or varicose veins 
and lipodermatosclerosis) 
 oedema (also measured as leg volume and leg, ankle or  
calf circumference) 
 ulcer 
                                                             
4
 Surrogate parameters measuring one of the stated outcomes were NOT extracted 
(e.g., haemodynamic parameters like blood pressure, etc.). 
5
 Outcomes were extracted at 1; 2; 3; 6; 12 months and the study’s individual latest 
point of time of outcome reporting after begin of treatment. 
Endpunkte, wie 
Änderung des 
Krankheits-Stadiums ... 
... Anzeichen der CVI 
(Hauveränderungen, 
Ödeme, Geschwüre) ... 
... Symptome der CVI 
(Schmerzen, Krämpfe, 
ruhelose, schwere Beine, 
Juckreiz, Schwellungen, 
Parästhesie) ... 
... Lebensqualität ... 
... sowie unerwünschte 
Ereignisse 
Zusammenfassung 
Endpunkte 
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 CVI symptoms: 
 general 
 pain 
 cramps 
 restless legs 
 itching (sometimes described as tingling sensation) 
 heaviness (sometimes described as heavy legs) 
 swelling (sometimes describes as sensation of tension) 
 paraesthesia 
 Quality of life (QoL) 
Safety: 
 General adverse events  
 major 
 minor 
 Treatment-related adverse events 
 major  
 minor 
 
2.7.2 Haemorrhoidal disease 
One of the aims of treating HD is avoiding the worsening of the disease stage 
(see Chapter 1.1.3). Therefore, “change of the HD stage” was chosen as one 
patient-relevant outcome. 
The disease will cause typical HD-related signs, like prolapses (sometimes de-
fined as swellings), discharge (sometimes called leakage) and (faecal) inconti-
nence. Therefore, the assessment of these signs was chosen as patient-relevant 
outcomes.  
HD is primarily diagnosed by the presence of symptoms (see also Chapter 
1.1.3) such as pain, bleeding, and itching (or pruritus). The intensity of the 
symptoms can cause discomfort and limitations in common daily activities 
and in bowel movement. Hence, the assessment of these symptoms was de-
fined as patient-relevant. In addition, the assessment of symptoms in general 
was selected, e.g., if studies did not report individual symptoms. 
Furthermore, the quality of life and the recurrence rate were chosen as addi-
tional patient-relevant outcomes. 
To assess the safety we selected adverse events in general and treatment-re-
lated adverse events. If possible, the adverse events were classified by major 
and minor adverse events.  
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Änderung des 
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Hämorrhoiden (Prolaps, 
Nässen, Inkontinenz) ... 
... Symptome der 
Hämorrhoiden 
(Schmerzen, Blutungen, 
Juckreiz) ... 
... Lebensqualität, 
Rückfallrate ... 
... sowie unerwünschte 
Ereignisse 
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In summary, the following patient-relevant outcomes have been analysed to 
assess the efficacy and safety of capillary stabilising agents for the treatment 
of HD
6
: 
Efficacy
7
: 
 Change of the HD stage 
 HD signs: 
 general 
 prolapse (improvement, change or visibility, sometimes described 
as swelling) 
 discharge (sometimes described as leakage) 
 incontinence 
 HD symptoms: 
 general 
 pain 
 bleeding 
 itching (sometimes described as pruritus) 
 Quality of life (QoL) 
 Recurrence rate 
Safety: 
 General adverse events  
 major 
 minor 
 Treatment-related adverse events 
 major  
 minor 
 
2.7.3 Clinical relevance of outcome indicators 
In the individual studies, the reported outcomes were measured with differ-
ent indicators. For measuring CVI and HD signs and symptoms scores with 
different scales (0-3, 0-10) have often been used. Oedema has been primarily 
measured by leg volume (in ml or cm
3
) or leg circumference (in mm). Another 
very frequently used indicator was the percentage of patients with signs/ 
symptoms or with improvement of signs/symptoms. 
For evaluating the clinical benefit for patients it is important to assess the 
clinical relevance of the presented measurements, e.g., the change in scores 
from baseline or the difference between groups. Our definitions of clinical 
relevance are based on consultations of two clinical experts (both are angiol-
ogists).  
 
                                                             
6
 Surrogate parameters measuring one of the stated outcomes were NOT extracted 
(e.g., biochemical parameters). 
7
 Outcomes were extracted at <1, 1; 2; 4; 8; 12; 24; 50 weeks and the study’s individual 
latest point of time of outcome reporting after beginning of treatment. 
Zusammenfassung 
Endpunkte 
Anzeichen und 
Symptome oft mit 
Scores gemessen, 
Ödeme als Volumen 
oder Umfang 
angegeben 
klinische Relevanz  
von Indikatoren von 
ExpertInnen eingestuft 
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In terms of leg volume for assessing oedema, this indicator is a surrogate pa-
rameter and of little value concerning the assessment of patient-relevant ben-
efits.  
Outcomes measured with scores on a scale from 0-10 have been defined as 
clinically relevant, if the score is reduced by 5 or more. A measurement on 
scales from 0-3, 0-100 or 0-40 – which has often been used in the studies – 
has been rated as inappropriate according to clinical experts, as the validity 
of the results measured on such scales is severely limited.  
In terms of calf and ankle circumference in mm – which has been used for 
measuring oedema – a reduction of ≥10mm has been defined as clinically 
relevant, by the consulted clinical experts 
Regarding days of bleeding which has been used for assessing HD, a differ-
ence between the treatment groups of 3 days and more has been considered 
as clinically relevant. 
With respect to presenting the benefit of the treatment in % of patients with 
(improved) signs/symptoms, it needs to be noted that even in cases where the 
difference between groups is statistically significant, there may be still a large 
number of patients who have signs and symptoms or patients without im-
provement despite treatment. This has additionally been taken into account 
when rating the overall evidence. 
 
Beinvolumen  
wenig relevant 
Skalen von 0-3, 0-40 
und 0-100 veraltet 
erst Reduktion Umfang 
≥10 mm relevant (CVI) 
Gruppenunterschied 
Blutungen ≥3 Tage 
relevant 
oft signifikanter 
Gruppenunterschied  
bei Verbesserung 
Anzeichen/Symptome, 
aber Veränderung  
nur marginal 
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3 Results 
3.1 Chronic venous insufficiency 
Overall, 2 systematic reviews, 1 meta-analysis, 24 randomised controlled trials 
(RCTs), 4 non-randomised controlled trials (2 of them were registry studies) 
and 6 uncontrolled trials (called single-arm studies),were identified to assess 
either the efficacy or safety or both of capillary stabilising agents for the treat-
ment of chronic venous insufficiency (CVI). 
 
3.1.1 Oxerutin-containing agents 
Study characteristics 
For evaluating the efficacy and safety of oxerutin (0-beta-hydroxyethyl-ruto-
side, HR) containing capillary stabilising agents, we identified 10 RCTs [20, 
21, 30-38] and 2 additional non-randomised controlled registry studies [39, 
40] that met our inclusion criteria. The studies are comparing the treatment 
of CVI using oxerutin-containing agents with either placebo [20, 30-38], com-
pression stockings [21, 39, 40] or no treatment [39]. The dosages of oxerutin 
varied from 300 mg three times a day [34] over 500 mg two to four times a 
day [21, 33-36, 38] up to 1,000 mg one to three times a day [20, 32, 37, 40].  
The study characteristics and results are summarised in Table 3.1-1 for RCTs 
and in Table 3.1-2 for non-randomised controlled trials. 
There were no studies identified comparing oxerutin-containing agents with 
other interventions, such as lifestyle changes or further local, medical and 
surgical treatment, mentioned in Chapter 1.1.2. 
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Table 3.1-1: Efficacy and safety-related outcomes of randomised controlled trials of oxerutin-containing agents vs. placebo and/or compression stockings for CVI 
Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Country Italy UK UK Netherlands France Germany Germany Italy, UK Italy, UK Italy 
Study design RCT RCT8 RCT RCT RCT RCT9 RCT RCT10 RCT RCT 
Sponsor n/a Zyma n/a n/a n/a n/a n/a n/a n/a n/a 
Intervention/ 
product 
3x 1,000 mg 
HR granulate 
(Venoruton®) 
per day 
2x 500 mg 
HR tablets 
(Paroven®) 
per day 
4x 500 mg HR 
tablets 
(Paroven®) 
per day 
2x 500 mg HR 
tablets 
(Venoruton®) 
per day 
2x 1,000 mg 
HR granulate 
(Relvene®) 
per day 
3x 300 mg | 2x 
500 mg HR 
tablets 
(Venoruton®) 
per day 
2x 500 mg HR 
tablets 
(Venoruton®) 
per day + 
compression 
stockings 
3x 500 mg | 3x 
1,000 mg HR 
(Venoruton®/
Paroven®)  
per day  
2x 1,000 mg 
HR granulate 
(Venoruton®/
Paroven®)  
per day + 
compression 
stockings 
1-3x 1,000 mg 
HR granulate 
(Venoruton®) 
per day11 
Comparator Placebo Placebo Placebo Compression 
stockings 
Placebo Placebo Placebo + 
compression 
stockings 
Placebo Placebo + 
compression 
stockings 
Placebo 
Number of pts. 10 vs. 10 69 vs. 69 19 vs. 21 12 vs. 12 53 vs. 51 20 | 20 vs. 20 64 vs. 56 15 | 16 vs. 15  20 vs. 20 40 vs. 20 
Age of patients 
(yrs.)  
19-42 Ø 67 vs. 68 n/a Ø 49 vs. 45 Ø 48 vs. 54 Ø 58 | 58 vs. 59 Ø 59 vs. 61 Ø 45 | 44 vs. 44 46 vs. 46 52 vs. 53 
Sex (% female) 100 vs. 100 56 vs. 64 n/a 73 vs. 83 81 vs. 88 100 | 100 vs. 100 100 vs. 100 47 | 44 vs. 47 30 vs. 35 90 vs. 70 
Height (cm)/ 
weight (kg)/ 
BMI (kg/m²) 
n/a n/a / n/a / n/a n/a / n/a / n/a n/a / n/a / 26 
vs. 26 
Unclear 
information 
167 | 167 vs. 
167/64 | 66 vs. 
66 / n/a 
165 vs. 163 / 76 
vs. 74 / n/a 
n/a / n/a / n/a n/a / n/a / n/a n/a / n/a / n/a 
Clinical 
classification 
n/a n/a12 n/a Grade I + II 
acc. to Widmer 
Grade II acc. 
to Widmer 
Grade II acc. 
to Widmer 
Grade II acc. to 
Widmer 
n/a n/a Grade I + II 
acc. to Widmer 
Primary endpoint Increase of 
venous 
distensibility 
Recurrence 
rate of ulcer 
n/a n/a Leg 
circumference 
at calf + ankle 
Change of leg 
volume 
Change of 
oedema and 
associated 
symptoms 
Capillary 
filtration rate 
(CFR) 
Improvement 
of plasma free 
radicals (PFRs) 
Venous 
capacity 
                                                             
  
8
 All patients were wearing compression stockings. 
  
9
 Study contained of five study groups, whereas data of three groups were extracted only: for patients who received 300 mg tablets, 500 mg tablets and placebo as treatment.  
Treatment in the other groups met not inclusion criteria and was therefore not extracted. 
10
 Study contained of two groups receiving 0-beta-hydroxyethyl-rutosides (it is not clear if patients received Paroven and/or Venoruton), a placebo-group and a group of healthy 
subjects, whereas the results for the group of healthy subjects were not extracted. 
11
 Patients with grade I (acc. to Widmer) CVI received 2 x 1,000 mg HR per day in the first two weeks and 1 x 1,000 mg HR per day in the last two weeks of the treatment phase.  
Patients with grade II (acc. to Widmer) CVI received 3 x 1,000 mg HR per day in the first two weeks and 2 x 1,000 mg HR per day in the last two weeks of the treatment phase.  
12
 All patients had recently healed venous ulcers. 
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Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Inclusion criteria Female 
patients, 
taking oral 
contraceptives, 
with 
symptoms and 
plethysmo-
graphic signs 
of moderate 
CVI 
n/a Patients with 
ankle oedema 
due to mild to 
moderste 
venous 
hypertension 
due to deep or 
superficial 
incompetence 
Patients with 
uni- or 
bilateral CVI 
grade I or II 
(Widmer), 
with no 
previous 
surgical or 
sclerosing 
therapy, aged 
20-75 years, 
venous refill 
time <20 
seconds, 
Transcutaneo
us oxygen ≤55 
mm Hg 
Patients of 
both sexes, 
aged 20-70 
years, with 
uni- or 
bilateral CVI 
grade II 
(Widmer), 
with pitting 
oedema in 
minimum one 
leg and 
minimum two 
symptoms of 
CVI 
Female 
patients, 
postmeno-
pausal, with 
CVI grade II 
(Widmer), 
generally 
rejected 
compression 
therapy 
Female 
patients, aged 
18-75 with  
CVI grade II 
(Widmer) with 
uni- or bilateral 
clinical leg 
oedema  
Patients with 
venous hyper-
tension (evalu-
ated by colour 
duplex scanning 
and AVP 
measurement 
with intrave-
nous needle), 
selected on ba-
sis of severe 
superficial  
venous incom-
petence with 
normal deep 
venous system, 
on waiting list 
for surgery 
Patients with 
severe venous 
hypertension 
(ambulatory 
venous 
pressure >55 
mm Hg, 
refilling time 
<8 seconds) 
with ankle 
swelling and 
lipodermatosc
lerosis 
Patients with 
grade I or II 
CVI, aged 18-
65 years. 
Duration of 
Treatment 
(months) 
1 18 1 4 213 314 315 1 116 1 
Follow-up 
(months) 
0 0 0 0 0 0 1.5 0 0 0 
Drop-outs, n (%) n/a n/a 4 (21) vs. 5 (24) 1 (8) vs. 0 (0) 5 (5)17 n/a 11 (9)18 n/a n/a n/a 
Efficacy-related outcomes 
Change of CVI 
stage 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
CVI signs 
(general) 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Trophic 
alterations 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
                                                             
13
 The study started with a placebo-run-in-phase of four weeks, followed by an 8-week treatment phase. 
14
 The study started with a placebo-run-in-phase of two weeks, followed by a 12-week treatment phase. 
15
 The study started with a placebo-run-in-phase of one week, followed by a 12-week treatment phase and a 6-week follow-up phase without treatment. 
16
 The study started with a wash-out phase of 2 weeks. 
17
 Of the 109 patients who entered study, a total of 5 patients withdrew from study, but these patients were not considered for any results of the study. 
18
 Of the 133 patients who entered the study, a total of 13 patients withdrew from study. 
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Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Oedema  
(or leg volume or 
circumference) 
n/a n/a Oedema score 
(0-10)19: 
Foot: 
Baseline: 1.5 
vs. 2.7; p=n/a 
After 1 month: 
0.5 vs. 1; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
Ankle: 
Baseline: 1.2 
vs. 2.8; p=n/a 
After 1 month: 
1 vs. 1.5; p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
Leg volume 
(ml)20: 
Baseline: 3,233 
vs. 3,430; 
p=n/a 
After 1 month: 
3,204 vs. 
3,176; p<0.001 
(in favour of 
stockings) 
After 2, 3 
months: n/a 
After 4 
months: 3,143 
vs.3,200; 
p=0.005 (in 
favour of 
stockings) 
After 6; 12 
months: n/a 
Oedema21:  
Baseline: 51 vs. 
50; p=n/a 
After 1 month: 
49 vs. 50; p=n/a 
After 2 months: 
38 vs. 49; p=n/a 
After 3; 6;  
12 months: n/a 
Calf circum-
ference (mm): 
Baseline: 347 
vs. 339; p=n/a 
After 1 month: 
344 vs. 339; 
p<0.01 
After 2 months: 
340 vs. 339; 
p<0.01 
After 3; 6; 12 
months: n/a 
Ankle circum-
ference (mm): 
Baseline: 227 
vs. 223; p=n/a 
After 1 month: 
225 vs. 223; 
p<0.01 
After 2 months: 
221 vs. 225; 
p<0.01 
After 3; 6; 12 
months: n/a 
Leg volume 
change (ml)22: 
Baseline: 0 | 0 
vs. 0 
After 1 month: 
-4.6 | -7.4 vs. 
6.5; p=0.008 | 
p<0.0001 
After 2 
months: -23.0 
| -23.9 vs. -2.6; 
p<0.001 | 
p<0.001 
After 3 
months: -29.8 
| -29.2 vs. 2.1; 
p<0.001 | 
p<0.001 
After 6; 12 
months: n/a 
Leg volume (ml): 
Baseline: 2,165 
vs. 2,167; p=N.S. 
After 1 month: 
2,111 vs. 2,142; 
p=0.028 
After 2 months: 
2,116 vs. 2,138; 
p=N.S. 
After 3 months: 
2,101 vs. 2,134; 
p=0.033 
After 4.5 months: 
2,133 vs. 2,159; 
p=N.S. 
After 6; 12 
months: n/a 
Leg volume 
change (ml): 
Baseline: 0 vs. 0 
After 1 month: 
--53.9 vs. -24.9; 
p=0.028 
After 2 months: 
-48.9 vs. -28.7; 
p=N.S. 
After 3 months: 
-63.9 vs.+8.6; 
p=0.004 
After 4.5 months: 
-32.2 vs.-8.3; 
p=N.S. 
After 6; 12 
months: n/a 
n/a n/a Oedema score 
(0-3)23: 
Baseline: 1.73 
vs. 1.9; p=n/a 
After 1 month: 
0.65 vs. 1.55; 
p<0.01 
After 2; 3; 6; 
12 months: 
n/a  
                                                             
19
 Oedema was measured with an analogue scale (0-10) by asking the patients.  
20
 Oedema/leg volume was measured with an opto-electronic volometer in ml. 
21
 Oedema was measured as the presence of pitting oedema in number of legs. 
22
 Oedema/leg volume was measured with a rectangular glass container, filled with water. Results were only given as volume reduction from baseline (in ml). 
23
 Oedema was measured with a composite analogue scale (0-3). 
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Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Ulcer n/a Recurrence 
rate (%): 
Baseline: - 
After 1; 2; 3;  
6 months: n/a 
After 12 
months: 23 
vs. 22; p=N.S. 
After 18 
months: 34 
vs. 32; p=N.S. 
n/a n/a n/a n/a n/a n/a n/a n/a 
CVI symptoms 
(general) 
Improvement 
(%)24: 
Baseline: - 
After 1 month: 
97 vs. 60; 
p<0.002 
After 2; 3; 6; 
12 months: 
n/a 
n/a n/a25 n/a26 Score (0-15)27: 
Baseline: 10.0 
vs. 10.6; p=n/a 
After 1 month: 
7.0 vs. 9.6; 
p<0.001 
After 2 
months: 4.3 
vs. 9.5; 
p<0.001 
After 3;6; 12 
months: n/a. 
n/a28 n/a29 Score (0-10)30: 
Baseline: 7.8 | 
7.9 vs. 7.9; 
p=n/a 
After 1 month: 
4.0 | 3.1 vs.6; 
p=n/a  
After 2; 3; 6; 
12 months: 
n/a 
Score (0-10)31: 
Baseline: 8.5 
vs8.3; p=n/a 
After 1 month: 
3.1 vs. 8.5; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
n/a32 
                                                             
24
 Subjective symptoms were measured by the following score: 0=absent, 1= light, 2=mild, 3=severe, 4= very severe; whereas only the improved number of legs after 1 month was shown. 
25
 Subjective symptoms were measured with an analogue scale (scaling was not described) for pain, cramps, restless legs and paraesthesia. 
26
 Only a general statement for subjective symptoms was given, without presenting any data. 
27
 Subjective symptoms were measured with an arbitrary scale (0-3) for pain, cramps, restless legs, heaviness and swelling. Maximum score for general symptoms is 15. 
28
 Subjective symptoms were measured with a visual analogue scale (0-10 cm) for heaviness, swelling and itching. The results for 300 and 500 mg treatment were pooled in the study. 
29
 Subjective symptoms were measured with a visual analogue scale (0-10 cm) for restless legs, itching and heaviness. 
30
 Subjective symptoms were measured with a visual analogue scale (0-10 cm), based on pain, cramps, restless legs, swelling and heaviness. 
31
 Subjective symptoms were measured with a composite analogue scale (0-10), based on pain, restless legs, swelling and skin alternations. 
32
 Subjective signs and symptoms were measured with a 4-point rating scale (0-3) for oedema, cramps, heaviness and paraesthesia. 
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Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Pain Improvement 
(%): 
Baseline: - 
After 1 month: 
100 vs. 100; 
p=N.S. 
After 2; 3; 6; 
12 months: 
n/a 
n/a Score (0-10): 
Baseline: 4.5 
vs. 2.3; p=n/a 
After 1 month: 
3.2 vs. 1.9; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
n/a Score (0-3): 
Baseline: 1.7 
vs. 1.9; p=n/a 
After 1 month: 
1.4 vs. 1.8; 
p=n/a 
After 2 
months: 0.9 
vs. 1.8; p=n/a 
After 3 
months: n/a 
n/a n/a n/a n/a n/a 
Cramps Improvement 
(%): 
Baseline: - 
After 1 month: 
100 vs. 25; 
p=N.S. 
After 2; 3; 6; 
12 months: 
n/a 
n/a Score (0-10): 
Baseline: 2.5 
vs. 3.1; p=n/a 
After 1 month: 
0.7 vs. 1; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
n/a Score (0-3): 
Baseline: 1.7 
vs. 2.1; p=n/a 
After 1 month: 
1.2 vs. 1.9; 
p=n/a 
After 2 
months: 0.6 
vs. 1.6; p=n/a 
After 3;6; 12 
months: n/a 
n/a n/a n/a n/a Score (0-3): 
Baseline: 1.5 
vs. 1.35; p=n/a 
After 1 month: 
0.28 vs. 0.3; 
p=N.S. 
After 2; 3; 6; 
12 months: 
n/a  
Restless legs Improvement 
(%): 
Baseline: - 
After 1 month: 
100 vs. 80; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
n/a Score (0-10): 
Baseline: 4 vs. 
3; p=n/a 
After 1 month: 
3.2 vs. 2.5; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
n/a Score (0-3): 
Baseline: 2.0 
vs. 2.2; p=n/a 
After 1 month: 
1.2 vs. 1.9; 
p=n/a 
After 2 
months: 0.6 
vs. 1.9; p=n/a 
After 3; 6; 12 
months: n/a 
n/a n/a n/a n/a n/a 
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Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Itching 
(= tingling 
sensation) 
Improvement 
(%): 
Baseline: - 
After 1 month: 
100 vs.100; 
p=N.S. 
After 2; 3; 6; 
12 months: 
n/a 
n/a n/a n/a n/a Score (0-10): 
Baseline: 2.3 
vs. n/a; p=n/a 
After 1 month: 
n/a 
After 2 
months: n/a 
After 3 
months: 0.1 
vs. n/a; p=n/a 
After 6; 12 
months: n/a 
Score (0-10): 
Baseline: 2.5 vs. 
2.8; p=n/a 
After 1 month: 
1.6 vs. 2.4; 
p=n/a  
After 2 months: 
1.7 vs. 2.1; 
p=n/a 
After 3 months: 
1.6 vs. 1.4; 
p=n/a 
After 4.5 
months: 1.9 vs. 
1.8; p=n/a 
After 6; 12 
months: n/a 
n/a n/a n/a 
Heaviness 
(= heavy legs) 
Improvement 
(%): 
Baseline: - 
After 1 month: 
89 vs. 67; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
n/a n/a n/a Score (0-3): 
Baseline: 2.3 
vs. 2.3; p=n/a 
After 1 month: 
1.7 vs. 2.0; 
p=n/a 
After 2 
months: 1.2 
vs. 2.2; p=n/a 
After 3; 6; 12 
months: n/a 
Score (0-10): 
Baseline: 5.2 
vs. 4.9; p=n/a 
After 1 month: 
n/a 
After 2 
months: n/a 
After 3 
months: 1.1 vs. 
4.1; p=n/a 
After 6; 12 
months: n/a 
Score (0-10): 
Baseline: 3.7 vs. 
4.0; p=n/a 
After 1 month: 
2.2 vs. 3.2; 
p=n/a  
After 2 months: 
2.7 vs. 2.6; 
p=n/a 
After 3 months: 
2.7 vs. 2.2; 
p=n/a 
After 4.5 
months:2.8 vs. 
2.2; p=n/a 
After 6; 12 
months: n/a 
n/a n/a Score (0-3): 
Baseline: 2.18 
vs. 2.15; p=n/a 
After 1 month: 
1.03 vs. 1.0; 
p<0.01 
After 2; 3; 6; 
12 months: 
n/a 
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Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Swelling 
(= sensation of 
tension) 
Improvement 
(%): 
Baseline: - 
After 1 month: 
100 vs. 100; 
p=N.S. 
After 2; 3; 6; 
12 months: 
n/a 
n/a n/a n/a Score (0-3): 
Baseline: 2.2 
vs. 2.3; p=n/a 
After 1 month: 
1.5 vs. 2.0; 
p=n/a 
After 2 
months: 1.0 
vs. 2.0; p=n/a 
After 3; 6; 12 
months: n/a 
Score (0-10): 
Baseline: 4.7 
vs. n/a; p=n/a 
After 1 month: 
n/a 
After 2 
months: n/a 
After 3 
months: 0.7 
vs. n/a; p=n/a 
After 6; 12 
months: n/a 
Score (0-10): 
Baseline: 3.5 vs. 
3.7; p=n/a 
After 1 month: 
2.3 vs. 2.7; 
p=n/a 
After 2 months: 
2.5 vs. 2.4; 
p=n/a 
After 3 months: 
2.3 vs. 2.0; 
p=n/a 
After 4.5 
months: 2.8 vs. 
2.2, p=n/a 
After 6; 12 
months: n/a 
n/a n/a n/a 
Paraesthesias n/a n/a Score (0-10): 
Baseline: 4.1 
vs. 2.7; p=n/a 
After 1 month: 
2 vs. 0.7; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
n/a n/a n/a n/a n/a n/a Score (0-3): 
Baseline: 1.48 
vs. 1.05; 
p=N.S. 
After 1 month: 
0.35 vs. 0.45; 
p=n/a 
After 2; 3; 6; 
12 months: 
n/a 
QoL n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Safety-related outcomes 
Adverse events, 
general in % (n) 
pts. 
0 vs. 0 n/a n/a n/a 21 (11) vs.  
14 (7); p=n/a 
(flatulence, 
abdominal pain, 
nausea, diar-
rhoea, etc. in 
both groups)33 
n/a34 6 (4) vs. 4 (3)35; 
p=n/a 
(muscle cramps 
for stockings, 
gastrointestinal 
complaints, etc. 
in both groups)33 
n/a 0 vs. 0 0 vs. 0 
                                                             
33
 Adverse events were described only in general terms. 
34
 In total 7 patients reported abdominal pain or vomiting. 
35
 Originally, 133 patients were enrolled in the study, whereas 13 were excluded from efficacy analysis but all 133 patients were included in the safety analysis. 
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Author, year,  
reference number 
Capelli  
1987 [32] 
Wright  
1991 [38] 
Renton  
1994 [35] 
Neumann 
1995 [21] 
Cloarec  
1996 [20] 
Rehn  
1996 (a) [34] 
Unkauf 1996 [33] 
Großmann  
1997 [36] 
Cesarone 
2002 (a) [31] 
Cesarone 
2002 (b) [30] 
Petruzellis 
2002 [37] 
Major adverse 
events 
0 vs. 0 n/a n/a n/a n/a n/a n/a n/a 0 vs. 0 0 vs. 0 
Minor adverse 
events 
0 vs. 0 n/a n/a n/a n/a n/a n/a n/a 0 vs. 0 0 vs. 0 
Adverse events, 
treatment-related 
in % (n) pts. 
0 vs. 0 n/a 0 vs. 0 0 vs. 0 n/a n/a n/a n/a 0 vs. 0 0 vs. 0 
Major adverse 
events 
0 vs. 0 n/a 0 vs. 0 0 vs. 0 n/a n/a n/a n/a 0 vs. 0 0 vs. 0 
Minor adverse 
events 
0 vs. 0 n/a 0 vs. 0 0 vs. 0 n/a n/a n/a n/a 0 vs. 0 0 vs. 0 
Abbreviations: acc. = according; CVI = chronic venous insufficiency; HR = 0(beta-hydroxyethyl)-rutosides (also called oxerutin);n = number (of patients); n/a = data not available;  
N.S. = not statistically significant; pts. = patients; QoL = quality of life; RCT = randomised controlled trial;vs. = versus; yrs. = years 
 
 
  
V
aso
pro
tectives 
50
 
LB
I-H
T
A
 | 20
14
 
Table 3.1-2: Safety-related outcomes of non-randomised trials of oxerutin-containing agents for CVI 
Author, year, reference number Belcaro 2008 (a) [39] Belcaro 2008 (b) [40] 
Country Italy Italy 
Study design Registry study Registry study 
Sponsor None None 
Intervention/Product 3x 500 mg HR tablets (Venoruton®) | 2x 1,000 mg HR granulate 
(Venoruton®) per day 
2x 1,000 mg HR granulate (Venoruton®) per day36 
Comparator No treatment | compression stockings Compression stockings 
Number of pts. 98 | 87 vs. 90 |113 24 vs. 20 
Age of patients (yrs.)  Ø 46 | 45 vs. 46 vs. 46 46 vs. 45 
Sex (% female) n/a 63 vs. 60 
Height (cm)/Weight (kg)/BMI (kg/m²) n/a / n/a / n/a n/a / n/a / n/a 
Clinical classification n/a n/a 
Primary endpoint n/a n/a 
Inclusion criteria Patients with severe CVI (ambulatory venous pressure >56 mm Hg, 
refilling time <10 seconds, deep venous incompetence shown  
by duplex scanning) 
Patients with severe CVI (ambulatory venous pressure >56 mm Hg, 
refilling time <10 seconds and deep venous incompetence shown 
by duplex scanning) 
Duration of treatment (months) 60 2 
Follow-up (months) 0 0 
Drop-outs, n (%) 4 (4) | 4 (5) vs. 7 (8) | 8 (7) n/a 
Safety-related outcomes 
Adverse events, general in % (n) pts. 0 | 0 vs. 0 | 0 0 vs. 0 
Major adverse events 0 | 0 vs. 0 | 0 0 vs. 0 
Minor adverse events 0 | 0 vs. 0 | 0 0 vs. 0 
Adverse events, treatment-related in % (n) pts. 0 | 0 vs. 0 | 0 0 vs. 0 
Major adverse events 0 | 0 vs. 0 | 0 0 vs. 0 
Minor adverse events 0 | 0 vs. 0 | 0 0 vs. 0 
Abbreviations: CVI = chronic venous insufficiency, HR = 0(beta-hydroxyethyl)-rutosides (also called Oxerutin), n = number (of patients); n/a = data not available; pts. = patients; yrs. = years 
 
                                                             
36
 The study included an additional treatment group that received oral HR and additional topical HR as a gel. The results of this group were not extracted, since the treatment with 
gel is not meeting the inclusion criteria. The results of another group with healthy subjects were also not extracted. Furthermore, all groups received topical treatment with a gel, 
whereas the gel was placebo. 
Results 
LBI-HTA | 2014 51 
Efficacy 
For evaluating the efficacy of oxerutin (0-beta-hydroxyethyl-rutoside, HR) 
containing capillary stabilising agents, we identified a total of 10 RCTs [20, 
21, 30-38] that met our inclusion criteria (one study was published twice [33, 
36]). Of these, 9 were placebo-controlled [20, 30-38] and 1 compared HR against 
compression therapy [21]. Furthermore, in 2 of the identified studies, patients 
have additionally worn compression stockings in both study groups [30, 33, 36].  
Overall, there were 652 patients in the studies, of whom 139 were treated with 
1,000 mg oxerutin granulate, 199 received the 500 mg and 20 the 300 mg tab-
lets. A total of 282 patients in the control groups received placebo and 12 were 
treated with compression stockings only [20, 21, 30-38]. The patients were on 
average between 45 and 67 years in the treatment groups and between 44 and 
68 years in the control groups. The majority of the patients – except in two 
studies [30, 31] -were females: 30-100% in the oxerutin groups and 35-100% 
in the control groups [20, 21, 32, 33, 36-38]. Furthermore, the patients had 
CVI grade I and II according to Widmer [20, 21, 33, 34, 36, 37]. In addition, 
the duration of treatment was 1-18 months, whereby there was mostly no fol-
low-up without treatment [20, 21, 30-32, 34, 35, 37, 38], except in one study 
(follow-up was 1.5 months) [33, 36].The drop-out rate differed between 4 and 
23% [20, 21, 33, 35,36]. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Tables 3.1-3 to 3.1-4. 
 
Oxerutin-containing agents (+ compression stockings) versus  
placebo (+ compression stockings) 
None of the identified studies assessed the change of the CVI stage, the CVI 
signs in general, trophic alternations (a sign for CVI) and the quality of life 
of a treatment with oxerutin versus placebo. 
Regarding individual signs of CVI, oedema was assessed in 6 studies and 
measured by several parameters: in two studies the change of the score (0-10) 
was reduced slightly in the oxerutin groups and in the placebo groups with  
-1; -0.2 and -3.3 vs. -1.7; -1.3 and -1.3 for oedema at the foot, ankle and in 
general respectively. Whether the difference is statistically significant is un-
known [35, 37]. 
Furthermore, in two other studies, oedema was measured by leg volume (in 
ml) and in both studies the volume was more reduced during 3 months of 
treatment in the treatment than in the control groups. The difference between 
the study groups was statistically significant [33, 36, 41]. However, one of 
these studies measured the leg volume 1.5 months after treatment and the val-
ues did not show a statistically significant difference anymore [33, 36]. 
The results from the meta-analysis on leg volume change after 1, 2 and 3 
months of treatment are displayed in the Figures 3.1-1, 3.1-2 and 3.1-3. The 
individual forest plots are showing that the reduction of the leg volume is in-
creasing with every month with a mean difference in the first month of -13.1 ml, 
of -20.8 ml in second month and of -31.5 ml in the third month. The differ-
ence is statistically significant in favour of a treatment with oxerutin-contain-
ing agents compared to placebo in every month (the shown p-values are re-
lated to the overall effect and not to I²). Furthermore, the forest plot shows 
that the study with more patients [33, 36] does not provide more precise es-
timated effect, due to a low weight of the study (small square) and a wide con-
fidence interval (long horizontal line). 
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In addition, another study assessed oedema by measuring the ankle and calf 
circumference (in mm) and by stating the number of legs with pitting oedema, 
whereby all values were reduced slightly more in the treatment groups than 
in the placebo groups during 2 months of treatment (in mm: -7 to -6 vs. ±0 to 
+2; number of legs: -13 vs. -1) [20]. 
Ulcer, another consequence of CVI, was measured as the recurrence rate which 
was slightly, but not statistically significantly, higher after 18 months of treat-
ment in the oxerutin group compared to the placebo group (34 vs. 32%) [38]. 
 
Study name Statistics for each study Sample size Mean difference, 95% CI 
 Difference 
in means 
Lower 
limit 
Upper 
limit 
Oxerutin Placebo  
Rehn 1996 (a) (300 mg HR) -11.10 -18.50 -3.70 20 10 
Rehn 1996 (a) (500 mg HR) -13.90 -20.78 -7.02 20 10 
Unkauf 1996/Großmann 1997 -29.00 -58.46 0.46 64 56 
Total (95% CI) -13.07 -18.03 -8.10 104 76 
  
Random effects meta-analysis; I²: 0.0%; p<0.001 Favours oxerutin Favours placebo 
Figure 3.1-1: Leg volume change (in ml) after 1 month for oxerutin-containing agents (+ compression stockings) vs. 
placebo (+ compression stockings) 
Study name Statistics for each study Sample size Mean difference, 95% CI 
 Difference 
in means 
Lower 
limit 
Upper 
limit 
Oxerutin Placebo  
Rehn 1996 (a) (300 mg HR) -20.40 -27.40 -13.40 20 10 
Rehn 1996 (a) (500 mg HR) -21.30 -29.17 -13.43 20 10 
Unkauf 1996/Großmann 1997 -20.20 -54.70 14.30 64 56 
Total (95% CI) -20.78 -25.95 -15.61 104 76 
  
Random effects meta-analysis; I²: 0.0%; p<0.001 Favours oxerutin Favours placebo 
Figure 3.1-2: Leg volume change (in ml) after 2 months for oxerutin-containing agents (+ compression stockings) vs. 
placebo (+ compression stockings) 
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Study name Statistics for each study Sample size Mean difference, 95% CI 
 Difference 
in means 
Lower 
limit 
Upper 
limit 
Oxerutin Placebo  
Rehn 1996 (a) (300 mg HR) -31.90 -40.49 -23.31 20 10 
Rehn 1996 (a) (500 mg HR) -31.30 -38.87 -23.73 20 10 
Unkauf 1996/Großmann 1997 -31.00 -68.72 1.72 64 56 
Total (95% CI) -31.55 -37.14 -25.95 104 76 
  
Random effects meta-analysis; I²: 0.0%; p<0.0001 Favours oxerutin Favours placebo 
Figure 3.1-3: Leg volume change (in ml) after 3 months for oxerutin-containing agents (+ compression stockings) vs. 
placebo (+ compression stockings) 
The symptoms of CVI, in general, were more reduced (on a score of 0-10) 
and improved (in %) in the oxerutin groups than in the placebo groups dur-
ing the first month of treatment (score: -5.4 to -2 vs. -1.9 to +0.2; percentage: 
97 vs. 60%) [20, 30-32]. The reduction or improvement was described as sta-
tistically significant [20, 32]. The meta-analysis of the symptom score reduc-
tion after 1 month is displayed in Figure 3.1-4. The forest plot is showing that 
the reduction of the symptom score and the difference is statistically signifi-
cant in favour of a treatment with oxerutin-containing agents compared to 
placebo. However, the meta-analyses shows also a high heterogeneity with 
I²>80%. That means the studies are measuring different effects due to e.g., 
differences in subject population or intervention. In addition, the reduction 
of the general symptom score in one study was higher in the treatment group 
after 2 months of treatment (-3.8 vs. -0.8). The difference between groups was 
statistically significant [20].  
The individual symptoms of CVI (score 0-10) could mostly be more reduced 
(was not stated if statistically significant) after 2 months (and also after 1 
month) of treatment in the oxerutin groups than in the placebo groups for 
pain (-2.7 vs. -0.3.), cramps (-3.7 vs. 1.7) and restless legs (-4.7 vs. -1) [20]. 
The scores (0-10) for itching, heaviness and swelling were improved slightly 
more (was not stated if statistically significant) after 3 months of treatment 
in the oxerutin groups compared to the placebo groups (itching: -2.2 to -0.9 
vs. -1.4; heaviness: -4.1 to -1 vs. -1.8 to -0.8; swelling: -4 to -1.2 vs. -1.7) [33, 
35, 36]. However, the reduction of scores for itching, heaviness and swelling 
after 1.5 months of treatment were slightly lower in the oxerutin groups than 
in the placebo groups (itching: -0.6 vs. -1; heaviness: -0.9 vs. -1.8; swelling: -
0.7 vs. -1.5) [33, 36]. The percentage of patients with improvement after 1 
month of treatment was in both study groups similar (and therefore not sta-
tistically significantly higher of lower in one group) for pain, cramps, itching 
and swelling (respective 100 vs. 100%) and slightly higher in the treatment 
groups than in the placebo groups for restless legs (100 vs. 80%) and heavi-
ness (89 vs. 67%) [32].The score after 1 month for paraesthesias could be re-
duced slightly more (was not stated if statistically significant) in the oxeru-
tin groups compared to placebo (-3.8 to -2.1 vs. -2) [35, 37]. 
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Study name Statistics for each study Sample size Mean difference, 95% CI 
 Difference 
in means 
Lower 
limit 
Upper 
limit 
Oxerutin Placebo  
Cloarec 1996  -1.73 -2.58 -0.88 53 51 
Cesarone 2002(a) (500 mg HR) -2 -3.24 -0.76 15 7 
Cesarone 2002(a) (1,000 mg HR) -2.90 -4.17 -1.63 16 8 
Cesarone 2002(b) -5.40 -6.64 -4.16 20 20 
Total (95% CI) -2.98 -4.60 -1.36 104 86 
  
Random effects meta-analysis; I²: 87.8%; p<0.001 Favours oxerutin Favours placebo 
Figure 3.1-4: Symptom change (score 0-10) after 1 month for oxerutin-containing agents (+ compression stockings) vs. 
placebo (+ compression stockings) 
 
Oxerutin-containing agents versus compression stockings only 
There was no evidence available assessing the change of the CVI stage, the 
CVI signs in general, trophic alternations and ulcer, CVI-related symptoms 
and quality of life for a treatment with oxerutin-containing agents compared 
to compression stockings. 
The only reported efficacy-related outcome was the leg volume (in ml). After 
4 months of treatment, leg volume was statistically significantly more reduced 
in the group that was wearing compression stockings (-230 ml) than in the 
group that received oxerutin-containing agents (-90 ml) [21]. 
 
Safety 
For evaluating the safety of oxerutin-containing capillary stabilising agents, 
we identified, besides 7 out of the 10 previously described RCTs, 2 addition-
al non-randomised controlled registry studies (non-RCTs) [39, 40] that met 
our inclusion criteria. The study characteristics and results of the non-RCTs 
are summarised in the Table 3.1-2. 
In the non-RCTs, a total of 432 patients were included in the studies, of whom 
98 received 500 mg of oxerutin-containing agents three times a day and 111 
received 1,000 mg of oxerutin-containing agents twice a day. In the control 
groups 133 of the patients were wearing compression stockings and 90 did 
not receive any treatment [39, 40]. The mean ages of the patients were 45 to 
46 years in the treatment and in the control groups [39, 40]. Around 60% of 
the patients in both groups were females [39]. The duration of treatment 
ranged from 2-60 months, whereas there was no follow-up after treatment 
[39, 40]. Furthermore, the drop-out rate in the oxerutin groups was 4-5% and 
in the control groups 7-8% [40]. 
A summary of the effect sizes for the individual outcome indicators is pre-
sented in Tables 3.1-3 to 3.1-5. 
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Oxerutin-containing agents (+ compression stockings) versus  
placebo (+ compression stockings) 
If reported, the general adverse events differed between 6 and 21% in the 
oxerutin groups and between 4 and 14% in the control groups. The most 
common adverse events in both groups were pain, gastrointestinal com-
plaints and nausea, plus muscle cramps for patients who were wearing stock-
ings [20, 33, 36]. 
There were no treatment-related adverse events in any of the study groups 
[30, 32, 35, 37]. 
 
Oxerutin-containing agents versus compression stockingsonly 
There were no general or treatment-related adverse events in neither the ox-
erutin group nor the group that was wearing compression stockings [21, 39, 
40]. 
 
Oxerutin-containing agents versus no treatment 
There was no available evidence that analysed adverse events in general of a 
treatment with oxerutin-containing agents compared to no treatment. 
However, there were no treatment-related adverse events in the oxerutin group 
or the group that did not receive a treatment [39]. 
 
Risk of bias 
The majority of the identified RCTs for a treatment of CVI with oxerutin-
containing agents have an unclear risk of bias for several types of biases (see 
Figure 3.1-5). Half of the studies show a high risk of reporting bias due to not 
reported baseline values, no reported scaling of outcome measurement or no 
detailed description of outcomes. In summary, the risk of bias is unclear. 
 
Figure 3.1-5: Risk of bias of RCTs for treatment of CVI with oxerutin-containing agents 
 
0% 25% 50% 75% 100%
Random sequence generation (selection bias)
Allocation conealment (selection bias)
Blinding (performance and detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Low risk of bias Unclear risk of bias High risk of bias
allgemeine 
unerwünschte 
Ereignisse:  
6-21 % vs. 4-14 % 
keine Nebenwirkungen 
keine unerwünschten 
Ereignisse oder 
Nebenwirkungen 
unerwünschte 
Ereignisse unberichtet 
keine Nebenwirkungen 
Bias-Risiko für RCTs 
insgesamt unklar 
Vasoprotectives 
56 LBI-HTA | 2014 
Partly, the non-RCTs have a high risk of selection bias due to a missing de-
scription of the allocated prognostic factors. Furthermore there is a high risk 
of performance and detection bias due to no blinding of the studies. There is 
also an existing risk of reporting bias due to a missing analysis of confound-
ing (see Figure 3.1-6). 
 
Figure 3.1-6: Risk of bias of non-randomised controlled studies for treatment of CVI with oxerutin-containing agents 
 
Strength of evidence 
Overall, the strength of evidence of the efficacy and safety of a treatment of 
CVI with oxerutin-containing agents compared to placebo, compression ther-
apy and no treatment (only safety) is low to very low. Although the majority 
of studies were RCTs, due to several study limitations and a low number of 
patients in the studies, the strength of evidence was downgraded. The strength 
of evidence is summarised in the Tables 3.1-3, 3.1.-4 and 3.1-5. 
There was no evidence available to compare a treatment of CVI with oxeru-
tin-containing agents with other interventions, such as lifestyle changes or 
further local, medical and surgical treatment, mentioned in Chapter 1.1.2. 
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Table 3.1-3: Evidence profile: Efficacy and safety of oxerutin-containing agents for treatment of CVI compared to placebo 
No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: oxerutin-containing agents (+ compression stockings) versus placebo (+ compression stockings) 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): change at foot from baseline (score 0-10) 
1/40 RCT 1 mo: -1 vs.-1.7; p=n/a Serious limitations (-1)37 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI signs (oedema): change at ankle from baseline (score 0-10) 
1/40 RCT 1 mo: -0.2 vs. -1.3; p=n/a Serious limitations (-1)37 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI signs (oedema): general change from baseline (score 0-10) 
1/60 RCT 1 mo: -3.33 vs. -1.33; p=n/a Serious limitations (-1)39 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI signs (oedema): leg volume change from baseline (in ml) 
2/180 
2/180 
2/180 
1/120 
RCTs 
RCTs 
RCTs 
RCT 
1 mo: -4.6 to -53.9 vs. -24.9 to +6.5; p=S.S.  
2 mo: -48.9 to -23 vs. -2.6 to -28.7; p=S.S. 
3 mo: -63.9 to -29.8 vs. +2.1 to +8.6; p=S.S. 
4.5 mo: -32.2 vs. -8.3; p=N.S. 
Serious limitations (-1)40 
Serious limitations (-1)40 
Serious limitations (-1)40  
Serious limitations (-1)40 
Important inconsistency (-1)41 
No important inconsistency 
No important inconsistency 
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Very low 
Low 
Low 
Low 
CVI signs (oedema): number of legs change from baseline 
1/104 RCT 1 mo: -2 vs. ±0; p=n/a 
2 mo: -13 vs. -1; p=n/a 
Serious limitations (-1)42 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI signs (oedema): calf/ankle circumference change from baseline (in mm) 
1/104 RCT 1 mo: -3/-2 vs. ±0/±0; p=S.S./p=S.S. 
2 mo: -7/-6 vs. ±0/+2; p=S.S./p=S.S. 
Serious limitations (-1)42 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
                                                             
37
 Unclear random sequence generation and blinding of outcome assessors (patients were asked to evaluate signs and symptoms). 
38
 Low incidence, study/studies not powered to detect difference. 
39
 Unclear blinding of participants, personnel and outcome assessor, plus random sequence generation. 
40
 Unclear random sequence generation in one trial, the other study was conducted as single-blind and unclear blinding of outcome assessment in both studies. 
41
 Values of control group increased in one study and decreased in the other study. 
42
 Unclear random sequence generation and blinding of outcome assessors. 
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No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI signs (ulcer): recurrence rate (in %) 
1/138 RCT 12 mo: 23 vs. 22; p=N.S. 
18 mo: 34 vs. 32; p=N.S. 
Serious limitations (-1)42 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (general): improvement (in %) 
1/20 RCT 1 mo: 97 vs. 60; p=S.S. Serious limitations (-1)43 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (general): change from baseline (score 0-10) 
3/190 
1/104 
RCT 
RCT 
1 mo: -5.4 to -2 vs. -1.9 to +0.2; p=S.S.44 
2 mo: -3.8 vs. -0.8; p=S.S.44 
Serious limitations (-1)45 
Serious limitations (-1)42 
Important inconsistency (-1)41 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Very low 
Low 
CVI symptoms (pain): improvement (in %) 
1/20 RCT 1 mo: 100 vs. 100; p=N.S. Serious limitations (-1)43 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (pain): change from baseline (score 0-10) 
2/144 
1/104 
RCT 
RCT 
1 mo: -1.3 to -1 vs. -0.4 to -0.3; p=n/a46 
2 mo: -2.7 vs. -0.3; p=n/a46 
Serious limitations (-1)47 
Serious limitations (-1)42 
No important inconsistency  
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Low 
Low 
CVI symptoms (cramps): improvement (in %) 
1/20 RCT 1 mo: 100 vs. 25; p=N.S. Serious limitations (-1)43 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (cramps): change from baseline (score 0-10) 
3/204 
1/104 
RCT 
RCT 
1 mo: -4 to -1.7 vs. -3.5 to -0.7; p=N.S. in one study48 
2 mo: -3.7 vs. 1.7; p=n/a46 
Serious limitations (-1)49 
Serious limitations (-1)42 
No important inconsistency  
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Low 
Low 
CVI symptoms (restless legs): improvement (in %) 
1/20 RCT 1 mo: 100 vs. 80; p=n/a Serious limitations (-1)43 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (restless legs): change from baseline (score 0-10) 
                                                             
43
 Unclear blinding of outcome assessor. 
44
 The score in one study was 0-15; the values were multiplied with 0.67 to adopt them to a score of 0-10. 
45
 Unclear random sequence generation in all 3 studies and unclear blinding of outcome assessor in 1 study. 
46
 The scores of studies on a scale of 0-3 were multiplied with 3.33 to adopt them to a score of 0-10. 
47
 Unclear random sequence generation in both studies and unclear blinding of outcome assessor in 1 study. 
48
 The score in two studies was 0-3, the values were multiplied with 3.33 to adopt them to a score of 0-10. 
49
 Unclear random sequence generation in and unclear blinding of outcome assessor all 3 studies. 
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No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
2/144 
1/104 
RCT 
RCT 
1 mo: -2.7 to -0.8 vs. -1 to -0.5; p=n/a46 
2 mo: -4.7 vs. -1; p=n/a46 
Serious limitations (-1)47 
Serious limitations (-1)42 
No important inconsistency  
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Low 
Low 
CVI symptoms (itching): improvement (in %) 
1/20 RCT 1 mo: 100 vs. 100; p=N.S. Serious limitations (-1)43 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (itching): change from baseline (score 0-10) 
1/120 
1/120 
2/180 
1/120 
RCT 
RCT 
RCT 
RCT 
1 mo: -0.9 vs. -0.4; p=n/a 
2 mo: -0.8 vs. -0.7; p=n/a 
3 mo: -2.2 to -0.9 vs. -1.4; p=n/a 
4.5 mo: -0.6 vs. -1; p=n/a 
Serious limitations (-1)50 
Serious limitations (-1)50 
Serious limitations (-1)51 
Serious limitations (-1)50 
n/a (only 1 trial) 
n/a (only 1 trial) 
No important inconsistency  
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Low 
Low 
Low 
Low 
CVI symptoms (heaviness): improvement (in %) 
1/20 RCT 1 mo: 89 vs. 67; p=n/a Serious limitations (-1)43 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (heaviness): change from baseline (score 0-10) 
3/284 
2/224 
2/180 
1/120 
RCT 
RCT 
RCT 
RCT 
1 mo: -3.8 to -1.5 vs. -3.8 to -0.8; p=s.s in one study46 
2 mo: -3.7 to -1 vs. -1.4 to -0.3; p=n/a46 
3 mo: -4.1 to -1 vs. -1.8 to -0.8; p=n/a 
4.5 mo: -0.9 vs. -1.8; p=n/a 
Serious limitations (-1)52 
Serious limitations (-1)53 
Serious limitations (-1)54 
Serious limitations (-1)50 
No important inconsistency  
No important inconsistency  
No important inconsistency  
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Low 
Low 
Low 
Low 
CVI symptoms (swelling): improvement (in %) 
1/20 RCT 1 mo: 100 vs. 100; p=N.S. Serious limitations (-1)43 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI symptoms (swelling): change from baseline (score 0-10) 
2/224 
2/224 
2/180 
1/120 
RCT 
RCT 
RCT 
RCT 
1 mo: -2.3 to -1.2 vs. -1; p=n/a46 
2 mo: -4 to -1 vs. -1.3 to -1; p=n/a46 
3 mo: -4 to -1.2vs. -1.7; p=n/a 
4.5 mo: -0.7 vs. -1.5; p=n/a 
Serious limitations (-1)53 
Serious limitations (-1)53 
Serious limitations (-1)54 
Serious limitations (-1)50 
No important inconsistency  
No important inconsistency  
No important inconsistency  
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Imprecise data (-1)38 
Low 
Low 
Low 
Low 
                                                             
50
 Unclear random sequence generation and blinding of outcome assessor. 
51
 Unclear random sequence generation in one study, one study was conducted as single-blinded and unclear blinding of outcome assessor in one study. 
52
 Unclear random sequence generation in all 3 studies and unclear blinding of outcome assessor in 2 studies. 
53
 Unclear random sequence generation and unclear blinding of outcome assessor in 1 study. 
54
 Unclear random sequence generation in one study, one study was conducted as single-blinded and unclear blinding of outcome assessor in both studies. 
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No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI symptoms (paraesthesias): change from baseline (score 0-10) 
2/100 RCT 1 mo: -3.8 to -2.1 vs. -2; p=n/a Serious limitations (-1)55 No important inconsistency  Direct Imprecise data (-1)38 Low 
Quality of life: no evidence 
Safety: oxerutin-containing agents (+ compression stockings) versus placebo (+ compression stockings) 
Adverse events (general): in % 
2/224 RCT 6 to 21 vs. 4 to 14; p=n/a Serious limitations (-1)55 No important inconsistency  Direct Imprecise data (-1)38 Low 
Adverse events (treatment-related): in % 
4/160 RCT 0 vs. 0; p=N.S. Serious limitations (-1)56 No important inconsistency  Direct Imprecise data (-1)38 Low 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
  
                                                             
55
 Unclear random sequence generation and unclear blinding of outcome assessor in both studies. 
56
 Unclear random sequence generation in 3 studies and unclear blinding of outcome assessor in all studies. 
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Table 3.1-4: Evidence profile: Efficacy and safety of oxerutin-containing agents for treatment of CVI compared to compression stockings 
No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: oxerutin-containing agents versus compression stockings alone 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): leg volume change from baseline (in ml) 
1/24 RCT 1 mo: -29 vs. -254; p=S.S. (in favour of stockings) 
4 mo: -90 vs. -230; p=S.S. (in favour of stockings 
Serious limitations (-1)57 n/a (only 1 trial) Direct Imprecise data (-1)38 Low 
CVI signs (ulcer): no evidence 
CVI symptoms: no evidence 
Quality of life: no evidence 
Safety: oxerutin-containing agents versus compression stockings alone 
Adverse events (general): in % 
2/34258 CT 0 vs. 0; p=N.S. Serious limitations (-1)59 No important inconsistency Direct Imprecise data (-1)38 Very low 
Adverse events (treatment-related): in % 
1/24 
3/34258 
RCT 
CT 
0 vs. 0; p=N.S. 
0 vs. 0; p=N.S. 
Serious limitations (-1)57 
Serious limitations (-1)59 
n/a (only 1 trial) 
No important inconsistency 
Direct 
Direct 
Imprecise data (-1)38 
Imprecise data (-1)38 
Low 
Very low 
Abbreviations: CT = controlled trial; n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
  
                                                             
57
 Unclear random sequence generation and unclear blinding of outcome assessor. 
58
 One study consisted of four study groups, whereas one group (90 patients) did not receive a treatment and was therefore excluded from this analysis. 
59
 Studies were conducted as not blinded (and not randomised). 
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Table 3.1-5: Evidence profile: Safety of oxerutin-containing agents for treatment of CVI compared to no treatment 
No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Safety: oxerutin-containing agents versus no treatment 
Adverse events (general): in % 
1/18560 CT 0 vs. 0; p=N.S. Serious limitations (-1)61 No important inconsistency Direct Imprecise data (-1)38 Very low 
Adverse events (treatment-related): in % 
1/18560 CT 0 vs. 0; p=N.S. Serious limitations (-1)61 No important inconsistency Direct Imprecise data (-1)38 Very low 
Abbreviations: CT = controlled trial; n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
                                                             
60
Study consisted of four study groups, whereas one group (113 patients) received a treatment with compression stockings and was therefore excluded from this analysis. 
61
Study was conducted as not blinded (and not randomised). 
Results 
LBI-HTA | 2014 63 
3.1.2 Flavonoid fraction-containing agents 
Study characteristics 
For evaluating the efficacy and safety of flavonoid fraction-containing capil-
lary stabilising agents for a treatment of CVI, we identified 1 meta-analysis 
[42], 8 RCTs [43-49], 1 additional non-randomised controlled study [50] and 
5 single-arms studies [51-55] that met our inclusion criteria.  
Two of these RCTs are summarised in one study [45]. Furthermore, two ex-
tracted RCTs [43, 49] are already included in the meta-analysis, thus the out-
comes that are included in the meta-analysis and the RCTS will not be men-
tioned twice (marked grey in the extraction Table 3.1-6). Two single-arm stud-
ies reported the results of the same study with different information and were 
therefore merged [51, 53]. 
The included studies are comparing flavonoid fraction-containing agents with 
either placebo or no treatment [42-50] for the treatment of CVI.  
The dosage of drugs was similar in every study: 500 mg two times a day [42-55]. 
The study characteristics and results are summarised in Table 3.1-6 for RCTs 
and in Table 3.1-7 for non-randomised controlled trials and single-arm stud-
ies.  
There were no studies identified comparing flavonoid fraction-containing 
agents with other interventions, such as lifestyle changes or further local, 
medical and surgical treatment, mentioned in Chapter 1.1.2. 
 
 
 
1 Meta-Analyse,  
8 RCTs, 1 non-RCT,  
5 Ein-Arm-Studien mit 
13.613 PatientInnen 
eingeschlossen 
 
zwei RCTs bereits in 
Meta-Analyse 
Vergleich: Placebo oder 
keine Behandlung 
Dosis: 500 mg 2x täglich 
Studienergebnisse in 
Extraktionstabellen 
keine Studien  
mit anderen 
Vergleichsgruppen 
  
V
aso
pro
tectives 
6
4
 
LB
I-H
T
A
 | 20
14
 
Table 3.1-6: Efficacy and safety-related outcomes of a meta-analysis and randomised controlled trials of flavonoid fraction-containing agents vs. placebo or compression stockingsor surgery for CVI 
Author, year,  
reference number 
Boineau-Geniaux 
1988 [47] 
Laurent  
1988 [45] 
Burnand  
1989 [46] 
Guilhou  
1997 [43] 
Danielsson  
2002 [44] 
Roztocil  
2003 [49] 
Coleridge-Smith 
2005 [42] 
Veverková  
2006 [48] 
Country France France UK France Sweden Czech Republic, 
Slovakia 
UK, France, 
Switzerland 
Czech Republic 
Study design RCT 2 RCTs62 RCT RCT RCT RCT Meta-Analysis63 RCT 
Sponsor n/a n/a n/a n/a IRIS n/a Servier n/a 
Intervention/ 
Product 
2x 500 mg MPFF 
(Daflon®) per day 
2x 500 mg MPFF 
(Daflon®) per day 
2x 500 mg MPFF 
(Daflon®) per day 
2x 500 mg MPFF 
(Daflon®) per 
day64 
2x 500 mg MPFF 
(Daflon®) per day 
2x 500 mg MPFF 
(Daflon®) per day 
+ compression 
stockings 
2x 500 mg MPFF 
(Daflon®) per day 
+ compression 
stockings 
2x 500 mg MPFF 
(Daflon®) per day 
+ surgery65 
Comparator Placebo Placebo Placebo Placebo Placebo Compression 
stockings  
2 RCTs: Placebo + 
compression 
stockings 
3 RCTs: no treat-
ment + compres-
sion stockings 
No treatment + 
surgery 
Number of pts 16 vs. 20 100 vs. 100 24 vs. 25 52 vs. 55 51 vs. 50 82 vs. 68 723 92 vs. 89 
Age of patients 
(yrs.) 
Ø 59 Ø 49 Ø 53 Ø 71 vs. 71 Ø 48 vs. 48 Ø 64 vs. 65 Ø 65 n/a 
Sex (% female) 78 87 58 vs. 68 62 vs. 76 76 vs. 68 77 vs. 57 5866 n/a 
Height (cm)/ 
Weight (kg)/ 
BMI (kg/m²) 
n/a / n/a / n/a n/a / n/a / n/a n/a / n/a / n/a n/a / n/a / n/a n/a / n/a / n/a 168 vs. 170 / 88 vs. 
87 / 31 vs. 30 
n/a / n/a / n/a n/a / n/a / n/a 
Clinical 
classification 
n/a n/a n/a Grade III acc. to 
Widmer 
C1-6 (CEAP 
classification) 
n/a C6 (CEAP 
classification) 
n/a 
Primary endpoint n/a n/a n/a Complete healing 
of the reference 
ulcer 
n/a Fully healed ulcers 
after 6 months and 
time to complete 
healing 
Complete ulcer 
healing after  
6 months 
n/a 
                                                             
62
 Study summarised the results of two RCTs, published in 1987 in French (Frileux, C. and Gilly, R.). 
63
 Meta-analysis of five RCTs. two never published and three published RCTS (Guilhou et al. 1997 [43], Glinski et al. 1999 and Roztocil et al. 2003 [49]).  
Since not all outcomes of Guilhou et al. and Roztocil et al. were reported in the meta-analysis, the two studies were extracted separately in this report. 
64
 Wearing compression stockings was allowed. 
65
 All patients of this study were undergoing varicose vein stripping. The intervention group was treated with MPFF und the control group did not receive MPFF.  
Medical treatment started 2 weeks before surgery and ended 2 weeks after surgery. 
66
 Rate was only stated for all studies together. 
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Author, year,  
reference number 
Boineau-Geniaux 
1988 [47] 
Laurent  
1988 [45] 
Burnand  
1989 [46] 
Guilhou  
1997 [43] 
Danielsson  
2002 [44] 
Roztocil  
2003 [49] 
Coleridge-Smith 
2005 [42] 
Veverková  
2006 [48] 
Inclusion criteria n/a Trials with one 
single aetiology, 
precise definition 
of each symptom, 
stable patients for 
at least the 6 
previous months, 
informed consent 
Patients with 
abnormal half-
volume refilling 
time on foot 
volumetry + ankle 
to arm arterial 
Doppler pressure 
ratio <1 
Patients of both 
sexes, aged 18-85 
years, agree to 
wear compression 
stockings with 
ulcer of chronic 
venous origin 
Patients, aged  
18-65 years, 
symptoms of CVI 
in the lower leg 
Ambulatory male 
and female 
patients, aged  
≥18 years, with 
primary or 
secondary varicose 
ulcer(s) with 
diameter 2-10 cm 
for ≥3 months 
Patients with clinical 
signs of venous leg 
ulceration (e.g., 
hyperpigmentation, 
lipodermato-
sclerosis and ulcer 
located in gaiter 
region), previous 
history of varicose 
veins or post-
thrombotic 
syndrome, duration 
of ulcer at least  
3 months  
Patients, aged 18-
60 yrs., scheduled 
to undergo 
stripping of the 
great saphenous 
vein (due to CVI) 
Duration of 
Treatment 
(months) 
2 2 1 2 (or less) 2 667 2-6 1 
Follow-up 
(months) 
0 0 0 0 0 0 n/a 0 
Drop-outs, n (%) 0 (0) vs. 1 (5) 1 (1) vs. 2 (2) n/a 2 (4) vs. 4 (7) 3 (6) vs. 1 (2) 2 (2) vs. 16 (24) n/a n/a 
Efficacy-related outcomes 
Change of CVI stage n/a n/a n/a n/a n/a n/a n/a n/a 
CVI signs 
(general) 
n/a n/a n/a n/a n/a n/a n/a n/a 
Trophic 
alterations 
Improved pts. 
(%)68: 
Baseline: - 
After 1 month: n/a 
After 2 months: 
88 vs. 21; p=n/a 
After 3; 6; 12 
months: n/a 
n/a n/a n/a n/a n/a n/a n/a 
                                                             
67
 The study started with a run-in-phase of two weeks where patients had to stop any unauthorized treatment, followed by a 6 month treatment phase. 
68
 Measurement for trophic alternations was given as percentage of patients (in %) with improvement (for ulcer, dermitis and hypodermitis). 
  
V
aso
pro
tectives 
6
6
 
LB
I-H
T
A
 | 20
14
 
Author, year,  
reference number 
Boineau-Geniaux 
1988 [47] 
Laurent  
1988 [45] 
Burnand  
1989 [46] 
Guilhou  
1997 [43] 
Danielsson  
2002 [44] 
Roztocil  
2003 [49] 
Coleridge-Smith 
2005 [42] 
Veverková  
2006 [48] 
Oedema  
(or leg volume 
or 
circumference) 
Ankle 
circumference: 
Baseline: n/a 
After 1 month: n/a 
After 2 months: 
n/a; p<0.0569 
After 3; 6; 12 
months: n/a 
Ankle 
circumference 
(mm)70: 
Baseline: n/a 
After 1 month: -4.1 
vs. -0.7; p=n/a 
After 2 months:-
6.5 vs. -0.8; p=n/a 
After 3; 6; 12 
months: n/a 
Leg volume 
(ml)71:  
Baseline: 1,088 vs. 
1,206; p=n/a 
After 1 month: 
1,098 vs. 1,200; 
p=n/a 
After 2; 3; 6; 12 
months: n/a 
n/a Leg volume 
(ml)72: 
Baseline: n/a 
After 1 month: n/a 
After 2 months: 
+11.9 vs. +4.4: 
p=N.S. 
After 3; 6; 12 
months: n/a 
n/a n/a Oedema decrease 
(%): 
Baseline: - 
After 1 month: 84 
vs. n/a; p<0.001 
After2; 3; 6; 12 
months: n/a 
Ulcer n/a n/a n/a Healing rate 
(%)73: 
Baseline: - 
After 1 month: n/a 
After 2 months: 32 
vs. 13; p=0.028 
After 3; 6; 12 
months: n/a 
n/a Healing rate 
(%)74: 
Baseline: - 
After 1 month: n/a 
After 2 months: 27 
vs. 13; p<0.05 
After 3 months: 
44 vs. 28; p<0.05 
After 6 months: 
65 vs. 41; p<0.01 
After 12 months: 
n/a 
Reduction ulcer 
size (%): 
After 1; 2; 3 
months: n/a 
After 6 months: 77 
vs. 69; p=0.012 
After 12 months: 
n/a 
Healing rate 
(%)75: 
Baseline: - 
After 1; 2; 3 
months: n/a 
After 6 months: 61 
vs. 48 (RR 32%; CI 
3-70%); p=0.014 
After 12 months: 
n/a 
n/a 
                                                             
69
 Measurement for oedema was given only as p-value of variation between the study groups for ankle circumference. 
70
 Measurement for oedema was given as reduction in ankle circumferences from baseline (in mm). 
71
 Measurement for oedema was given as foot volume (in ml), measured by water displacement. 
72
 Measurement for oedema was given as reduction in leg volume from baseline (in ml). 
73
 Measurement for ulcer was given in % of patients with complete healing. 
74
 Measurement for ulcer was given in % of patients with complete healing. Reduction of the ulcer size after 6 months was 77% vs. 69% (p=0.012). 
75
 Measurement for ulcer was given in % of patients with complete healing. Only four RCTs were considered for this outcome. 
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Author, year,  
reference number 
Boineau-Geniaux 
1988 [47] 
Laurent  
1988 [45] 
Burnand  
1989 [46] 
Guilhou  
1997 [43] 
Danielsson  
2002 [44] 
Roztocil  
2003 [49] 
Coleridge-Smith 
2005 [42] 
Veverková  
2006 [48] 
CVI symptoms 
(general) 
Improved pts. 
(%)76: 
Baseline: - 
After 1 month: 48 
vs. 31; p=n/a 
After 2 months: 35 
vs. 67; p=n/a 
After 3; 6; 12 
months: n/a 
Improvement 
(%)77: 
Baseline:- 
After 1 month: 49 
vs. 24; p=n/a 
After 2 months: 
69 vs. 37; p=S.S. 
After 3; 6; 12 
months: n/a 
n/a n/a Improved pts. 
(%)78: 
Baseline:- 
After 1 month: n/a 
After 2 months: 
44 vs. 33; p=N.S.  
After 3; 6; 12 
months: n/a 
n/a n/a n/a79 
Pain n/a n/a n/a n/a n/a n/a n/a n/a80 
Cramps n/a n/a n/a n/a Improved pts. 
(%): 
Baseline: - 
After 1 month: n/a 
After 2 months: 
n/a p=S.S. 
After 3; 6; 12 
months: n/a 
n/a n/a n/a 
Restless legs n/a n/a n/a n/a n/a n/a n/a n/a 
Itching  
(= tingling 
sensation) 
n/a n/a n/a n/a n/a n/a n/a Improvement 
(%)81: 
Baseline: - 
After 1 month: 92 
vs. n/a; p<0.001 
After 3; 6; 12 
months: n/a 
                                                             
76
 Symptoms were measured on a score (0-3), but only the percentage of patients (in %) with regressed symptoms was stated. 
77
 Symptoms were measured on a score (0-3) for discomfort, heaviness, pain, cramps, paraesthesia, oedema and skin redness, whereas only the overall symptom reduction (in %) was stated. 
78
 Symptoms were measured with a scale (0-3), whereas only the percentage of patients (in %) with reduced score for general symptoms were reported. 
79
 Symptoms were measured on a 10-cm visual analogue scale (VAS) at baseline and after 1 month of treatment. 
80
 Pain was measured, whereas only the values one day and 8 days after surgery were stated. 
81
 Measured as decrease in percent (%) from baseline. 
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Author, year,  
reference number 
Boineau-Geniaux 
1988 [47] 
Laurent  
1988 [45] 
Burnand  
1989 [46] 
Guilhou  
1997 [43] 
Danielsson  
2002 [44] 
Roztocil  
2003 [49] 
Coleridge-Smith 
2005 [42] 
Veverková  
2006 [48] 
Heaviness 
(=heavy legs) 
n/a n/a n/a Patients (%)82: 
Baseline: n/a 
After 1 month: n/a 
After 2 months: 4 
vs. 17; p=0.03 
After 3; 6; 12 
months: n/a 
n/a Score (0-3)83: 
Baseline: 2.3 vs. 
2.0: p<0.001 
After 1 month: 1.7 
vs. 1.8; p<0.05 
After 2; 3 months: 
n/a 
After 6 months: 
1.5 vs. 1.7; p<0.01 
After 12 months: 
n/a 
n/a Improvement 
(%)81: 
Baseline: - 
After 1 month: 89 
vs. n/a; p<0.001 
After 3; 6; 12 
months: n/a 
Swelling 
(=sensation of 
tension) 
n/a n/a n/a n/a n/a n/a n/a n/a 
Paraesthesias n/a n/a n/a n/a n/a n/a n/a n/a 
QoL n/a n/a n/a n/a n/a n/a n/a Improved pts.(%): 
Baseline84: - 
After 1 month: 21 
vs. 3; p=n/a 
After 3; 6; 12 
months: n/a 
Safety-related outcomes 
Adverse events, 
general in % (n) 
pts. 
6 (1) vs. 5 (1); 
p=n/a 
(headache vs. 
nausea) 
9 (9) vs. 13 (13); 
p=n/a 
(nausea, 
headache, pain, 
insomnia, 
hypotension in 
both groups) 
n/a 12 (6) vs. 9 (5); 
p=n/a  
(venous 
thrombosis, skin 
changes around 
ulcer, asthenia, 
headache, 
exacerbation of 
chronic colopathy 
vs. eczema, 
urticaria, pruritus 
of the scalp, pain) 
n/a n/a n/a n/a 
                                                             
82
 Results for heaviness includes also atonic aspect of the ulcer. Only the percentage of patients (in %) with heaviness and atonic aspect at the end of the treatment phase was given. 
83
 Heaviness was measured on a 4-item scale (0-3).  
84
 QoL was measured with a 20-question quality of life questionnaire (CIVIQ), results are given in percentage of patients (in %) with better QoL than before treatment. 
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Author, year,  
reference number 
Boineau-Geniaux 
1988 [47] 
Laurent  
1988 [45] 
Burnand  
1989 [46] 
Guilhou  
1997 [43] 
Danielsson  
2002 [44] 
Roztocil  
2003 [49] 
Coleridge-Smith 
2005 [42] 
Veverková  
2006 [48] 
Major adverse 
events 
n/a n/a n/a n/a n/a n/a n/a n/a 
Minor adverse 
events 
n/a n/a n/a n/a 12 (6) vs. 4 (2); 
p=n/a 
(types of events 
not stated) 
n/a n/a n/a 
Adverse events, 
treatment-related 
in % (n) pts. 
n/a n/a n/a 8 (4) vs. 9 (5); 
p=n/a 
(skin changes 
around ulcer, 
asthenia, 
headache, 
exacerbation of 
chronic colopathy 
vs. eczema, 
urticaria, pruritus 
of the scalp, pain) 
n/a 0 vs. n/a; p=n/a n/a n/a 
Major adverse 
events 
n/a n/a n/a n/a n/a n/a n/a n/a 
Minor adverse 
events 
n/a n/a n/a n/a n/a n/a n/a n/a 
Abbreviations: acc. = according; CVI = chronic venous insufficiency; MPFF = micronised purified flavonoid fraction; n = number (of patients); n/a = data not available;  
N.S. = not statistically significant; pts. = patients; QoL = quality of life; RCT = randomised controlled trial; SLT = standard local therapy (mostly wound cleaning and application of saline);  
vs. = versus; yrs. = years 
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Table 3.1-7: Safety-related outcomes of non-randomised trials of flavonoid fraction-containing agents for CVI 
Author, year,  
reference number 
Guillot 1989 [51] 
Pointel 1988 [53] Roux 1990 [55] Pinjala 2004 [52] Saveljev 2008 [50] Navrátilová 2010 [54] 
Country France France India Russia Czech Republic 
Study design Single-arm study Single-arm study Single-arm study Non-randomised controlled 
study 
Single-arm study 
Sponsor n/a n/a Serdia Pharmaceuticals n/a n/a 
Intervention/Product 2x 500 mg MPFF (Daflon®) 
per day 
2x 500 mg MPFF (Daflon®) 
per day 
2x 500 mg MPFF (Daflon®) 
per day 
2x 500 mg MPFF (Daflon®) 
per day + surgery85 
2x 500 mg MPFF (Daflon®) 
per day 
Comparator none none none No treatment + surgery none 
Number of pts 215 11,342 308 200 vs. 45 213 
Age of patients (yrs.)  Ø 47 Ø 50 Ø 43 Ø 42 vs. 43 Ø 48 
Sex (% female) 87 87 58 100 92 
Height (cm)/Weight (kg)/ 
BMI (kg/m²) 
164 / 62 / n/a 164 / 65 / n/a n/a / n/a / n/a n/a / n/a / 24.5 vs. 24.9 169 / 77 / 27 
Clinical classification n/a n/a CEAP classification 0-4 CEAP classification C 2 CEAP classification C3 
Primary endpoint n/a n/a n/a n/a Ankle and calf 
circumferences 
Inclusion criteria Patients of both sexes, aged 
19-81 years, suffering from 
functional symptoms of 
venous insufficiency. 
n/a Outpatients with at least 
one symptom with or 
without signs of CVI 
corresponding to CEAP 
classification 0-4, untreated 
for at least 15 days. 
Female patients, aged 25-60 
yrs., CEAP classification C2, 
ultrasound angiological 
features of reflux and 
unilateral lesion in the great 
saphenous vein, clinical 
symptoms 
Patients of both sexes, aged 
≥18 yrs., with venous 
oedema without skin 
changes 
Duration of treatment 
(months) 
12 2 6 1.5 686 
Follow-up (months) 0 0 0 0 0 
Drop-outs, n (%) 45 (36) n/a 20 (6.5) n/a 17 (8) 
                                                             
85
 All patients of this study were undergoing varicose vein stripping. The intervention group was treated with MPFF und the control group did not receive MPFF.  
Medical treatment started 2 weeks before surgery and ended 4 weeks after surgery. All patients had to wear compression stockings. 
86
 Study started with a run-in phase without treatment of 2 weeks. 
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Author, year,  
reference number 
Guillot 1989 [51] 
Pointel 1988 [53] Roux 1990 [55] Pinjala 2004 [52] Saveljev 2008 [50] Navrátilová 2010 [54] 
Safety-related outcomes 
Adverse events,  
general in % (n) pts. 
9 (20) 
(gastralgia, dizziness, 
gynaecological signs, 
cutaneous eruption) 
n/a 6 (12) 
(dyspepsia, nausea, 
giddiness, ankle oedema, 
breathlessness, low pulse 
rate, headache) 
0 (0) vs. 0(0) n/a 
Major adverse events n/a n/a n/a 0 (0) vs. 0(0) n/a 
Minor adverse events n/a n/a n/a 0 (0) vs. 0(0) n/a 
Adverse events, treatment-
related in % (n) pts. 
n/a 3.3 (374) 
(types of events not stated) 
n/a 2 (4) vs. n/a, p=n/a 
(gastric irritation vs. n/a) 
0 (0) 
Major adverse events n/a n/a n/a 0 (0) vs. 0(0) 0 (0) 
Minor adverse events n/a n/a n/a n/a 0 (0) 
Abbreviations: CVI = chronic venous insufficiency, MPFF = micronised purified flavonoid fraction;n = number (of patients); n/a = data not available; pts. = patients; yrs. = years 
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Efficacy 
For evaluating the efficacy of flavonoid fraction-containing capillary stabilis-
ing agents, we identified 1 meta-analysis [42]and 8 RCTs [43-48, 56] that met 
our inclusion criteria.  
Overall, there were 1,290 patients in the studies (without the two studies al-
ready included in the meta-analysis). All patients in the treatment groups 
received 500 mg MPFF (Daflon
®
) per day [42, 44-48]. Patients in the control 
groups received either placebo [42, 44-47], were treated with compression stock-
ings alone [42] or did not receive a treatment [48]. Furthermore, one study 
was conducted before and after surgery [48]. The patients were on average be-
tween 48 and 71 years in the treatment groups and in the control groups, re-
spectively [42-49]. The majority of the patients were females: 58-87% [42-49]. 
Furthermore, the CVI grade was stated in the meta-analysis (C6 after the CEAP 
classification, see Chapter 1.1.2) [42] and in one additional RCT (C1 to 6 after 
the CEAP classification) [44]. The duration of treatment was 1-6 months. No 
study had a follow-up without treatment [42-49] and the drop-out rate differed 
between 0 and 6% in the treatment groups and 2 and 24% in the control groups 
[43-45, 47, 49]. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Tables 3.1-8 to 3.1-10. 
 
Flavonoid fraction-containing agents (+ compression stockings) versus 
placebo (+ compression stockings) 
None of the identified studies assessed the change of the CVI stage, the CVI 
signs in general, several symptoms of CVI: pain, restless legs, itching, swell-
ing plus paraesthesia, and the quality of life of a treatment with flavonoid frac-
tion-containing agents versus placebo. 
Trophic alternations, a typical sign of CVI, were measured in 1 study as im-
proved patients (in %) after 2 months, whereby 88% patients in the treatment 
group and 21% in the control group had an improvement [47]. It was not stat-
ed whether the difference was statistically significant or not. 
Regarding the other signs of CVI, oedema was assessed in 4 studies and meas-
ured by two different parameters. In two studies oedema was measured by leg 
volume (in ml), whereby in one study the volume increased during 1 month 
of treatment in the flavonoid group and decreased in the placebo groups (+10 
vs. -6 ml) [46] and in the other study, leg volume increased during 2 months 
of treatment in both study groups (+12 vs. +4 ml) [44]. It was not stated 
whether the differences of the volume changes were statistically significant. 
In addition, two other studies assessed oedema by measuring the ankle cir-
cumference (in mm) [45, 47]. However, only 1 study allowed the appraisal of 
the change from baseline until 1 month of treatment: The reduction of the 
ankle circumference was slightly higher in the treatment group than in the 
placebo group (-4 vs. -1 mm) [45]. However, it was not stated whether the 
difference between the groups was statistically significant. 
Ulcer, another consequence of CVI, was reported in the meta-analysis (based 
on the results of 2 RCTs) in terms of the healing rate (in %) which was high-
er after 2 months of treatment in the flavonoid fraction group compared to 
the control group in one study (25.5 vs. 11.5%) and lower in the treatment 
compared to the control group in the other study (20.4 vs. 25.3%) [42]. It was  
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not possible to identify whether the differences between the study groups were 
statistically significant or not, since the systematic review summarised the re-
sults across studies with different comparators. 
The symptoms of CVI, in general, were measured in 3 studies after 1 and 2 
months of treatment. The improvement of the general symptoms after 2 
months (reported in one study) was statistically significantly higher in the 
flavonoid fraction group than in the placebo group (69 vs. 37%) [45]. Fur-
thermore, the percentage of improved patients after 2 months of treatment 
was higher in the treatment group than in the placebo group (44 vs. 33%) in 
one study (but not statistically significant) [44], though, in another study there 
were less improved patients in the treatment group than in the placebo group 
(35 vs. 67%) [47]. 
The only reported symptom of CVI – cramps – could statistically significant-
ly be more improved after 2 months of treatment in the flavonoid fraction 
groups than in the placebo groups, however detailed data were not presented 
[44]. For heaviness no change from baseline could be calculated and there-
fore this outcome was excluded (see Table 3.1-6). 
 
Flavonoid fraction-containing agents + compression stockings versus 
compression stockings alone 
There was no evidence available assessing the change of the CVI stage, the 
CVI signs in general, trophic alternations and oedema, CVI-related symptoms 
in general, the change in pain, cramps, restless legs, itching, swelling or par-
aesthesias and the quality of life after treatment with flavonoid fraction-con-
taining agents and compression stockings versus compression stockings alone. 
The only outcome reported was ulcer. It was analysed in the meta-analysis 
(based on the results of 3 RCTs) by the healing rate which was higher after 2 
months of treatment in the flavonoid fraction group compared to the control 
group (14.1 to 40.3% vs. 8.7 to 21%) [42]. The meta-analysis of the ulcer heal-
ing rate after 2 months of treatment (Figure 3.1-7) is showing that the differ-
ence is statistically significant in favour of a treatment with flavonoid frac-
tion-containing agents supplemented by compression stockings versus com-
pression stockings alone. The risk ratio is 1.90 for the probability of ulcer 
healing with flavonoid fraction and compression stockings compared to com-
pression stockings alone. 
After 3 and 6 months of treatment (measured in one RCT; also included in 
meta-analysis [42]),the healing rate was at both measured points of time sta-
tistically significantly higher in the treatment group than in the control group 
(3 months: 44 vs. 28%; 6 months: 65 vs. 41%) [49]. 
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Study name Statistics for each study Sample size Risk ratio, 95% CI 
 Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoid 
fraction 
No 
treatment 
 
Coleridge-Smith 2005 
(from Glinski 1999) 1.62 0.62 4.21 10/71 6/69 
Coleridge-Smith 2005 
(from Roztocil 2003) 
2.03 1.00 4.11 22/82 9/68 
Coleridge-Smith 2005  
(from Saveliev87) 1.92 1.09 3.40 25/62 13/62 
Total (95% CI) 1.90 1.27 2.84 57/215 28/199 
  
Random effects meta-analysis; I²: 0.0%; p=0.002 
Favours compr. 
alone  
Favours 
MPFF+compr. 
Figure 3.1-7: Ulcer healing rate (dichotomous) after 2 months for flavonoid fraction-containing agents + compression 
stockings vs. compression stockings alone 
The reduction of the ulcer size was reported in one study (also included in 
the previously mentioned meta-analysis [42]).The ulcer size was statistically 
significantly more reduced in the treatment than in the control group after 6 
months (77 vs. 69%) [49]. 
In addition, the score (0-10) of heaviness (a symptom of CVI) was statistically 
significantly more reduced in the treatment group than in the control group 
after 6 months of treatment (-2.7 vs. -1) [49].  
 
Flavonoid fraction-containing agents + surgery versus surgery only 
There was no evidence available assessing the change of the CVI stage, the 
CVI signs in general, trophic alternations and ulcer, CVI-related symptoms 
in general, the change in pain, cramps, restless legs, swelling and paraesthe-
sias after treatment with flavonoid fraction-containing agents and surgery ver-
sus surgery only. 
The only reported CVI sign was oedema, which decreased statistically signif-
icantly more in the treatment group than in the control group (84% versus 
no stated value for the control group) [48].  
In terms of CVI symptoms, itching and heaviness were statistically signifi-
cantly more improved in the treatment groups compared to the control groups, 
yet the values for the control groups were not stated [48]. 
Quality of life improved in more patients in the treatment group than in the 
control group (21 vs. 3%) [48]. It was not stated whether the difference was 
statistically significant or not. 
 
                                                             
87
 The original study from Saveliev was not published and has therefore no publication 
date. 
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Safety 
For evaluating the safety of flavonoid fraction-containing capillary stabilis-
ing agents, we identified, besides 5 out of the 8 previously described studies, 
1 additional non-randomised controlled registry studies (non-RCT) [50] and 
4 single-arm studies [51-55] (two studies reported the results of the same study 
with different information and were therefore merged [51, 53]) that met our 
inclusion criteria and described adverse events. The study characteristics and 
results of the non-RCT and single-arm studies are summarised in Table 3.1-7. 
In the non-RCT all patients received surgery and the treatment group was 
additionally treated with flavonoid fraction-containing agents. 
In the non-RCT and the 4 single-arm studies, a total of 12,323 patients were 
included, of whom 12,278 were in the treatment groups and received 500 mg 
of flavonoid fraction-containing agents (Daflon
®
) two times a day. The re-
maining 45 patients were in the control group and received surgery only [50]. 
The mean ages of the patients were 42 to 50 years in the treatment groups 
and 43 years in the control group. Between 58 and 100% of the patients in 
the studies were females. The duration of treatment differed from 1.5 to 12 
months. There was no follow-up after treatment. Furthermore, the drop-out 
rates in the studies were 6.5-36% [51-54]. 
A summary of the effect sizes for the individual outcome indicators is pre-
sented in Tables 3.1-8 to 3.1-11. 
 
Flavonoid fraction-containing agents (+ compression stockings) versus 
placebo (+ compression stockings) 
If reported, the general adverse events differed between 6 and 12% in the 
flavonoid fraction groups and between 5 and 13% in the control groups. It 
was not stated wheter the difference was statistically significant or not. The 
most common adverse events in both groups were headache, pain and nau-
sea [43, 45, 47]. 
The forest plot of the meta-analysis of the general adverse events is displayed 
in Figure 3.1-8. The forest plot shows that there is no statistically significant 
difference between adverse events that occurred in the treatment and those 
in the placebo group. 
 
Study name Statistics for each study Sample size Risk ratio, 95% CI 
 Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoid 
fraction 
No 
treatment 
 
Boineau-Geniaux 1988 1.25 0.08 18.46 1/16 1/20 
Laurent 1988 0.69 0.31 1.55 9/100 13/100 
Guilhou 1997 1.27 0.41 3.91 6/52 5/55 
Total (95% CI) 0.87 0.46 1.64 16/168 19/175 
  
Random effects meta-analysis; I²: 0.0%; p=0.66 Favours MPFF   Favours placebo 
Figure 3.1-8: Adverse events (dichotomous) for flavonoid fraction-containing agents (+ compression stockings) vs. 
placebo (+ compression stockings) 
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Treatment-related adverse events, reported in one study, occurred in 8% of 
the patients in the treatment and 9% of the patients in the control group. 
The most common events in the treatment group were skin changes, asthe-
nia and headache [43]. 
 
Flavonoid fraction-containing agents + compression stockings versus 
compression stockings alone 
There was no available evidence that analysed adverse events in general of a 
treatment with flavonoid fraction-containing agents combined with compres-
sion stockings compared to compression stockings alone.  
There were no treatment-related adverse events in the treatment group [49]. 
However, it was not stated whether treatment-related adverse events occurred 
in the control group. 
 
Flavonoid fraction-containing agents + surgery versus surgery alone 
There were no general adverse events in neither the flavonoid fraction group 
supplemented by surgery nor in the group that was receiving surgery alone 
[50]. 
However, there were 2% of treatment-related adverse events (gastric irrita-
tion) in the treatment group. It was not stated whether treatment-related ad-
verse events occurred in the control group [50]. 
 
Flavonoid fraction agents  
There were 6 to 9% of general [51-53]and 0 to 3.3% of treatment-related ad-
verse events [54, 55] after a treatment with flavonoid fraction-containing 
agents in the single-arm studies. The most common adverse events were gas-
tralgia, nausea, dizziness and headache [51-53]. 
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Risk of bias 
The identified meta-analysis shows an overall low risk of bias (figure 3.1-9), 
however, there is partially a high risk of selection bias due to an unclear re-
search question. Furthermore, a high risk of performance and detection bias 
exists due to no critical appraisal of the quality of the included studies and it 
is not clear if the studies were assessed by two persons.  
 
Figure 3.1-9: Risk of bias of meta-analysis for treatment of CVI with flavonoid fraction-containing agents 
The majority of the identified RCTs for a treatment of CVI with flavonoid 
fraction-containing agents have an unclear risk of bias for several types of 
biases (see Figure 3.1-10). Nearly half of the studies show a high risk of re-
porting bias due to not reported baseline values, not reported scaling of out-
come assessment or missing description of outcome indicators. In summary, 
the risk of bias is unclear. 
 
Figure 3.1-10: Risk of bias of RCTs for treatment of CVI with flavonoid fraction-containing agents 
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Due to the study design of the single-arm studies, several of the individual 
biases are not relevant (grey-coloured), since there was no control group. 
The risk of performance and detection bias is high, due to no blinding of the 
outcome assessor and half of the studies show a high risk of reporting bias 
due to no confounder adjustment (see Figure 3.1-11). In summary, the risk 
of bias is high. 
 
Figure 3.1-11: Risk of bias of (un)controlled studies fortreatment of CVI with flavonoid fraction-containing agents 
 
Strength of evidence 
Overall, the strength of evidence of the efficacy and safety of a treatment of 
CVI with flavonoid fraction-containing agents, supplemented by compression 
stockings or surgery compared to placebo, compression therapy alone or sur-
gery alone is low to very low. Although the majority of studies were RCTs, 
due to several study limitations and a low number of patients in the studies, 
the strength of evidence was downgraded. The strength of evidence is sum-
marised in the Tables 3.1-8 to 3.1-11. 
There was no evidence to compare a treatment of CVI with flavonoid frac-
tion-containing agents with other interventions, such as lifestyle changes or 
further local, medical and surgical treatment, mentioned in Chapter 1.1.2. 
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Table 3.1-8: Evidence profile: Efficacy and safety of flavonoid fraction-containing agents for treatment of CVI compared to placebo 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: flavonoid fraction-containing agents (+ compression stockings) versus placebo (+ compression stockings) 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): improved patients (in %) 
1/36 RCT 2 mo: 88 vs. 21; p=n/a Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI signs (oedema): leg volume change from baseline (in ml) 
1/49 
1/101 
RCT 1 mo: +10 vs. -6; p=n/a 
2 mo: +12 vs. +4; p=n/a 
Serious limitations (-1)90 n/a (only 1 trial) 
n/a (only 1 trial) 
Direct Imprecise data (-1)89 Low 
Low 
CVI signs (oedema): ankle circumference change from baseline (in mm) 
1/200 RCT 1 mo: -4 vs. -1; p=n/a Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI signs (ulcer): healing rate (in %) 
1/30991 Sytem. Review 2 mo: 20.4 to 25.5 vs. 11.5 to 25.3; p=S.S. Serious limitations (-1)92 Important inconsistency93 (-1) Direct Imprecise data (-1)89 Very low 
CVI symptoms (general): improvement (in %) 
1/200 RCT 1 mo: 49 vs. 24; p=n/a 
2 mo: 69 vs. 37; p=S.S. 
Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI symptoms (general): improved patients (in %) 
1/36 
1/137 
RCT 
RCTs 
1 mo: 48 vs. 31; p=n/a 
2 mo: 35 to 44 vs. 33 to 67;  
p=N.S. in one study 
Serious limitations (-1)88 
Serious limitations (-1)94 
n/a (only 1 trial) 
Important inconsistency (-1)95 
Direct 
Direct 
Imprecise data (-1)89 
Imprecise data (-1)89 
Low 
Very low 
CVI symptoms (pain): no evidence 
                                                             
88
 Unclear random sequence generation and blinding of outcome assessor. 
89
 Low incidence, study/studies not powered to detect difference. 
90
 Unclear random sequence generation in one trial and unclear blinding of outcome assessor in each study. 
91
 The systematic summarised five studies with 723 patients, since there were only two of these studies with a placebo receiving control group, only this two studies were extracted. 
92
 Systematic review was not based on research question and it is unclear if extracted data were reviewed by a second person. 
93
 Review included studies comparing flavonoid fraction-containing agents (+ compression stockings) with placebo or nothing (+ compression stockings). In this table we only 
used the data from studies with a placebo receiving control group, thus it was not possible to use the risk ratio and confidence interval of the systematic review. 
94
 Unclear random sequence generation in both studies an unclear blinding of outcomes assessor in one study. 
95
 In one study there were more improved patients in the control group than in the treatment group and in the second study the values were the other way round. 
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No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI symptoms (cramps): improved patients (in %) 
1/101 RCT 2 mo: n/a; p=S.S. Serious limitations (-1)94 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI symptoms (restless legs): no evidence 
CVI symptoms (itching): no evidence 
CVI symptoms (heaviness): no evidence 
CVI symptoms (swelling): no evidence 
CVI symptoms (paraesthesias): no evidence 
Quality of life: no evidence 
Safety: flavonoid fraction-containing agents (+ compression stockings) versus placebo (+ compression stockings) 
Adverse events (general): in % 
3/343 RCTs 6 to 12 vs. 5 to 13; p=N.S. Serious limitations (-1)96 No important inconsistency  Direct Imprecise data (-1)89 Low 
Adverse events (treatment-related): in % 
1/107 RCT 8 vs. 9; p=n/a Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
Table 3.1-9: Evidence profile: Efficacy and safety of flavonoid fraction-containing agents + compression stockings for treatment of CVI compared to compression stockings alone 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: flavonoid fraction-containing agents + compression stockings versus compression stockings alone  
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): no evidence 
                                                             
96
 Unclear random sequence generation in all 3 studies and unclear blinding of outcome assessor in 2 studies. 
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1 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI signs (ulcer): healing rate (in %) 
1/41497 
1/150 
1/150 
Sytem. Review 
RCT 
RCT 
2 mo: 14.1 to 40.3 vs. 8.7 to 21; p=n/a 
3 mo: 44 vs. 28; p=S.S. 
6 mo: 65 vs. 41; p=S.S. 
Serious limitations (-1)98 
Serious limitations (-1)88 
Serious limitations (-1)88 
Important inconsistency99 (-1) 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Direct 
None 
Imprecise data (-1)89 
Imprecise data (-1)89 
Low 
Low 
Low 
CVI signs (ulcer): reduction of size (in %) 
1/150 RCT 6 mo: 77 vs. 69; p=S.S. Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI symptoms (general): no evidence 
CVI symptoms (pain): no evidence 
CVI symptoms (cramps): no evidence 
CVI symptoms (restless legs): no evidence 
CVI symptoms (itching): no evidence 
CVI symptoms (heaviness): score (0-10) 
1/150 RCT 1 mo: -2 vs. -0.7; p=S.S.100 
6 mo: -2.7 vs. -1; p=S.S.100 
Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI symptoms (swelling): no evidence 
CVI symptoms (paraesthesias): no evidence 
Quality of life: no evidence 
Safety: flavonoid fraction-containing agents + compression stockings versus compression stockings alone  
Adverse events (general): no evidence 
Adverse events (treatment-related): in % 
1/150 RCT 0 vs. n/a; p=n/a Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
                                                             
  
97
 The systematic review summarised five studies with 723 patients, since there were only three of these studies with a control group only receiving compression stockings, only 
these three studies were extracted. 
  
98
 Systematic review was not based on research question and it is unclear if extracted data were reviewed by a second person. 
  
99
 Review included studies comparing flavonoid fraction-containing agents (+ compression stockings) with placebo or nothing (+ compression stockings). In this table we only 
used the data from studies with a compression stocking (and nothing else) receiving control group, thus it was not possible to use the risk ratio and confidence interval of the sys-
tematic review. 
100
 The score in this study was originally 0-3; the values were multiplied with 3.33 to adopt them to a score of 0-10. 
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Table 3.1-10: Evidence profile: Efficacy and safety of flavonoid fraction-containing agents + surgery for treatment of CVI compared to surgery alone 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: flavonoid fraction-containing agents + surgery versus surgery alone 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): decrease (in %) 
1/181 RCT 1 mo: 84 vs. n/a; p=S.S. Serious limitations (-1)101 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI signs (ulcer): no evidence 
CVI symptoms (general): no evidence 
CVI symptoms (pain): no evidence 
CVI symptoms (cramps): no evidence 
CVI symptoms (restless legs): no evidence 
CVI symptoms (itching): improvement (in %) 
1/181 RCT 1 mo: 92 vs. n/a; p=s.s Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI symptoms (heaviness): improvement (in %) 
1/181 RCT 1 mo: 89 vs. n/a; p=s.s Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
CVI symptoms (swelling): no evidence 
CVI symptoms (paraesthesias): no evidence 
Quality of life: Improved patients (in %) 
1/181 RCT 1 mo: 21 vs. 3; p=n/a Serious limitations (-1)88 n/a (only 1 trial) Direct Imprecise data (-1)89 Low 
Safety: flavonoid fraction-containing agents + surgery versus surgery alone 
Adverse events (general): in % 
1/245 CT 0 vs. o; p=N.S. Serious limitations (-1)102 n/a (only 1 trial) Direct Imprecise data (-1)89 Very low 
Adverse events (treatment-related): in % 
1/245 CT 2 vs. n/a; p=n/a Serious limitations (-1)233 n/a (only 1 trial) Direct Imprecise data (-1)89 Very low 
Abbreviations: CT = controlled trial; n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
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Table 3.1-11: Evidence profile: Safety of flavonoid fraction-containing agents for treatment of CVI (results from single-arm studies) 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Safety: flavonoid fraction-containing agents (results from single-arm studies) 
Adverse events (general): in % 
2/523 Single-arm studies 6 to 9 Serious limitations (-1)103 No important inconsistency Direct Imprecise data (-1)89 Very low 
Adverse events (treatment-related): in % 
2/11,555 Single-arm studies 0 to 3.3 Serious limitations (-1)103 No important inconsistency Direct None  Very low 
Abbreviations: n/a = data not available; N.S. = not statistically significant; S.S. = statistically significant; vs. = versus 
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3.1.3 20 mg aescin-containing agents 
Study characteristics 
There were no studies to assess the efficacy of capillary stabilising agents con-
taining 20 mg of aescin for the treatment of CVI. Furthermore, there were 
no studies identified comparing agents containing 20 mg of aescin with oth-
er interventions, such as lifestyle changes or further local, medical and sur-
gical treatment, mentioned in Chapter 1.1.2. 
For evaluating the safety of capillary stabilising agents containing 20 mg of 
aescin, we identified 1 non-randomised controlled study [57] that met our 
inclusion criteria. The studies compared agents containing 20 mg of aescin 
taken six times a day with placebo for the treatment of CVI [57]. The study 
characteristics and results are summarised in Table 3.1-12.  
Table 3.1-12: Safety-related outcomes of non-randomised controlled trials of 20 mg aescin-containing agents vs.  
placebo for CVI 
Author, year, reference number Shah 1997 [57] 
Country Germany, Switzerland 
Study design Non-randomised controlled trial 
Sponsor n/a 
Intervention/product 6x 20 mg aescin (HCSE) tablets per day 
Comparator Placebo 
Number of pts. 30 vs. 30 
Age of patients (yrs.)  54 vs. 56 
Sex (% female) 93 
Height (cm)/weight (kg)/BMI (kg/m²) 166 vs. 166 / 75 vs. 75 / n/a 
Clinical classification Grade I + II acc. to Widmer 
Primary endpoint Ankle circumference and symptoms 
Inclusion criteria Patients >18 yrs. with CVI grade I + II (acc. to Widmer) with  
certain scores for signs and symptoms 
Duration of Treatment (months) 1.5 
Follow-up (months) 0 
Drop-outs, n (%) 9 (15)104 
Safety-related outcomes 
Adverse events, general in % (n) pts. 10(3) vs. 10 (3); p=n/a 
(gastrointestinal disorders, pain, urinary tract infection vs. 
gastrointestinal disorders, thrombophlebitis) 
Major adverse events n/a 
Minor adverse events n/a 
Adverse events, treatment-related in % (n) pts. 3 (1) vs. 7 (2); p=n/a 
(pain vs. gastrointestinal disorders) 
Major adverse events n/a 
Minor adverse events n/a 
Abbreviations: acc. = according; CVI = chronic venous insufficiency, HCSE = horse chestnut seed extract;  
n = number (of patients); n/a = data not available; pts. = patients; yrs. = years 
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 A total of 9 patients withdraw from study, whereas one patient was replaced. 
keine Studien zu 
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eingeschlossen 
 
Dosis: 20 mg 6x täglich 
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Efficacy 
As stated above, we could not identify any studies assessing the efficacy of ca-
pillary stabilising agents containing 20 mg of aescin for the treatment of CVI. 
 
Safety 
In the only relevant trial identified, 30 patients received agents containing 
20 mg of aescin six times a day (treatment group) and the 30 patients in the 
control group received placebo. The mean age of the patients was 54 years in 
the treatment and 56 years in the control groups and 93% of the patients were 
females. The duration of treatment was 1.5 months and there was no follow-
up after treatment. The drop-out rate was 15% [57]. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.1-14. 
 
20 mg aescin-containing agents versus placebo 
General adverse events occurred in 10% of the patients in the treatment and 
in the control group, respectively. The most common adverse events were 
gastrointestinal disorders, pain and urinary tract infections in the group that 
received 20 mg aescin versus gastrointestinal disorders and thrombophlebi-
tis in the group that received placebo [57]. 
Additionally, there occurred treatment-related adverse events in 1% of the 
patients in the treatment group (pain) and 2% of the patients in the control 
group (gastrointestinal disorders) [57]. 
 
Risk of bias 
The identified non-RCT has a high risk of reporting bias due to a missing 
analysis of confounder (see Figure 3.1-12). The risks for other types of biases 
are low. Thus, the overall risk of bias is low. 
 
Figure 3.1-12: Risk of bias of non-randomised controlled studies for 20 mg aescin-containing agents  
for treatment of CVI 
0% 25% 50% 75% 100%
Patients from same population and period (selection
bias)
Allocation between groups (selection bias)
Blinding (performance and detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Low risk of bias Unclear risk of bias High risk of bias
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Strength of evidence 
Overall, the strength of evidence of the safety (there was no evidence for as-
sessing the efficacy) of a treatment of CVI with agents containing 20 mg of 
aescin compared to placebo is very low, since the only identified study was a 
non-RCT. The strength of evidence is summarised in the Tables 3.1-13 (for 
efficacy, whereby there was no available evidence) and 3.1-14. 
There was no evidence to compare a treatment of CVI with agents contain-
ing 20 mg of aescin to other interventions, such as lifestyle changes or fur-
ther local, medical and surgical treatment, mentioned in Chapter 1.1.2. 
Table 3.1-13: Evidence profile: Efficacy of 20 mg aescin-containing agents for treatment of CVI compared to placebo 
No of 
studies/patien
ts 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifyin
g factors 
Strength  
of 
evidence 
Efficacy: 20 mg aescin-containing agents 
Change of CVI stage: no evidence 
CVI signs: no evidence 
CVI symptoms: no evidence 
Quality of life: no evidence 
Table 3.1-14: Evidence profile: Safety of 20 mg aescin-containing agents for treatment of CVI compared to placebo 
No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency 
Indirect
ness 
Other  
modifying 
factors 
Strength  
of 
evidence 
Safety: 20 mg aescin-containing agents vs. placebo 
Adverse events (general): in % 
1/60 CT 10 vs. 10; p=n/a No serious 
limitations 
n/a (only 1 trial) Direct Imprecise 
data (-1)105 
Very low 
Adverse events (treatment-related): in % 
1/60 CT 3 vs. 7; p=n/a No serious 
limitations 
n/a (only 1 trial) Direct Imprecise 
data (-1)105 
Very low 
Abbreviations: CT = controlled trial; n/a = data not available; N.S. = not statistically significant;  
S.S. = statistically significant; vs. = versus 
 
3.1.4 50 mg aescin-containing agents 
Study characteristics 
For evaluating the efficacy and safety of capillary stabilising agents contain-
ing 50 mg of aescin, we identified 1 systematic review [58]. 
There were a total of 1,292 patients in the systematic review comparing agents 
containing 50 mg of aescin, supplemented by compression stockings with either 
placebo or compression stockings alone for the treatment of CVI [58]. Patients 
received agents containing 50 mg of aescin once or twice per day. However, the 
systematic review included also two studies in which patients received a 75 mg 
aescin dosage form. Since this dosage form is not included in the Austrian 
EKO, we excluded the outcomes of these two studies from our extraction.  
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The patients were on average between 41 and 53 years in the treatment groups 
and between 38 and 48 years in the control groups. The majority of the pa-
tients were females: 50-100%. Furthermore, patients had CVI grade I-II ac-
cording to Widmer (see Chapter 1.1.2), the duration of treatment was 0.5-4 
months. It was not stated whether any study had a follow-up without treat-
ment. The drop-out rate of all studies together was 9% [58]. 
The study characteristics and results (for efficacy and safety) are summarised 
in Table 3.1-15. 
There were no studies identified comparing agents containing 50 mg of aes-
cin with other interventions, such as lifestyle changes or further local, medi-
cal and surgical treatment, mentioned in Chapter 1.1.2. 
Table 3.1-15: Efficacy and safety-related outcomes of a systematic review of 50 mg aescin-containing agents vs.  
placebo or compression stockings for CVI 
Author, year,  
reference number Pittler 2012 [58] 
Country Germany 
Study design Systematic review106 
Sponsor None 
Intervention/Product 1-2x 50 mg aescin (HCSE) capsules per day 
2x 75 mg aescin (HCSE) capsules per day107 
Comparator Placebo, compression stockings 
Number of pts 1,292 
Age of patients (yrs.)  Ø 41-53 vs. 38-48 
Sex (% female) 50-100 
Height (cm)/Weight 
(kg)/BMI (kg/m²) 
n/a / n/a / n/a 
Clinical classification Grade I-II acc. to Widmer 
Primary endpoint CVI-related symptoms and oedema (of included studies) 
Inclusion criteria Patients with CVI, comparing oral preparations of HCSE with placebo or  
reference therapy, measuring clinical outcomes 
Duration of Treatment 
(months) 
0.5-4 
Follow-up (months) n/a 
Drop-outs, n (%) 114 (9) 
Efficacy-related outcomes 
Change of CVI stage n/a 
CVI signs (general) n/a 
Trophic alterations n/a 
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 This systematic review included 17 RCTs on aescin-containing agents. Of these, 
11 compared aescin against placebo and/or against compression stockings and four 
against O-beta-hydroxyethyl rutosides (HR). Information about age, sex ratio and 
clinical classification was not stated in all included studies.  
107
 Outcomes of studies for 75 mg aescin were not extracted, since this dosage form is 
not in the Austrian EKO. 
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Author, year,  
reference number Pittler 2012 [58] 
Oedema (or leg volume 
or circumference) 
HCSE vs. placebo 
1 study (15 vs. 15 pts.) for reduction of oedema (100 mm VAS): 41.2 vs. 1.1;  
mean difference=40.10; p=S.S. 
1 study (173 vs. 173 pts.) for improvement of oedema (dichotomous): 114 (66%) vs.  
71 (41%); odds ratio=2.78; p=S.S. 
5 studies108 (292 vs. 171 pts.) for reduction of leg volume (ml): 18-114 vs. (-)34-0.55; 
mean difference=31.44; p=0.00073 
3 studies (40 vs. 40 pts.) for reduction of circumference at ankle (mm): 6-7.7 vs. -4.3-3; 
mean difference=4.71; p=0.0099 
3 studies (40 vs. 40 pts.) for reduction of circumference at calf (mm): 1.3-6.1 vs. -2.3 - 1; 
mean difference=3.51; p=0.019 
HCSE vs. compression 
2 studies (238 vs. 241 pts) for reduction of leg volume (ml): 18-43.8 vs. 46.7-89;  
mean difference=-37.34; p=N.S. 
Ulcer n/a 
CVI symptoms (general) HCSE vs. compression 
1 study (143 vs. 142 pts.) for improvement of symptom score (40 point scale): 4.9 vs. 
4.6; p=N.S. 
Pain HCSE vs. placebo: 
1 study (209 vs. 209 pts.) for improvement of pain (dichotomous): 132 (63%) vs.  
91 (44%); odds ratio=2.22; p=S.S. 
1 study (15 vs. 15 pts.) for reduction of pain (100 mm VAS): 42.6 vs. 0.21,  
mean difference=42.4; p=S.S. 
Cramps n/a 
Restless legs n/a 
Itching (=tingling 
sensation) 
n/a 
Heaviness (=heavy legs) n/a 
Swelling (=sensation of 
tension) 
n/a 
Paraesthesias n/a 
QoL n/a 
Safety-related outcomes 
Adverse events, general  
in % (n) pts. 
6 studies (a total of 758 pts. in both groups): 1-36% vs. n/a; p=n/a 
(gastrointestinal complaints, dizziness, nausea, headache, pruritus vs. n/a) 
Major adverse events n/a 
Minor adverse events n/a 
Adverse events, treatment-
related in % (n) pts. 
4 studies (a total of 356 pts. in both groups): 0 vs. n/a; p=n/a 
Major adverse events n/a 
Minor adverse events n/a 
Abbreviations: acc. = according; CVI = chronic venous insufficiency; HCSE = horse chestnut seed extract;  
n = number (of patients); n/a = data not available; N.S. = not statistically significant; pts. = patients; QoL = quality of life; 
RCT = randomised controlled trial; VAS = visual analogue score; vs. = versus; yrs. = years 
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 In one additional study (20 vs. 19 pts.), HCSE was standardised to 75 mg aescin. 
The outcomes of this study were not extracted and the mean difference excludes 
this study, but the p-value calculation is included in this study. 
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Efficacy 
For evaluating the efficacy of flavonoid fraction-containing capillary stabi-
lising agents, we identified 1 systematic review that met our inclusion crite-
ria [58]. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.1-16. 
 
50 mg aescin-containing agents (+ compression stockings) versus 
placebo (+ compression stockings) 
There was no evidence available to assess the efficacy of a treatment with 
agents containing 50 mg of aescin versus placebo regarding the following out-
comes: change of the CVI stage, CVI signs in general, trophic alternations, 
ulcer, symptoms of CVI: cramps, restless legs, itching, heaviness, swelling, 
paraesthesias and quality of life. 
Concerning CVI signs, oedema was measured by five different parameters. 
In one study oedema was measured as the reduction on a score (0-10) and in 
another study this outcome was measured as improvement (in %) after 1 
month. The reduction was statistically significant in favour of 50 mg aescin 
compared to placebo in both studies (mean difference of score reduction be-
tween groups: 4.01 and odds ratio of improvement: 0.278) [58]. 
The meta-analysis of the leg volume change (displaying the 5 relevant stud-
ies for 50 mg aescin) shows that the difference is statistically significant in 
favour of a treatment with agents containing 50 mg of aescin versus placebo 
with a mean difference of -30.66 ml between the groups (Figure 3.1-13). 
 
Study name Statistics for each study Sample size Mean difference, 95% CI 
 Difference 
in means 
Lower 
limit 
Upper 
limit 
50 mg 
aescin Placebo 
 
Pittler 2012  
(from Rudofsky 1986)  
-78.2 -182.59 26.19 19 20 
Pittler 2012  
(from Steiner 1986)  -114.5 -345.08 116.08 10 10 
Pittler 2012  
(from Steiner 1990 a) -31.09 -142.68 80.5 25 25 
Pittler 2012  
(from Diehm 1996 a) -53.6 -91.67 -15.53 95 46 
Pittler 2012  
(from Diehm 2000) -20.0 -42.12 2.12 143 70 
Total (95% CI) -30.66 -49.15 -12.17 292 171 
  
Random effects meta-analysis; I²: 0.0%; p=0.001 Favours 50 mg aescin  Favours placebo 
Figure 3.1-13: Leg volume change (in ml) after 0.5-4 months for 50 mg aescin-containing agents versus placebo 
Furthermore, oedema was measured as ankle and calf circumference change 
in three studies and both indicators decreased statistically significantly more 
in the treatment group than in the placebo group (mean differences of change 
between groups: -4.71 and -3.51) after 0.5 to 1 month of treatment [58]. The 
forest plots for ankle and calf circumference change are displayed in Figures 
3.1-14 and 3.1-15 below.  
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Study name Statistics for each study Sample size Mean difference, 95% CI 
 
Difference 
in means 
Lower 
limit 
Upper 
limit 
50 mg 
aescin Placebo 
 
Pittler 2012  
(from Steiner 1986)  
-5.9 -16.12 4.32 10 10 
Pittler 2012  
(from Pilz 1990) -4.0 -7.95 -0.05 15 15 
Pittler 2012  
(from Cloarec 1992) -12.0 -26.69 2.69 15 15 
Total (95% CI) -4.71 -8.28 -1.12 40 40 
  
Random effects meta-analysis; I²: 0.0%; p=0.01 Favours 50 mg aescin  Favours placebo 
Figure 3.1-14: Ankle circumference (in mm) change after 0.5-1 month for 50 mg aescin-containing agents versus placebo 
 
Study name Statistics for each study Sample size Mean difference, 95% CI 
 
Difference 
in means 
Lower 
limit 
Upper 
limit 
50 mg 
aescin Placebo 
 
Pittler 2012  
(from Steiner 1986)  -0.6 -7.84 6.64 10 10 
Pittler 2012  
(from Pilz 1990) 
-4.0 -7.24 -0.76 15 15 
Pittler 2012  
(from Cloarec 1992) -8.4 -31.23 14.43 15 15 
Total (95% CI) -3.51 -6.45 -0.58 40 40 
  
Random effects meta-analysis; I²: 0.0%; p=0.02 Favours 50 mg aescin  Favours placebo 
Figure 3.1-15: Calf circumference (in mm) change after 0.5-1 month for 50 mg aescin-containing agents versus placebo 
The only reported symptom of CVI – pain – was statistically significantly 
more improved after 3 weeks of treatment in the 50 mg aescin groups than 
in the placebo groups (dichotomous variable: odds ratio of 2.2). Likewise the 
score for pain (scale 0-10) was statistically significantly more reduced after 1 
month of treatment (mean difference: 42.4) [58]. 
 
50 mg aescin-containing agents + compression stockings versus 
compression stockings alone 
There was no evidence available assessing the change of the CVI stage, the 
CVI signs in general, trophic alternations and ulcer, CVI-related symptoms 
(pain, cramps, restless legs, itching, heaviness, swelling, paraesthesias) and 
quality of life after a treatment with agents containing 50 mg of aescin and 
compression stockings versus compression stockings alone. 
One CVI sign – oedema – was reported (based on the results of 2 RCTs) in 
terms of leg volume change from baseline (in ml). Reduction in leg volume 
was not statistically significantly higher after 3 to 4 months of treatment in 
the 50 mg aescin group supplemented by compression stockings compared 
to the control group (mean difference of reduction: 37.34 ml) [58].  
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In terms of CVI signs, the score (0-10) for general symptoms was more im-
proved in the treatment group compared to the control group, after 4 months 
of treatment (mean difference of score improvement: 0.095). However, the dif-
ference between the study groups was not statistically significant [58]. 
 
Safety 
The identified systematic review did not present data on general adverse events 
in the control groups and therefore general adverse events of the treatment 
groups only (if reported) were summarised. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.1-17. 
 
50 mg aescin-containing agents  
The general adverse events (stated in 6 studies) ranged from 1 to 36% in the 
50 mg aescin groups. The most common events were gastrointestinal com-
plaints, dizziness, nausea, headache and pruritus [58].  
Treatment-related adverse events, reported in 4 studies, occurred in 0% of the 
patients in the treatment groups [58].  
 
Risk of bias 
The identified systematic review shows an overall low risk of bias (see Figure 
3.1-16), however, there is some high risk of selection bias due to an unclear 
research question.  
 
Figure 3.1-16: Risk of bias of systematic review for treatment of CVI with 50 mg aescin-containing agents 
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Strength of evidence 
Overall, the strength of evidence of the efficacy and safety of a treatment of 
CVI with agents containing 50 mg of aescin, supplemented by compression 
stockings compared to placebo or compression stockings alone is low. Alt-
hough the identified study was a systematic review, the majority of the RCTs 
the systematic review was based on, have shown several limitations and, there-
fore, the strength of evidence was downgraded. Solely for pain, measured as 
the percentage of improved patients, the quality of evidence is moderate. 
The strength of evidence is summarised in Tables 3.1-16 and 3.1-17. 
There was no evidence to compare a treatment of CVI with agents contain-
ing 50 mg of aescin to other interventions, such as lifestyle changes or fur-
ther local, medical and surgical treatment, mentioned in Chapter 1.1.2. 
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Table 3.1-16: Evidence profile: Efficacy of 50 mg aescin-containing agents (+ compression stockings) for treatment of CVI compared to placebo or compression stockings alone 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: 50 mg aescin-containing agents (+compression stockings) versus placebo (+compression stockings) 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): reduction (score 0-10) 
1/30 (0f 1,292) 1 RCT (in syst. Rev.) 1 mo: mean difference: 4.01;  
CI: 3.16, 4.86; p=S.S. 
Serious limitations (-1)109 n/a (only 1 trial) Direct Imprecise data (-1)110 Low 
CVI signs (oedema): improvement (in %) 
1/346 (0f 1,292) 1 RCT (in syst. Rev.) 1 mo111: OR: 2.78; CI: 1.79, 4.3; p=S.S. Serious limitations (-1)109 n/a (only 1 trial) Direct Imprecise data (-1)110 Low 
CVI signs (oedema): leg volume change from baseline (in ml) 
6/502 (of 1,292) 5 RCTs (in syst. Rev.) 0.5-4 mo: mean difference: -32.10;  
CI: -13.49, -50.72; p=S.S. 
Serious limitations (-1)112 Important 
inconsistency113 (-1) 
Direct None Low 
CVI signs (oedema): ankle circumference change from baseline (in mm) 
3/80 (of 1,292) 3 RCTs (in syst. Review) 0.5-1 mo: mean difference: -4.71;  
CI: -1.13, -8.28; p=S.S. 
No serious limitations114 Important 
inconsistency113 (-1) 
Direct Imprecise data (-1)110 Low 
CVI signs (oedema): calf circumference change from baseline (in mm) 
3/80 (of 1,292) 3 RCTs (in syst. Review) 0.5-1 mo: mean difference:- 3.51;  
CI:- 0.58, -6.45; p=S.S. 
No serious limitations114 Important 
inconsistency113 (-1) 
Direct Imprecise data (-1)110 Low 
CVI signs (ulcer): no evidence 
CVI symptoms (general): no evidence 
CVI symptoms (pain): improved patients (in %) 
1/418 1 RCT (in syst. Review) 0.75 mo: OR: 2.2; CI: 1.11, 3.53; p=S.S. Serious limitations (-1)109 n/a (only 1 trial) Direct None Moderate 
CVI symptoms (pain): reduction (score 0-10) 
1/30 1 RCT (in syst. Review) 1 mo: mean difference: 4.24;  
CI: 3.49, 4.99; p=S.S. 
Serious limitations (-1)109 n/a (only 1 trial) Direct Imprecise data (-1)110 Low 
                                                             
109
 Systematic review itself has no limitations, but study the review is based on has serious limitation due to unclear allocation concealment. 
110
 Systematic review itself shows no other modifying factors, but the study/studies the review is based on is/are limited by imprecise data due to low incidence/patient number. 
111
 Study duration was 20 days. 
112
 Systematic review itself has no limitations, but studies the review is based on have serious limitation due to unclear allocation concealment in only 1 of 3 studies. 
113
 Systematic review summarised outcomes of studies from different times (e.g., after 0.5, 1, 3 or 4 months) and in one study patients received 75 mg aescin. 
114
 Systematic review itself has no limitations and studies the review is based on have serious limitation due to unclear allocation concealment in 4 of 5 studies. 
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No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI symptoms (cramps): no evidence 
CVI symptoms (restless legs): no evidence 
CVI symptoms (itching): no evidence 
CVI symptoms (heaviness): no evidence 
CVI symptoms (swelling): no evidence 
CVI symptoms (paraesthesias): no evidence 
Quality of life: no evidence 
Efficacy: 50 mg aescin-containing agents + compression stocking versus compression stockings alone 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): leg volume change from baseline (in ml) 
2/479 (of 1,292) 2 RCTs (in syst. Rev.) 3-4 mo: mean difference: 37.34;  
CI: -29.39, 104.07; p=N.S. 
Serious limitations (-1)115 Important 
inconsistency116 (-1) 
Direct None Low 
CVI signs (ulcer): no evidence 
CVI symptoms (general): improvement (score 0-10) 
1/285 (of 1,292) 1 RCT (in syst. Rev.) 4 mo: mean difference: 0.095;  
CI: -0.27, 0.46; p=N.S. 
Serious limitations (-1)117 n/a (only 1 trial) Direct Imprecise data (-1)110 Low 
CVI symptoms (pain): no evidence 
CVI symptoms (cramps): no evidence 
CVI symptoms (restless legs): no evidence 
CVI symptoms (itching): no evidence 
CVI symptoms (heaviness): no evidence 
CVI symptoms (swelling): no evidence 
CVI symptoms (paraesthesias): no evidence 
Quality of life: no evidence 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
                                                             
115
 Systematic review itself has no limitations, but studies the review is based on have serious limitation due to unclear allocation concealment in 2 of 2 studies. 
116
 Systematic review summarised outcomes of studies from different times (e.g., after 3 or 4 months). 
117
 Systematic review itself has no limitations, but study the review is based on has serious limitation due to unclear allocation concealment. 
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Table 3.1-17: Evidence profile: Safety of 50 mg aescin-containing agents for treatment of CVI 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Safety: 50 mg aescin-containing agents 
Adverse events (general): in % 
6/1,516 6 RCTs (in syst. Rev.) 1 to 36 vs. n/a; p=n/a Serious limitations (-1)118 No important inconsistency  Direct Imprecise data (-1)119 Low 
Adverse events (treatment-related): in % 
4/712 4 RCTs (in syst. Rev.) 0 vs. n/a; p=n/a Serious limitations (-1)120 No important inconsistency Direct Imprecise data (-1)119 Low 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
                                                             
118
 Systematic review itself has no limitations, but studies the review is based on have serious limitation due to unclear allocation concealment in 6 of 6 studies. 
119
 Low incidence, study/studies not powered to detect difference. 
120
 Systematic review itself has no limitations, but studies the review is based on have serious limitation due to unclear allocation concealment in 3 of 4 studies. 
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3.1.5 Calcium dobesilate-containing agents 
Study characteristics 
For evaluating the efficacyand safety of calcium dobesilate-containing capil-
lary stabilising agents, we identified 1 systematic review [10], 4 RCTs [59-62], 
1 additional non-randomised study [63] and 2 single-arm studies [64, 65] that 
met our inclusion criteria. The studies are comparing calcium dobesilate-con-
taining agents (in addition to surgery) with either placebo [10, 59-62], or sur-
gery alone [63] or there was no control group [64, 65] for a treatment of CVI. 
The dosages of calcium dobesilate varied from 500 mg two times to four times 
a day. 
The study characteristics and results are summarised in Table 3.1-18 for RCTs 
and in Table 3.1-19 for the non-randomised controlled trials plus the single-
arm studies.  
There were no studies identified comparing calcium dobesilate-containing 
agents with other interventions, such as lifestyle changes or further local, 
medical and surgical treatment, mentioned in Chapter 1.1.2. 
 
 
1 systematischen Review, 
4 RCTs, 1 non-RCT,  
2 Ein-Arm-Studien mit 
2.768 PatientInnen 
eingeschlossen 
 
Dosis: 500 mg  
2-4 x täglich 
Zusammenfassung 
Studiencharakteristika 
keine Studien  
mit anderen 
Vergleichsgruppen 
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Table 3.1-18: Efficacy and safety-related outcomes of a systematic review and randomised controlled trials of calcium dobesilate-containing agents vs. placebo for CVI 
Author, year,  
reference number Martinez 2005 [10] Flota-Cervera 2008 [59] Martinez-Zapata 2008 [62] Rabe 2011 [60] Labs 2004 [61] 
Country Spain Mexico Spain Germany Switzerland, France 
Study design Systematic review121 RCT RCT RCT RCT 
Sponsor none Quimica Knoll de Mexico Laboratories Dr. Esteve OM Pharma OM Pharma 
Intervention/ 
Product 
2-4x 500 mg calcium 
dobesilate per day 
3x 500 mg calcium dobesilate 
capsules (Doxium®) per day 
2x 500 mg calcium dobesilate 
capsules (Doxium®) per day 
3x 500 mg calcium dobesilate 
(Doxium®) per day122 
3x 500 mg s calcium dobes-
ilate (Doxium®) per day 
Comparator Placebo Placebo Placebo Placebo Placebo 
Number of pts 854 25 vs. 24 246 vs. 263 132 vs. 124 128 vs. 125 
Age of patients (yrs.)  10-70 Ø 54 vs. 51 Ø 53 vs. 55 Ø 53 vs. 54 Ø 49 vs. 49 
Sex (% female) 86 92 vs. 88 88 vs. 86 84 vs. 86 88 vs. 93 
Height (cm)/Weight 
(kg)/BMI (kg/m²) 
n/a / n/a / n/a 158 vs. 158 / 73 vs. 70 / n/a n/a / n/a / n/a 169 vs. 168 / 74 vs. 73 / n/a 165 vs. 164 / 69 vs. 68 / 
n/a 
Clinical classification Grade I-III123 acc. to Widmer 
or CEAP classification 1-5 
Grade I-V acc. to Widmer CEAP classification 1-6 CEAP classification 3-5 CEAP classification C3-4 
Primary endpoint CVI symptoms + signs n/a QoL Relative leg volume change after 8 
weeks compared with baseline 
Change of leg volume of 
the more diseased leg 
after 1 month 
Inclusion criteria Patients with: CVI grade I-II 
(Widmer), primary CVI + 
post-thrombotic syndrome, 
CEAP 3-5, recent onset of 
CVI + presence of symptoms 
and venous oedema 
Patients of both sexes, 
aged >25 yrs. with CVD 
Patients of both sexes, aged ≥18 
yrs. with CVD, CEAP grade 1-6 and 
able to complete a QoL 
questionnaire 
Outpatients of both sexes, aged  
20-70 yrs., with pitting oedema due 
to CVI (CEAP classification 3-5) and 
at least one symptom such as 
discomfort and pain 
Outpatients of both 
sexes, aged 20-70 yrs., 
with pitting oedema due 
to CVI (CEAP 
classification C3-4) 
Duration of 
Treatment (months) 
1-2.8 1.75124 3 2125 1126 
Follow-up (months) n/a 0 9 0.5 0.5 
Drop-outs, n (%) 68 of 774 (9) n/a 61 (25)vs. 70 (27) 23 (17) vs. 9 (7) 14 (11) vs. 7 (6)127 
                                                             
121
 This systematic review included 44 studies of oral phlebotonics in the analysis, but only the extracted data of 7 RCTs for calcium dobesilate was used for our review. 
122
 Wearing compression stockings was allowed. 
123
 One study included, beside 30 CVI patients, also 30 healthy subjects. 
124
 The study started with a wash-out phase of one week. 
125
 The study started with a run-in phase of two weeks. 
126
 The study started with a run-in phase of 1 week. 
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Author, year,  
reference number Martinez 2005 [10] Flota-Cervera 2008 [59] Martinez-Zapata 2008 [62] Rabe 2011 [60] Labs 2004 [61] 
Efficacy-related outcomes 
Change of CVI stage n/a n/a n/a n/a n/a 
CVI signs (general) n/a n/a n/a n/a n/a 
Trophic alterations n/a n/a n/a n/a n/a 
Oedema  
(leg volume or 
circumference) 
2 studies (148 vs. 142 pts.) 
for oedema (dichotomous): 
13-23% vs. 23-93%; risk 
ratio=0.41; p=N.S. 
3 studies (252 vs. 250 pts.) 
for leg circumference (mm): 
230-336 vs.228-356; mean 
difference=-0.09; p=N.S. 
2 studies (118 vs. 118 pts.) for 
leg volume (ml): -3.8-1,097 
vs. -1.15-1,205;  
mean difference=-0.64; 
p=0.03 
Leg circumference (cm): 
Baseline: 51.2 vs. 48.4; 
p=n/a 
After 1 month: n/a 
After 1.75 months: 50.3 vs. 
48.1; p=n/a 
After 2; 3; 6; 12 months: 
n/a 
Calf circumference (cm): 
Baseline: 40.6 vs. 39.7; 
p=n/a 
After 1 month: n/a 
After 1.75 months: 39.0 vs. 
39.7; p=n/a 
After 2; 3; 6; 12 months: 
n/a 
Ankle circumference (cm): 
Baseline: 36.2 vs. 35.9; 
p=n/a 
After 1 month: n/a 
After 1.75 months: 33.6 vs. 
35.6; p=n/a 
After 2; 3; 6; 12 months: 
n/a 
Ankle circumference (mm): 
Baseline: 258.2 vs. 270.1; p=N.S. 
After 1, 2 months: n/a 
After 3 months: 254.9 vs. 266.8; 
p=N.S. 
After 6; 12 months: n/a 
Change of leg volume (%)128: 
Baseline: - 
After 1 month: n/a 
After 2 months: -2 vs. 0; p=0.001 
After 3; 6, 12 months: n/a 
Change of leg volume (cm³)128: 
Baseline: - 
After 1 month: n/a 
After 2 months: -64.72 vs. +0.76; 
p=0.002 
After 3; 6, 12 months: n/a 
Leg volume (cm³): 
Baseline: 3,088 vs. 3,062; p=n/a 
After 1 month: n/a 
After 2 months: 3,039 vs. 3,073; 
p=n/a 
After 2.5 months: 3,050 vs. 3,022; 
p=n/a 
After 3; 6, 12 months: n/a 
Calf circumference (cm): 
Baseline: 39.1 vs. 38.9; p=n/a 
After 1 month: n/a 
After 2 months: 38.8 vs. 38.9; p=n/a 
After 2,5 months: 38.9 vs. 38.6; 
p=n/a 
After 3; 6, 12 months: n/a 
Change of leg volume 
(ml/l)129: 
Baseline: 0 vs. 0 
After 1 month: -25.5 vs. -
13.3; p=0.0109 
After 1.5 months -15 vs. -
17.3; p=N.S. 
After 2; 3; 6, 12 months: 
n/a 
Ankle circumference 
(mm): 
Baseline: 231.7 vs. 230.2; 
p=n/a 
After 1 month: 227.7 vs. 
227.5; p=n/a 
After 1.5 months: 228.7 
vs. 228.2; p=n/a 
After 2; 3; 6, 12 months: 
n/a 
Calf circumference (mm): 
Baseline: 370 vs. 371.7; 
p=n/a 
After 1 month: 366.2 vs. 
369.4; p=n/a 
After 1.5 months: 368.7 
vs. 369.7; p=n/a 
After 2; 3; 6, 12 months: 
n/a 
                                                                                                                                                                                                                                                                                   
127
 A total of 114 patients in the treatment and of 118 patients in the control group completed the trial. Additional, 5 patients in the treatment and 2 in the control group were ex-
cluded after randomization and prior treatment. However, the intention to treat population comprised 128 pts. vs. 125 pts. 
128
 Leg volume was given as relative reduction (in %) after 2 months compared with baseline, based on a truncated cone model by using circumferences of the ankle and calf of the 
most pathological leg, compared with optoelectronic volumetry. 
129
 Leg volume was given as absolute reduction (in ml/l) after 1 month compared with baseline, based on a truncated cone model by using circumferences of the ankle and calf. 
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Author, year,  
reference number Martinez 2005 [10] Flota-Cervera 2008 [59] Martinez-Zapata 2008 [62] Rabe 2011 [60] Labs 2004 [61] 
Ankle circumference (cm): 
Baseline: 24.2 vs. 24.2; p=n/a 
After 1 month: n/a 
After 2 months: 24.1 vs. 24.3; p=n/a 
After 2,5 months: 24.1 vs. 24.1; p=n/a 
After 3; 6, 12 months: n/a 
Ulcer n/a n/a n/a n/a n/a 
CVI symptoms 
(general) 
n/a n/a n/a130 Score (100 mm VAS)131: 
Baseline: 21.4 vs. 21.0; p=n/a 
After 1 month: n/a 
After 2 months:14.8 vs. 21.1; p=n/a 
After 2.5 months:15.2 vs. 20.8; 
p=n/a 
n/a 
Pain 4 studies (179 vs. 175 pts.) 
for presence of pain 
(dichotomous): 12-54% vs. 
60-100%; risk ratio=0.39; 
p=0.034 
1 study (35 vs. 31 pts.) for pain 
score (100 mm): 33 vs. 30; 
mean difference=0.12; p=N.S. 
Patients (%)132: 
Baseline: n/a; p=n/a 
After 1 month: n/a 
After 1.75 months: 32 vs. 
100; p<0.001 
After 2; 3; 6; 12 months: 
n/a 
Score (100 mm VAS): 
Baseline: 48.8 vs. 50.3; p=N.S. 
After 1, 2 months: n/a 
After 3 months: 37.8 vs. 37.8; 
p=N.S. 
After 6; 12 months: n/a 
Score (100 mm VAS, reduction  
from baseline in mm): 
Baseline: - 
After 1 month: n/a 
After 2 months: -10.2 vs. 0.92; 
p=0.0071 
After 3; 6, 12 months: n/a 
n/a 
Cramps 2 studies (129 vs. 126 pts.) 
for presence of cramps 
(dichotomous): 36-53% vs. 
59-67%; mean 
difference=0.65; p=0.0011 
n/a Score (100 mm VAS): 
Baseline: 34.3 vs. 35.9; p=N.S. 
After 1, 2 months: n/a 
After 3 months: 24.1 vs. 26.9; p=N.S. 
After 6; 12 months: n/a 
n/a n/a 
Restless legs 2 studies (129 vs. 126 pts.) 
for presence of restless legs 
(dichotomous): 46-67% vs. 
62-93%; risk ratio=0.73; 
p=0.0027 
n/a n/a n/a n/a 
                                                             
130
 Subjective symptoms were measured with a visual analogue scale (0-100 mm) for pain, swelling, heaviness, cramps and itching. 
131
 Subjective symptoms were measured with a visual analogue scale (0-100 mm) for pain and discomfort. 
132
 Pain is given in percentage of people without any pain, whereas the baseline values were not stated in the study. 
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Author, year,  
reference number Martinez 2005 [10] Flota-Cervera 2008 [59] Martinez-Zapata 2008 [62] Rabe 2011 [60] Labs 2004 [61] 
Itching  
(= tingling 
sensation) 
n/a n/a Score (100 mm VAS): 
Baseline: 42.4 vs. 42.2; p=N.S. 
After 1, 2 months: n/a 
After 3 months: 35.9 vs. 31.3; p=N.S. 
After 6; 12 months: n/a 
n/a n/a 
Heaviness  
(= heavy legs) 
3 studies (154 vs. 151 pts.) for 
presence of heaviness 
(dichotomous): 7-71% vs. 
52-93%; risk ratio=0.33; 
p=N.S. 
1 study (35 vs. 31 pts.) for 
heaviness score (100 mm): 
36 vs. 32; mean 
difference=0.17; p=N.S. 
n/a Score (100 mm VAS): 
Baseline: 55.2 vs. 59.7; p=N.S. 
After 1, 2 months: n/a 
After 3 months: 44.5 vs. 46.9; 
p=N.S. 
After 6; 12 months: n/a 
n/a n/a 
Swelling  
(= sensation of 
tension) 
2 studies (40 vs. 40 pts.) 
presence of swelling 
(dichotomous): 12-13% vs. 
56-100%; risk ratio=0.19; 
p<0.001 
n/a Score (100 mm VAS): 
Baseline: 45.8 vs. 50.7; p=N.S. 
After 1, 2 months: n/a 
After 3 months: 36.2 vs. 37.5; p=N.S. 
After 6; 12 months: n/a 
n/a n/a 
Paraesthesias 3 studies (154 vs. 151 pts.) for 
presence of paraesthesia 
(dichotomous): 33-44% vs. 
41-80%; risk ratio=0.74; 
p=N.S. 
n/a n/a n/a n/a 
QoL n/a n/a Score (100 mm VAS, measured)133: 
Baseline: 44.5 vs.47.5: p=N.S. 
After 1; 2 months: n/a 
After 3 months: 37.8 vs. 38.2: p=N.S. 
After 6; 12 months: n/a 
Score (100 mm VAS,  
after multi-factorial analysis): 
Baseline: 48.8 vs.45.3: p=N.S. 
After 1; 2 months: n/a 
After 3 months: 39.8 vs. 40.8: p=N.S. 
After 6 months: n/a 
After 12 months: 34.3 vs. 50.3; p=0.02 
Score (100 mm VAS): 
Baseline134: 45.4 vs. 44.4; p=n/a 
After 1 month: n/a 
After 2 months: 40.6 vs. 40.7; p=n/a 
After 2.5 months: 41.2 vs. 39.2; 
p=N.S. 
After 3; 6, 12 months: n/a 
n/a 
                                                             
133
 QoL was measured with the Spanish validated Chronic Insufficiency Venous International Questionnaire (CIVIQ), ranging 0-100 points. 
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Author, year,  
reference number Martinez 2005 [10] Flota-Cervera 2008 [59] Martinez-Zapata 2008 [62] Rabe 2011 [60] Labs 2004 [61] 
Safety-related outcomes 
Adverse events, 
general in % (n) pts. 
5 studies (379 vs. 328 pts.): 
4-36 vs. 0-68 (Risk ratio: 
0.95; CI: 0.44,2.08); 
p=N.S.135 
(type of events not stated) 
n/a n/a; p=N.S. 40 (53) vs. 20 (25); p=n/a 
(type of events not stated) 
39 (50) vs. 39 (49); p=n/a 
(type of events not 
stated) 
Major adverse 
events 
n/a n/a 1 (3) vs. 1 (3); p=N.S 
(digestive intolerance: gastric pain, 
nausea, vomiting vs. digestive 
intolerance, urticarial, lymphoma) 
4 (5) vs. 1 (1); p=n/a 
(type of events not stated) 
n/a 
Minor adverse 
events 
n/a n/a n/a; p=N.S. 36 (48) vs. 19 (24); p=n/a 
(gastrointestinal, general and 
skin/tissue complaintsin both 
groups) 
n/a 
Adverse events, 
treatment-related  
in % (n) pts. 
n/a 4 (1) vs. 4 (1); p=n/a 
(rash vs. n/a) 
n/a; p=N.S. 27 (33) vs. 8 (10); p=n/a 
(type of events not stated) 
7 (9) vs. 6 (8); p=n/a 
(type of events not 
stated) 
Major adverse 
events 
n/a n/a n/a; p=N.S. 2 (2) vs. 0 (0); p=n/a 
(abdominal pain and 
gastroenteritis) 
n/a 
Minor adverse 
events 
n/a n/a n/a; p=N.S. 25 (33) vs. 8 (10); p=n/a 
(type of events not stated) 
n/a 
Abbreviations: acc. = according; CVI = chronic venous insufficiency; n = number (of patients); n/a = data not available; N.S. = not statistically significant; pts. = patients;  
QoL = quality of life; RCT = randomised controlled trial; VAS = visual analogue score; vs. = versus; yrs. = years 
 
 
                                                                                                                                                                                                                                                                                   
134
 QoL was measured with the Chronic Insufficiency Venous International Questionnaire (CIVIQ), ranging 0-100 points. 
135
 The rates of adverse events assume that all withdrawn patients presenting an adverse event.  
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Table 3.1-19: Safety-related outcomes of non-randomised trials for calcium dobesilate-containing agents for CVI 
Author, year,  
reference number Mühleder 1988 [63] Angehrn 1995 [64] Arceo 2002 [65] 
Country Austria Switzerland Mexico 
Study design Non-randomised controlled 
study136 
Single-arm study Single-arm study 
Sponsor n/a OM Laboratories Ltd. Quimica Knoll de Mexico 
Intervention/Product 2x 500 mg calcium dobesilate 
capsules (Doxium®) per day  
+ surgery 
3x 500 mg calcium dobesilate 
capsules (Doxium®) per day 
3x 500 mg calcium dobesilate 
(Doxium®) per day 
Comparator No treatment + surgery none none 
Number of pts 120 375 352 
Age of patients (yrs)  Ø 43 Ø 53 Ø 46 
Sex (% female) 73 83 81 
Height (cm)/Weight 
(kg)/ BMI (kg/m²) 
n/a / n/a / n/a 166 / 72 / n/a n/a / n/a / n/a 
Clinical classification n/a n/a Grade I-II acc. to Widmer 
Primary endpoint n/a n/a n/a 
Inclusion criteria Patients with moderate and 
serious varicosis (due to CVI) 
who had to undergo stripping 
surgery 
Patients with a known history 
of CVI, the presence of 
oedema, pain and/or other 
symptoms. 
Patients of both sexes, aged 
18-65 yrs., diagnosed with CVI 
grade I-II (Widmer) with at 
least two symptoms (heaviness, 
cramps, pain or edema) 
Duration of 
treatment (months) 
2 1 2.25 
Follow-up (months) 0 0 0 
Drop-outs, n (%) n/a 1 (0)137 1 (0) 
Safety-related outcomes 
Adverse events, 
general in % (n) pts. 
n/a 6 (22) 
(gastrointestinal disorders, 
urticarial, paraesthesia, tiredness, 
oppression and weight gain) 
n/a 
Major adverse  
events 
n/a n/a n/a 
Minor adverse 
events 
n/a n/a n/a 
Adverse events, 
treatment-related  
in % (n) pts. 
0 vs. n/a 6 (22) 
(gastrointestinal disorders, 
urticaria and exanthema, 
paraesthesia, tiredness, 
oppression, weight gain) 
18 (63) 
(headache, epigastralgia, 
dizziness, nausea, pyrosis) 
Major adverse  
events 
n/a n/a n/a 
Minor adverse 
events 
n/a n/a n/a 
Abbreviations: acc. = according; CVI = chronic venous insufficiency; n = number (of patients); n/a = data not available;  
pts. = patients; yrs. = years 
                                                             
136
 Study was divided in three groups: group I and II received calcium dobesilate 2 
weeks before and 6 weeks after surgery, group III received no medication. 
137
 A total 88 patients (23%) were excluded for efficacy analysis, mainly due to pro-
hibited medications. Only one patient withdrew from safety analysis (failed return 
to control visit). 
Results 
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Efficacy 
For evaluating the efficacy of calcium dobesilate-containing capillary stabi-
lising agents, we identified 1 systematic review [10] and a total of 4 additional 
RCTs [59-62]. All of these studies were placebo-controlled. 
Overall, there were 1,921 patients in the studies. The patients were on average 
between 49 and 54 years in the calcium dobesilate groups and between 49 and 
55 years in the placebo groups [59-62]. The patients in the systematic review 
were between 10 and 70 years old [10]. The majority of the patients were fe-
males: 84-92% in the treatment groups and 86-93% in the control groups [59-
62] of the single studies and 86% in the systematic review [10]. Furthermore, 
the patients had CVI grade I to V according to Widmer in two studies [10, 59] 
or were CEAP classified 1-6 in three studies [60-62]. In addition, the dura-
tion of treatment was 1-3 months [10, 59-62], and there was a follow-up with-
out treatment for 0.5-9 months in three studies [60-62]. The drop-out rate 
differed between 8 and 26% [10, 60-62]. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.1-20. 
 
Calcium dobesilate-containing agents (+ compression stockings) versus 
placebo (+ compression stockings) 
None of the identified studies assessed the change of the CVI stage, the CVI 
signs in general, trophic alternations and ulcer (both signs of CVI) of a treat-
ment with calcium dobesilate versus placebo (supplemented by compression 
stockings). 
Regarding CVI signs, oedema was assessed in all studies and measured by 
several parameters. The leg volume change (reduction) from baseline was sta-
tistically significantly higher after 1 month (-26 vs. -13 ml/l) in one study [61], 
and after 2 months (-2 vs. 0%/cm³ or -65 vs. +1 ml) in another study [61]. In 
the systematic review (1-1.5 months) the mean difference of change between 
the groups was -0.64 ml, based on 2 RCTs [10]. However, the change of leg 
volume was not statistically significant after 0.5 months after treatment has 
stopped in one study (-15 vs. -17 ml/l) [61]. 
Furthermore, ankle circumference (an indicator for oedema) decreased slightly 
in both study groups over the treatment periods in four different studies (e.g., 
-4 vs. -2.7 mm after 1 months or -1 vs. + 1 mm after 2 months) [59-62], where-
by after 3 months of treatment the difference of reduction between the treat-
ment and control group was not statistically significant (-3.3 vs. -3.3 mm) [62].  
The change of calf circumference (another indicator for oedema) decreased 
also slightly in both study groups in 3 different studies during the treatment 
phase [59-61] (after 1 month: -3.8 vs. -2.3 mm, after 2 months: -2 vs. -3 mm) 
and also in one study 0.5 months after treatment (-2 vs. -3 mm) [60]. Whether 
the differences are statistically significant was not stated. 
Leg circumference was reported in the systematic review (based on 3 RCTs), 
though, not the change of the leg volume from baseline. The mean differ-
ence between the study groups after 1-1.6 months of treatment was -0.09 mm 
which was not statistically significant [10]. However, due to missing baseline 
values, the results do not allow any conclusion on efficacy. 
In addition, the change of leg circumference after 1.75 months was reported 
in one RCT (-9 vs. -3 mm). Whether the difference between the calcium do-
besilate and the placebo group is statistically significant was not stated [59].  
1 systematischen Review 
+ 4 RCTs eingeschlossen 
insgesamt  
1.921 PatientInnen, 
durchschnittlich  
49-55 Jahre alt, 
vorrangig Frauen 
Zusammenfassung in 
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Knöchelumfang 
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Gruppen ähnlich 
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Oedema was additionally reported as dichotomous variable in percentage of 
patients with oedema in the systematic review (based on two RCTs). The dif-
ference between the study groups was not statistically significant after 1-1.5 
months of treatment (risk ratio: 0.41) [10]. 
The symptoms of CVI, in general, were more reduced (on a score of 0-10) in 
the calcium dobesilate groups than in the placebo groups during 2 months of 
treatment and 0.5 months after treatment (-0.66 vs. +0.01 and -0.62 vs. -0.02) 
[60]. It was not stated whether the difference between the groups was statis-
tically significant. 
Pain was reported in the systematic review (based on one RCT) and in an 
additional RCT (score 0-10). The difference between the study groups after 3 
months of treatment was reported as not statistically significant (3.3-3.8 vs. 
3.0-3.8) [10, 62]. However, because of missing baseline values or no stated 
changes of the scores from baseline, the results do not allow conclusions on 
the efficacy. 
In addition, pain was also measured as score reduction (0-10) in one study 
after 2 months (-1.0 vs. -0.1) [60] and in another study after 3 months (-1.1 vs. 
-1.25) of treatment [62]. After 2 months, the difference was statistically sig-
nificant, but not so after 3 months. 
Furthermore, pain was measured with a dichotomous variable: percentage of 
patients with pain (in %). After 1-1.6 months of treatment the difference be-
tween the study groups in the systematic review (based on 4 RCTs) was sta-
tistically significant (risk ratio: 0.39) [10]. After 1.75 months of treatment in an 
additional RCT the difference was still statistically significant (32 vs. 100%) 
[59]. 
The meta-analysis for pain (in % of patients, data come from the studies in 
the systematic review) shows that there are statistically significantly less pa-
tients with pain in the treatment than in the placebo group with a risk ratio 
of 0.40 (Figure 3.1-17). However, the meta-analyses shows also a high heter-
ogeneity with I²>80%. That means the studies are measuring different effects 
due to e.g., differences in subject population or intervention. 
 
Study name Statistics for each study Sample size Risk ratio, 95% CI 
 
Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoid 
fraction 
No 
treatment 
 
Martinez 2005  
(from Hachen 1982) 
0.60 0.33 1.11 9/25 15/25 
Martinez 2005  
(from Casley-Smith 1988) 0.21 0.08 0.59 3/15 14/15 
Martinez 2005  
(from Widmer 1990) 0.89 0.71 1.11 62/114 68/111 
Martinez 2005  
(from Flota 1999) 0.14 0.05 0.36 3/25 24/24 
Total (95% CI) 0.40 0.18 0.89 77/179 121/175 
  
Random effects meta-analysis; I²: 85.0%; p=0.03 Favours calc. dob. Favours placebo 
Figure 3.1-17: Pain (dichotomous) for calcium dobesilate-containing agents (+ compression stockings) vs.  
placebo (+ compression stockings) 
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Cramps were measured in 1 study in terms of change from baseline (on a scale 
of 0-10). The reduction was not statistically significant different between the 
study groups after 3 months of treatment (-1.0 vs. -0.9) [62]. Furthermore, 
cramps were reported by a dichotomous variable (in % of patients) in 2 stud-
ies, summarised in the systematic review, whereas the difference of the values 
was statistically significant (mean difference between groups of dichotomous 
variable: 0.65) after 1-1.5 months [10]. 
For restless legs, the difference between the treatment and the placebo group 
was also described as statistically significant in the systematic review (in % of 
patients, based on 2 RCTs) with a risk ratio of 0.73for the probability of rest-
less legs after 1-1.5 months of treatment with calcium dobesilate compared to 
placebo [10]. 
Itching was reported in 1 RCT with a slightly higher decrease of the score in 
the placebo groups after 3 months of treatment. However, the difference be-
tween the study groups was not statistically significant (change of score on 
scale 0-10: -0.65 vs. 1.09) [62]. 
Heaviness, measured on a score (0-10), did not show a statistically significant 
difference between the study groups in 2 RCTs (one was included in the sys-
tematic review) after 3 months (3.6 to 4.4 vs. 3.2 to 4.7) [10, 62]. However, since 
the results do not show a change from baseline, a conclusion on the efficacy 
cannot be drawn. Nevertheless, in one RCT, heaviness was also assessable as 
the change from baseline, whereby the difference of the change in the score 
(0-10) between the groups was not statistically significant (-1.1 vs. -1.3) [62]. 
The forest plot of the meta-analysis of heaviness (in % of patients, data come 
from the studies in the systematic review [10]) is displayed in Figure 3.1-18. 
The forest plot shows that there are fewer patients with heaviness in the treat-
ment than in the placebo group after 1-1.5 months of treatment, yet the dif-
ference is not statistically significant. However, the meta-analyses shows also 
a high heterogeneity with I²>80%. That means the studies are measuring dif-
ferent effects due to e.g., differences in subject population or intervention. 
 
Study name Statistics for each study Sample size Risk ratio, 95% CI 
 
Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoi
d fraction 
No 
treatment 
 
Martinez 2005  
(from Hachen 1982) 
0.31 0.12 0.81 4/25 13/25 
Martinez 2005  
(from Casley-Smith 1988) 0.07 0.01 0.48 1/15 14/15 
Martinez 2005  
(from Widmer 1990) 0.87 0.75 1.0 81/114 91/111 
Total (95% CI) 0.36 0.10 1.20 86/154 118/151 
  
Random effects meta-analysis; I²: 81.4%; p=0.96 Favours calc. dob.  Favours placebo 
Figure 3.1-18: Heaviness (dichotomous) for calcium dobesilate-containing agents (+ compression stockings) vs.  
placebo (+ compression stockings) 
Another symptom of CVI – swelling – was measured in 1 RCT by change from 
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Krämpfe in 
Behandlungsgruppen 
mehr reduziert 
weniger ruhelose Beine 
in Behandlungsgruppen 
Juckreiz in beiden 
Studiengruppen nicht 
verbessert 
Symptom  
„schwere Beine” in 
Studiengruppen ähnlich 
verbessert (auf Skala) 
etwas weniger 
PatientInnen (in %) mit 
schweren Beinen in 
Behandlungsgruppen 
Schwellungen in 
Placebogruppe etwas 
mehr reduziert 
0,01 0,1 1 10 100 
Vasoprotectives 
106 LBI-HTA | 2014 
of treatment [62]. In addition, swelling was given as the percentage of patients 
with this symptom in the systematic review (results are based on 2 RCTs). 
The difference between the study groups was statistically significant in fa-
vour of calcium dobesilate after 1-1.5 months. The risk ratio risk for the prob-
ability of swellings with calcium dobesilate compared to placebo was 0.19 [10]. 
Paraesthesias were reported in 3 RCTs (included in the systematic review) 
[10] by stating the percentage of patients with this symptom (in %). The dif-
ference between the calcium dobesilate and the placebo group was not statis-
tically significant after 1-1.5 months of treatment (see Figure 3.1-19). The risk 
ratio was 0.74 for the probability of paraesthesias after 1-1.5 months of treat-
ment with calcium dobesilate compared to placebo [10]. 
 
Study name Statistics for each study Sample size Risk ratio, 95% CI 
 
Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoid 
fraction 
No 
treatment 
 
Martinez 2005  
(from Hachen 1982) 
0.92 0.50 1.67 11/25 12/25 
Martinez 2005  
(from Casley-Smith 1988) 0.42 0.20 0.89 5/15 12/15 
Martinez 2005  
(from Widmer 1990) 0.82 0.58 1.16 38/114 45/111 
Total (95% CI) 0.74 0.51 1.08 54/154 69/151 
  
Random effects meta-analysis; I²: 32.8%; p=0.12 Favours calc. dob.   Favours placebo 
Figure 3.1-19: Paraesthesias (dichotomous) for calcium dobesilate-containing agents (+ compression stockings) vs. 
placebo (+ compression stockings) 
Finally, quality of life was assessed in 2 RCTs by change from baseline on a 
scale (0-10), after different durations of treatment. In 1 RCT the reduction 
of the score was slightly, but not statistically significantly higher in the pla-
cebo group after 2 months with treatment plus 0.5 months without treatment 
(-0.42 vs. -0.52) [60]. Furthermore, another study measured the quality of life 
after 3 months of treatment, whereby the difference of the score reduction 
was also not statistically significant (-6.7 vs. -9.3) [62]. 
 
Safety 
For evaluating the safety of calcium dobesilate-containing capillary stabilis-
ing agents, we identified, beside the previously mentioned systematic review 
[10] and 4 RCTs [59-62], 1 additional non-randomised controlled trial (non-
RCT) and 2 single-arm studies (studies with no control group) that met our 
inclusion criteria. The study characteristics and results of the non-RCTs are 
summarised in the Table 3.1-19. 
In the non-RCT a total of 120 patients were receiving either 500 mg calcium 
dobesilate-containing agents twice a day supplemented by surgery or surgery 
alone (control group) [63], and in the single-arm studies a total of 727 patients 
was receiving 500 mg calcium dobesilate-containing agents 3 times a day [64, 
65]. The mean ages of the patients were between 43 and 53 years. Between 73 
and 83% of the patients in both groups were females. The duration of treat-
ment varied from 1 to 2.25 months. There was no follow-up after treatment. In 
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addition, there were no drop-outs [64, 65]. Furthermore, the non-RCT did not 
report adverse events in the control group and was therefore only considered 
for adverse events of a treatment with calcium dobesilate-containing agents.  
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.1-22. 
 
Calcium dobesilate-containing agents (+ compression stockings) versus 
placebo (+ compression stockings) 
General adverse events were stated in the systematic review [10] and in 3 
RCTs [60-62]. The rates differed from 4 to 40% in the treatment and from 0 
to 68% in the control groups [10, 60, 61]. In the systematic review and in one 
RCT, the difference between the study groups was not statistically signifi-
cant [10, 62]. The types of general adverse events were not stated in any of 
these studies.  
The meta-analysis of general adverse events (dichotomous variables, data 
come from 5 studies in the systematic review [10]) is displayed in Figure 3.1-
20. The difference in adverse events between the groups is not statistically 
significant. The risk ratio was 1.08 for the probability of general adverse events 
with calcium dobesilate compared to placebo. However, the meta-analyses 
shows also a high heterogeneity with I²>80%. That means the studies are 
measuring different effects due to e.g., differences in subject population or 
intervention. 
 
Study name Statistics for each study Sample size Risk ratio, 95% CI 
 
Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoid 
fraction 
No 
treatment 
 
Martinez 2005  
(from Hachen 1982) 
7.00 0.38 128.87 3/25 0/25 
Martinez 2005  
(from Widmer 1990) 1.14 0.79 1.65 38/114 45/111 
Martinez 2005  
(from Flota 1999) 0.96 0.06 14.50 1/25 1/24 
Martinez 2005  
(from Jäger 2001) 1.43 0.72 2.85 18/133 12/127 
Martinez 2005  
(from Marinel lo 2002) 0.38 0.25 0.57 21/82 28/41 
Labs 2004 1.00 0.73 1.36 50/128 49/125 
Rabe 2011 1.99 1.32 2.99 53/132 25/124 
Total (95% CI) 1.08 0.65 1.80 184/639 160/577 
  
Random effects meta-analysis; I²: 82.7%; p=0.76 Favours calc. dob.   Favours placebo 
Figure 3.1-20: General adverse events (dichotomous) for calcium dobesilate-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) 
Treatment-related adverse events occurred in 4-27% of patients in the treat-
ment and in 4-8% of patients in the control groups [59-61]. Only one RCT 
stated that the difference of the rates between the study groups was not sta-
tistically significant [62]. 
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The results from the meta-analysis of general adverse events (dichotomous 
variables, coming from 3 studies) show that the difference of adverse events 
is not statistically significant (Figure 3.1-21).The risk ratio was 1.89 for the 
probability of treatment-related adverse events with calcium dobesilate com-
pared to placebo. 
 
Study name Statistics for each study Sample size Risk ratio, 95% CI 
 
Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoid 
fraction 
No 
treatment 
 
Labs 2004 1.10 0.44 2.76 9/128 8/125 
Rabe 2011 3.29 1.70 6.35 35/132 10/124 
Flota-Cervera 2008 0.96 0.06 14.50 1/25 1/24 
Total (95% CI) 1.89 0.78 4.59 45/285 19/273 
  
Random effects meta-analysis; I²: 49.7%; p=0.16 Favours calcium dob.   Favours placebo 
Figure 3.1-21: Treatment-related adverse events (dichotomous) for calcium dobesilate-containing agents  
(+ compression stockings) vs. placebo (+ compression stockings) 
 
Calcium dobesilate-containing agents  
General adverse events were reported in 1 single-arm study and occurred in 
6% of the patients. The most common events were gastrointestinal disorders 
and urticaria [64]. 
Furthermore there were 0 to 18% treatment-related adverse events in the 
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most common events were gastrointestinal disorders, headache, dizziness and 
nausea [63-65]. 
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Risk of bias 
The identified systematic review shows an overall low risk of bias (see Figure 
3.1-22), however, there is a high risk of selection bias due to an unclear re-
search question.  
 
Figure 3.1-22: Risk of bias of systematic review for treatment of CVI with calcium dobesilate-containing agents 
The majority of the identified RCTs for a treatment of CVI with calcium 
dobesilate-containing agents show a low risk of bias for several types of bias-
es (see Figure 3.1-23). A quarter of the studies show a high risk of reporting 
bias due to not reported baseline values. In summary, the risk of bias is low. 
 
Figure 3.1-23: Risk of bias of RCTs for treatment of CVI with calcium dobesilate-containing agents 
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Due to the study design of the single-arm studies, several of the individual 
biases are not relevant (grey-coloured), since there was no control group. The 
risk of the performance and detection bias is high, due to no blinding of the 
outcome assessor and two third of the studies show a high risk of reporting 
bias due to no confounder adjustment (see Figure 3.1-24). In summary, the 
risk of bias is high. 
 
Figure 3.1-24: Risk of bias of (un)controlled studies for treatment of CVI with calcium dobesilate-containing agents 
 
Strength of evidence 
Overall, the strength of evidence of the efficacy and safety of a treatment of 
CVI with calcium dobesilate-containing agents compared to placebo or no 
treatment (only safety) is moderate. The strength of evidence is summarised 
in the Tables 3.1-20 and 3.1-21. 
There was no evidence to compare the efficacy and safety of a treatment of 
CVI with calcium dobesilate-containing agents with other interventions, such 
as lifestyle changes or further local, medical and surgical treatment, men-
tioned in Chapter 1.1.2. 
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Table 3.1-20: Evidence profile: Efficacy of calcium dobesilate-containing agents (+ compression stockings) for treatment of CVI compared to placebo (+ compression stockings) 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: calcium dobesilate-containing agents (+ compression stockings) versus placebo (+ compression stockings) 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): leg volume change from baseline (in ml/l) 
1/253 RCT 1 mo: -26 vs. -13; p=S.S. 
1.5 mo: -15 vs. -17; p=N.S. 
No serious limitations138 n/a (only 1 trial) Direct Imprecise data (-1)139 Moderate 
CVI signs (oedema): leg volume change from baseline (in %/cm³) 
1/256 RCT 2 mo: -2/-65 vs. ±0/+1; p=S.S. No serious limitations138 n/a (only 1 trial) Direct Imprecise data (-1)139 Moderate 
CVI signs (oedema): leg volume change from baseline (in ml) 
2/236 (of 854) 2 RCTs (in syst. 
Review) 
1-1.5 mo: mean difference:-0.64;  
CI: -1.22,-0.06); p=S.S. 
Serious limitations (-1)140 Important 
inconsistency (-1)141 
Direct Imprecise data (-1)139 Low 
CVI signs (oedema): ankle circumference change from baseline (in mm) 
1/253 
1/253 
1/49 
1/156 
1/156 
1/509 
RCT 
RCT 
RCT 
RCT 
RCT 
RCT 
1 mo: -4 vs. -2.7; p=n/a 
1.5 mo: -3 vs. -2; p=n/a 
1.75 mo: -2.6 vs. -3; p=n/a 
2 mo: -1 vs. +1; p=n/a 
2.5 mo: -1 vs. -1; p=n/a 
3 mo: -3.3 vs. -3.3; p=N.S. 
No serious limitations138 
No serious limitations138 
Serious limitations (-1)142 
No serious limitations138 
No serious limitations138 
No serious limitations138 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Direct 
Direct 
Direct 
Imprecise data (-1)139  
Imprecise data (-1)139  
Imprecise data (-1)139  
Imprecise data (-1)139  
Imprecise data (-1)139  
None 
Moderate 
Moderate 
Low 
Moderate 
Moderate 
High 
                                                             
138
 Only unclear blinding of outcome assessor. 
139
 Low incidence, study/studies not powered to detect difference 
140
 Systematic review did not state random sequence generation and blinding of individual studies. 
141
 Systematic review summarised outcomes of studies from different times (e.g., after 0.5, 1, 3 or 4 months) and on different scales. 
142
 Unclear random sequence generation and blinding of outcome assessor. 
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No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI signs (oedema): calf circumference change from baseline (in mm) 
1/253 
1/253 
1/49 
256 
256 
RCT 
RCT 
RCT 
RCT 
RCT 
1 mo: -3.8 vs. -2.3; p=n/a 
1.5 mo: -1.3 vs. -2; p=n/a 
1.75 mo: -16 vs. ±0; p=n/a 
2 mo: -3 vs. ±0; p=n/a 
2.5 mo: -2 vs. -3; p=n/a 
No serious limitations138 
No serious limitations138 
Serious limitations (-1)142 
No serious limitations138 
No serious limitations138 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct Imprecise data (-1)139 
Imprecise data (-1)139 
Imprecise data (-1)139 
Imprecise data (-1)139 
Imprecise data (-1)139 
Moderate 
Moderate 
Low 
Moderate 
Moderate 
CVI signs (oedema): leg circumference change from baseline (in mm) 
3/302 (of 454) 
1/49 
3 RCTs  
(in syst. Review) 
RCT 
1-1.6 mo: mean difference: -0.09,  
CI: -0.34, 0.16; p=N.S.143 
1.75 mo: -9 vs. -3; p=n/a 
Serious limitations (-1)140 
Serious limitations (-1)142 
Important 
inconsistency (-1)141 
n/a (only 1 trial) 
Direct Imprecise data (-1)139 
Imprecise data (-1)139 
Low 
Low 
CVI signs (oedema): patients (in %) 
2/290 (of 854) 2 RCTs  
(in syst. Review) 
1-1.5 mo: risk ratio:0.41; CI: 0.06,2.82; p=N.S. Serious limitations (-1)140 Important 
inconsistency (-1)141 
Direct Imprecise data (-1)139 Low 
CVI signs (ulcer): no evidence 
CVI symptoms (general): change from baseline (score 0-10) 
1/256 RCT 2 mo: -0.66 vs. +0.01; p=n/a 
2.5 mo: -0.62 vs. -0.02; p=n/a 
No serious limitations138 n/a (only 1 trial) Direct Imprecise data (-1)139 Moderate 
CVI symptoms (pain): score (0-10) 
2/575  2 RCTs (1 in syst. 
Review) 
3 mo: 3.3 to 3.8 vs. 3.0 to 3.8;  
p=N.S. in both studies143 
Serious limitations (-1)140 No important 
inconsistency 
Direct None Moderate 
CVI symptoms (pain): change from baseline (score 0-10) 
1/256 
1/509 
RCT 
RCT 
2 mo: -1.0 vs. -0.1; p=s.s: 
3 mo: -1.1 vs. -1.25; p=N.S. 
No serious limitations138 
No serious limitations138 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)139 
None 
Moderate 
High 
CVI symptoms (pain): patients (in %) 
4/354 (of 854) 
1/49 
4 RCTs  
(in syst. Review) 
RCT 
1-1.6 mo: risk ratio: 0.39; CI: 0.16, 0.93; p=S.S. 
1.75 mo: 32 vs. 100; p=S.S. 
Serious limitations (-1)140 
Serious limitations (-1)142 
Important 
inconsistency (-1)141  
n/a (only 1 trial) 
Direct Imprecise data (-1)139 
Imprecise data (-1)139 
Very low 
Low 
CVI symptoms (cramps): change from baseline (score 0-10) 
1/509  RCT 3 mo: -1.02 vs. -0.9; p=N.S. No serious limitations138 n/a (only 1 trial) Direct None High 
                                                             
143
 Systematic review did not show the change from baseline, only the measured values during the treatment phase. 
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No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI symptoms (cramps): patients (in %) 
2/255 (of 854) 2 RCTs  
(in syst. Review) 
1-1.5 mo: mean difference: 0.65; CI: 0.5, 0.84; 
p=S.S. 
Serious limitations (-1)140 Important 
inconsistency (-1)141 
Direct Imprecise data (-1)139 Very low 
CVI symptoms (restless legs): patients (in %) 
2/255 (of 854) 2 RCTs  
(in syst. Review) 
1-1.5 mo: risk ratio: 0.73; CI: 0.59, 0.9; p=S.S. Serious limitations (-1)140 Important 
inconsistency (-1)141 
Direct Imprecise data (-1)139 Very low 
CVI symptoms (itching): change from baseline (score 0-10) 
1/509  RCT 3 mo: -6.5 vs. -10.9; p=N.S. No serious limitations138 n/a (only 1 trial) Direct None High 
CVI symptoms (heaviness): score (0-10) 
2/575 2 RCTs  
(1 in syst. Review) 
3 mo: 3.6 to 4.4 vs. 3.2 to 4.7; p=N.S. in both 
studies 
Serious limitations (-1)140 No important 
inconsistency 
Direct None Moderate 
CVI symptoms (heaviness): change from baseline (score 0-10) 
1/509  RCT 3 mo: -1.07 vs. -1.28; p=N.S. No serious limitations138 n/a (only 1 trial) Direct None High 
CVI symptoms (heaviness): patients (in %) 
3/305 3 RCTs  
(in syst. Review) 
1-1.5 mo: risk ratio: 0.33; CI: 0.08, 1.42; p=N.S. Serious limitations (-1)140 Important 
inconsistency (-1)141 
Direct Imprecise data (-1)139 Very low 
CVI symptoms (swelling): change from baseline (score 0-10) 
1/509  RCT 3 mo: -0.96 vs. -1.32; p=N.S. No serious limitations138 n/a (only 1 trial) Direct None High 
CVI symptoms (swelling): patients (in %) 
2/80 2 RCTs  
(in syst. Review) 
1-1.5 mo: risk ratio: 0.19; CI: 0.08, 0.41; p=S.S. Serious limitations (-1)140 Important 
inconsistency (-1)141 
Direct Imprecise data (-1)139 Very low 
CVI symptoms (paraesthesias): patients (in %) 
3/305 3 RCTs  
(in syst. Review) 
1-1.5 mo: risk ratio: 0.74; CI: 0.51, 1.08; p=N.S. Serious limitations (-1)140 Important 
inconsistency (-1)141 
Direct Imprecise data (-1)139 Very low 
Quality of life: change from baseline (score 0-10) 
1/256 
1/256 
1/509  
RCT 
RCT 
RCT 
2 mo: -0.48 vs. -0.37; p=n/a 
2.5 mo: -0.42 vs. -0.52, p=N.S. 
3 mo: -0.67 vs. -0.93; p=N.S. 
No serious limitations138 
No serious limitations138 
No serious limitations138 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct Imprecise data (-1)139 
Imprecise data (-1)139 
None 
Moderate 
Moderate 
High 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
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Table 3.1-21: Evidence profile: Safety of calcium dobesilate-containing agents (+ compression stockings) for treatment of CVI (compared to placebo) 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Safety: calcium dobesilate-containing agents (+ compression stockings) versus placebo (+ compression stockings) 
Adverse events (general): in % 
8/1,756 8 RCTs (5 in syst. Review) 4 to 40 vs. 0 to 68; p=N.S. Serious limitations (-1)140 Important inconsistency (-1)144 Direct None Low 
Adverse events (treatment-related): in % 
4/1,167 4 RCTs 4 to 27 vs. 4 to 8; p=N.S.  No serious limitations138 Important inconsistency (-1)144 Direct None Moderate 
Safety: calcium dobesilate-containing agents 
Adverse events (general): in % 
1/375 Single-arm study 6 Serious limitations (-1)145 n/a (only 1 trial) Direct Imprecise data (-1)146 Very low 
Adverse events (treatment-related): in % 
3/847 1 non-RCT +  
2 single-arm studies 
0 to 18 Serious limitations (-1)103 No important inconsistency Direct Imprecise data (-1)146 Very low 
Abbreviations: n/a = data not available; non-RCT = non randomised controlled trial; N.S. = not statistically significant; RCT = randomised controlled trial;  
S.S. = statistically significant; vs. = versus 
 
 
                                                             
144
 Huge difference between rates in studies. 
145
 No blinding of outcome assessor (and no randomisation) and no statistical analysis. 
146
 Low incidence, study/studies not powered to detect difference. 
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3.1.6 Comparison between capillary stabilising agents 
Study characteristics 
For evaluating the efficacy and safety of capillary stabilising agents in com-
parison to each other for a treatment of CVI, we identified 1 systematic review 
[58], 2 RCTs [41, 66] and 1 additional non-randomised study [67] that met our 
inclusion criteria. 
Furthermore, one extracted RCT [41] is already included in the systematic re-
view [58], thus the outcomes that are included in the systematic review and 
the RCT will not be reported twice (those are grey marked in the extraction 
Table 3.1-22) 
The studies are comparing agents containing oxerutin (0-beta-hydroxyethyl-
rutoside, HR) with either 50 mg aescin [41, 58] or with agents containing fla-
vonoid fraction (MPFF) [66, 67] for a treatment of CVI. 
The study characteristics and results are summarised in Table 3.1-22 for the 
systematic review and the RCTs and in Table 3.1-23 for the non-randomised 
controlled trial. 
There were no studies identified comparing other capillary stabilising agents 
with each other. 
 
 
 
1 systematischen 
Review, 2RCTs +  
1 non-RCT eingeschlossen 
ein RCT aus 
systematischen Review 
zusätzlich extrahiert 
Vergleich Oxerutin mit 
50 mg Aescin oder 
Flavonoidfraktion 
Studiencharakteristika 
in Tabelle 
keine Studien zu 
anderen Vergleichen 
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Table 3.1-22: Efficacy and safety-related outcomes of a systematic review and randomised controlled trials of capillary stabilising agents versus other capillary stabilising agents for CVI 
Author, year, reference number Rehn 1996 (b) [41] Belcaro 2002 [66] Pittler 2012 [58] 
Country Germany Italy, UK Germany 
Study design RCT147 RCT Systematic review148 
Sponsor n/a n/a None 
Intervention/Product 2x 500 mg HR per day | 2x 500 mg HR per day 
for 1 months, following 1x 500 mg per day 
(Venoruton®) tablet 
2x 1,000 mg HR granulate per day 
(Venoruton®) + compression stockings 
1-2x 50 mg aescin (HCSE) capsules per day 
2x 75 mg aescin (HCSE) capsules per day 
Comparator 2x 50 mg Aescin (HSCE) capsules per day 3x 500 mg MPFF tablets per day (Daflon) + 
compression stockings 
Rutoside, HR 
Number of pts 51 | 35 vs. 51 46 vs. 44 261 
Age of patients (yrs)  Ø 58 | 63 vs. 59 Ø 41 vs. 41 Ø 55-58 vs. 54-63 
Sex (% female) 100 | 100 vs. 100 ~50149 vs. 48  67-100 
Height (cm)/Weight (kg)/BMI (kg/m²) 163 | 162 vs. 165 / 75 | 78 vs. 81 / n/a n/a / n/a / n/a n/a / n/a / n/a 
Clinical classification Grade II acc. to Widmer n/a Grade I-II acc. to Widmer 
Primary endpoint Leg volume n/a CVI-related symptoms and oedema (of 
included studies) 
Inclusion criteria Female menopausal patients, maximum aged 
70 yrs., with uni- or bilateral CVI grade II 
(Widmer) 
Patients with severe venous hypertension 
(ambulatory venous pressure > 60 mm Hg, 
refilling time < 8 seconds), with ankle 
swelling and lipodermatosclerosis 
Patients with CVI, comparing oral 
preparations of HCSE with placebo or 
reference therapy, measuring clinical 
outcomes 
Duration of Treatment (months) 3150 2151 1-3 
Follow-up (months) 1.5 0 n/a 
Drop-outs, n (%) 21 (15) 0 (0) 24 (9) 
Efficacy-related outcomes 
Change of CVI stage n/a n/a n/a 
CVI signs (general) n/a n/a n/a 
Trophic alternations n/a n/a n/a 
                                                             
147
 This study is included in Pittler 2012, whereas not all outcomes of this study were extracted and, therefore, the study appears in this extraction table. 
148
 This systematic review included 17 RCTs on HCSE. Of these, 11 compared HCSE against placebo and/or against compression stockings and four against O-beta-hydroxyethyl 
rutosides (HR). Information about age, sex ratio and clinical classification was not stated in all included studies.  
149
 The shown number of the sex ratio in the HR-group is not exact. 
150
 The study started with a placebo run-in phase of 1 week. 
151
 The study started with a wash-out period of 2 weeks.  
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Author, year, reference number Rehn 1996 (b) [41] Belcaro 2002 [66] Pittler 2012 [58] 
Oedema  
(leg volume or circumference 
Leg volume (ml)152: 
Baseline: 2,182 | 2,220 vs. 2,219; p=n/a 
After 1; 2 months: n/a 
After 3 months: 2,124 |2,179 vs. 2,191; 
p=0.02153 
After 4.5 months: 2,135 | 2,199 vs. 2,193; p=n/a 
After 6; 12 months: n/a 
n/a HCSE vs. HR 
1 study (17 vs. 13 pts.) for reduction of oedema 
(VAS): 0.65 vs. 1.58; mean difference=-0.93; 
p=N.S. 
2 studies (32 vs. 28 pts.) for reduction of 
circumference at ankle (mm): 2-4 vs. 2-4; 
mean difference=2.38; p=N.S. 
1 study (17 vs. 13 pts.) for reduction of 
circumference at calf (mm): 1.8 vs. -5; mean 
difference=6.8; p=S.S. 
1 study (51 vs. 51 pts.) for leg volume (ml):  
26 vs. 46.4; mean difference=-20.4; p=N.S. 
Ulcer n/a n/a n/a 
CVI symptoms (general) n/a154 Score (0-10)155: 
Baseline: 9.6 vs. 9.5; p=n/a 
After 1 month: n/a 
After 2 months: 3.1 vs. 8.9; p=n/a 
After 3; 6; 12 months: n/a 
n/a 
Pain n/a n/a HCSE vs. HR 
1 study (17 vs. 13 pts.) for reduction of pain 
(VAS): 1.85 vs. 1.2; mean difference=0.65; 
p=N.S. 
Cramps n/a n/a n/a 
Restless legs n/a n/a n/a 
Itching (=tingling sensation) Score (0-10): 
Baseline: 2.8 | 3.1 vs. 1.9; p=n/a 
After 1 month: 1.9 | 3.0 vs. 2.1; p=n/a 
After 2 months: 1.9 | 3.0 vs. 1.9; p=n/a 
After 3 months: 1.9 | 2.4 vs. 2.0; p=n/a 
After 4.5 months: 1.7 | 2.4 vs. 2.7; p=n/a 
After 6; 12 months: n/a 
n/a n/a 
                                                             
152
 Leg volume was measured by water-displacement. This outcome is also extracted in Pittler 2012. 
153
 The difference of the reduction between the group that received 2 x 500 mg HR and the group that received HCSE was statistically significant. 
154
 Subjective symptoms were measured with a visual analogue scale (0-10) for itching (tingling sensation), heavy legs (heaviness) and swelling (tingling sensation). 
155
 Subjective symptoms were measured with a composite analogue scale (0-10), for oedema, pain, restless legs, swelling, skin alternations. 
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Author, year, reference number Rehn 1996 (b) [41] Belcaro 2002 [66] Pittler 2012 [58] 
Heaviness (=heavy legs) Score (0-10): 
Baseline: 4.1 | 3.8 vs. 3.0; p=n/a 
After 1 month: 3.1 | 3.3 vs. 3.8; p=n/a 
After 2 months: 2.9 | 3.3 vs. 3.0; p=n/a 
After 3 months: 2.8 | 2.4 vs. 2.7; p=n/a 
After 4.5 months: 2.6 | 2.8 vs. 2.8; p=n/a 
After 6; 12 months: n/a 
n/a n/a 
Swelling (=sensation of tension) Score (0-10): 
Baseline: 3.6 | 4.0 vs. 2.8; p=n/a 
After 1 month: 2.9 | 3.5 vs. 3.3; p=n/a 
After 2 months: 2.9 | 3.5 vs. 3.1; p=n/a 
After 3 months: 2.6 | 2.6 vs. 2.5; p=n/a 
After 4.5 months: 2.3 | 2.3 vs. 2.7; p=n/a 
After 6; 12 months: n/a 
n/a n/a 
Paraesthesia n/a n/a n/a 
QoL n/a n/a n/a 
Safety-related outcomes 
Adverse events, general in % (n) pts. n/a n/a n/a (see also Table 3.1-15) 
Major adverse events n/a n/a n/a (see also Table 3.1-15) 
Minor adverse events n/a n/a n/a (see also Table 3.1-15) 
Adverse events,  
treatment-related in % (n) pts. 
5.1 (3)| 16.2 (6) vs. 3.2 (2); p=n/a 
(gastrointestinal complaints, headache, 
dizziness in all groups) 
0 vs. 0 n/a (see also Table 3.1-15) 
Major adverse events n/a 0 vs. 0 n/a (see also Table 3.1-15) 
Minor adverse events n/a 0 vs. 0 n/a (see also Table 3.1-15) 
Abbreviations: acc. = according; CVI = chronic venous insufficiency; HCSE = horse chestnut seed extract; n = number (of patients); n/a = data not available; N.S. = not statistically significant; 
pts. = patients; QoL = quality of life; RCT = randomised controlled trial; VAS = visual analogue score; vs. = versus; yrs. = years 
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Table 3.1-23: Safety-related outcomes of controlled trials for capillary stabilising agents versus other capillary stabilising agents 
Author, year, reference number Cesarone 2005156 [67] 
Country Italy 
Study design Non-randomised controlled registry study 
Sponsor n/a 
Intervention/Product 2 x 1,000 mg HR granulate per day (Venoruton®) 
Comparator 3 x 500 mg MPFF tablets per day (Daflon
®) 
Number of pts. 62 vs. 60
157 
Age of patients (yrs.)  Ø 43 vs. 42 
Sex (% female) 47 vs. 53 
Height (cm)/Weight (kg)/BMI (kg/m²) n/a / n/a / n/a 
Clinical classification n/a 
Primary endpoint n/a 
Inclusion criteria Patients with chronic venous hypertension  
(ambulatory venous pressure > 60 mm Hg, refilling time < 8 seconds), 
associated with ankle swelling and lipodermatosclerosis 
Duration of Treatment (months) 2 
Follow-up (months) 2 
Drop-outs, n (%) 11 (18) vs. 10 (17)  
Safety-related outcomes 
Adverse events, general (in %) n/a 
Major adverse events n/a 
Minor adverse events n/a 
Adverse events, treatment-related (in %) 0 vs. 0 
Major adverse events 0 vs. 0 
Minor adverse events 0 vs. 0 
Abbreviations: CVI = chronic venous insufficiency, HR = 0(beta-hydroxyethyl)-rutosides; MPFF = miconised purified  
flavonoid fraction; n = number (of patients); n/a = data not available; pts. = patients; yrs. = years 
 
Efficacy 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.1-24. 
 
Oxerutin-containing agents versus 50 mg aescin-containing agents 
For evaluating the efficacy of oxerutin-containing capillary stabilising agents 
compared to agents containing 50 mg of aescin, we identified 1 systematic 
review and an additional RCT that met our inclusion criteria. The results of 
the systematic review are also extracted in Chapter 3.1.4. 
Overall, there were 398 patients in the relevant studies. Patients in the ox-
erutin group received a 500 mg dosage form 1-2 times per day (only stated in 
the RCT) and patients in the aescin group received a 50 mg dosage form1-2 
                                                             
156
 The results of two different studies were described in this article (one RCT and one 
registry study), but only the results of the registry study were extracted, whereas 
the results of the RCT are already described in the previous table under Belcaro 
2002 [66]. 
157
 A total of 143 pts. were included, but only 122 were considered in the study. 
Zusammenfassung in 
GRADE-Tabelle 
1 systematischen Review 
+ 1 RCT eingeschlossen 
insgesamt  
398 PatientInnen ... 
Vasoprotectives 
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times a day [41, 58]. Furthermore, in one study, included in the systematic 
review, patients received 75 mg aescin and therefore this study was excluded 
from our data extraction. 
The patients were on average between 54 and 63 years in the oxerutin groups 
and between 55 and 59 years in the 50 mg aescin groups. The majority of the 
patients in the studies were females: 6-100%. Furthermore, the patients had 
CVI grade I and II according to Widmer. In addition, the duration of treat-
ment was 1-3 months, whereby the follow-up without treatment was 1.5 months 
in the RCT. The drop-out rate ranged from 9 to 15% [41, 58]. 
None of the identified studies assessed the change of the CVI stage, the CVI 
signs in general, trophic alternations, ulcer, cramps, restless legs, paraesthsia 
and quality of life of a treatment of CVI with oxerutin versus 50 mg aescin. 
Regarding the signs of CVI, oedema was assessed in the systematic review by 
several parameters: In 1 study of the review, oedema, measured on a score 
(scaling was not stated), decreased slightly, but not statistically significant, 
more in the oxerutin group than in the aescin group (mean difference of re-
duction between groups: -0.93). The reduction of the circumference at the an-
kle (in mm) was nearly equal in both study groups (mean difference of reduc-
tion between groups: 2.38 mm, based on 2 studies). However, the reduction of 
the calf circumference was statistically significant higher in the aescin group 
than in the oxerutin group (mean difference of reduction between groups: 
6.8 ml, based on 1 study) [58]. Furthermore, the reduction of the leg volume 
(in ml) was reported in the additional RCT and after 3 months of treatment 
there was a statistically significant difference in favour of oxerutin (-58 to -41 
vs. -28 ml). Thus, 1.5 months after the treatment period the significance of the 
group difference was not stated anymore (-47 to -21 vs. -26 ml) [41]. 
Pain, a symptom of CVI, was reported in a study of the systematic review. 
The reduction in the score for pain (scaling not stated) was not statistically 
significantly different between the study groups after 2 months of treatment 
(mean difference of reduction between groups: 0.65) [58]. 
Itching, heaviness and swelling were reported in the additional extracted RCT 
on a scale (0-10), whereby it is unclear if the scores were statistically signifi-
cantly more reduced in one of the study groups. After 3 months of treatment 
and 1.5 months later the score for itching was reduced slightly in the oxeru-
tin group and increased in the 50 mg aescin group (-0.9 to -0.7 vs. +1 and -1.1 
to -0.7 vs. +0.8 respectively). The scores for heaviness and swelling were 
reduced slightly in both study groups after 3 months of treatment and 1.5 
months after treatment. 
 
Oxerutin-containing agents versus flavonoid fraction-containing agents 
For evaluating the efficacy of oxerutin-containing capillary stabilising agents 
compared to flavonoid fraction-containing agents, we identified 1 RCT with 
90 patients [66] that met our inclusion criteria.  
Patients in the oxerutin group received a 1,000 mg dosage form two times per 
day and patients in the flavonoid fraction group received a 500 mg dosage 
form 3 times a day [66].  
The patients were on average 41 years in the oxerutin and in the flavonoid 
fraction group, respectively. Around half of the patients were females. The 
CVI grade of patients was not stated. The duration of treatment was 2 months 
with no additional follow-up. There were no drop-outs [66]. 
... durchschnittlich  
über 50 Jahre alt,  
6-100 % Frauen 
mehrere nicht 
berichtete Endpunkte 
Ödeme verschiedentlich 
gemessen, jedoch 
Reduktion in 
Studiengruppenteilweise 
widersprüchlich 
Schmerzreduktion in 
Studiengruppen ähnlich 
keine eindeutige 
Überlegenheit eines 
Medikaments bei 
Reduktion von Juckreiz, 
schwere Beine und 
Schwellungen 
1 RCT mit  
90 PatientInnen 
eingeschlossen 
1.000 mg Oxerutin 2x 
vs. 500 mg Flavonoid-
fraktion 3x täglich 
PatientInnen 
durchschnittlich 41 
Jahre alt, ca. 50 % 
Frauen 
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The identified RCT did not report on the change of the CVI stage, the CVI 
signs in general, trophic alternations, oedema, ulcer, symptoms like pain, 
cramps, restless legs, itching, heaviness plus paraesthsia and quality of life of 
a treatment of CVI with oxerutin- versus flavonoid fraction-containing agents. 
The only efficacy-related outcome parameter available was general symptoms 
of CVI which was measured on a scale (0-10). The decrease of the score was 
slightly higher in the oxerutin group than in the flavonoid fraction group af-
ter 2 months of treatment (-6.5 vs. -0.6) [66]. It was not stated whether the dif-
ference was statistically significant. 
 
Safety 
Oxerutin-containing agents versus 50 mg aescin-containing agents 
For evaluating the safety of oxerutin-containing agents versus 50 mg aescin-
containing agents for the treatment of CVI only the previously mentioned 
identified RCT [41] was considered. The systematic review did only report 
safety-related outcomes for agents containing 50 mg of aescin in general (see 
also Chapter 3.1.4. 
There was no evidence available to assess general adverse events. Treatment-
related adverse events occurred in 5 to 16% in the oxerutin groups (the study 
contained of two groups receiving oxerutin-containing agents, but with dif-
ferent dosage forms) and in 3% of the 50 mg aescin group [41]. Whether the 
difference between the groups was statistically significant was not stated. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.1-25. 
 
Oxerutin-containing agents versus flavonoid fraction-containing agents 
For evaluating the safety of oxerutin-containing agents versus flavonoid frac-
tion-containing agents for the treatment of CVI we identified one RCT [66] 
and one additional non-randomised controlled trial [67]. 
The non-RCT included 122 patients, aged 43 years in the oxerutin and 42 
years in the flavonoid fraction group. Around 50% of the patients were fe-
males, the grade of the CVI disease was not stated, treatment lasted for at  
leasts 2 months, follow-up after treatment was 2 months and there were around 
17.5% of drop-outs [67]. 
Overall, there was no evidence available to assess general adverse events. Treat-
ment-related adverse events occurred in none of the study groups [66, 67].  
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Risk of bias 
The identified systematic review shows an overall low risk of bias (see Figure 
3.1-25), however, there is some high risk of selection bias due to an unclear 
research question (see also Chapter 3.1.4).  
 
Figure 3.1-25: Risk of bias of systematic review for treatment of CVI comparing capillary stabilising agents 
The majority of the identified RCTs for a treatment of CVI comparing capil-
lary stabilising agents with each other show a low or unclear risk of bias for 
several types of biases (see Figure 3.1-26). Around 40% of the studies show a 
high risk of performance and detection bias due to not reported blinding of 
study personnel or patients. Furthermore, half of the studies show a high risk 
of reporting bias due to reporting of pooled data for several outcomes. In 
summary, the risk of bias is unclear. 
 
Figure 3.1-26: Risk of bias of RCTs for treatment of CVI comparing capillary stabilising agents 
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In the non-RCTs the risk of the performance and detection bias is high, due 
to no blinding of the outcome assessor and two third of the indicators show a 
high risk of reporting bias due to missing confounder adjustment (see Figure 
3.1-27). In summary, the risk of bias is high. 
 
Figure 3.1-27: Risk of bias of non-RCT fortreatment of CVI comparing capillary stabilising agents 
 
Strength of evidence 
Overall, the strength of evidence of the efficacy and safety of comparing ca-
pillary stabilising agents with each other for a treatment of CVI is low to very 
low. Although the majority of studies were RCTs, due to several study limi-
tations and a low number of patients in the studies, the strength of evidence 
was downgraded. The strength of evidence is summarised in Tables 3.1-24 
for efficacy and 3.1-25 for safety comparing oxerutin-containing agents with 
agents containing 50 mg of aescin or flavonoid fraction-containing agents. 
There was no further evidence available to compare other capillary stabilis-
ing agents with each other, like 20 mg aescin- or calcium dobesilate-contain-
ing agents mentioned in Chapter 1.2. 
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Table 3.1-24: Evidence profile: Efficacy of capillary stabilising agents versus other capillary stabilising agents for treatment of CVI 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: oxerutin-containing agents (+ compression stockings) versus 50 mg aescin-containing agents (+ compression stockings) 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): change from baseline (score n/a) 
1/30 (of 261) RCT (in syst. 
Review) 
2 mo: mean difference: -0.93;  
CI: -3.52,-1.66; p=N.S. 
Serious limitations158 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
CVI signs (oedema): leg volume reduction (in ml) 
1/137160 RCT 3 mo: -58 to -41 vs. -28; p=S.S.161 
4.5 mo: -47 to -21 vs. -26; p=n/a 
Serious limitations (-1)162 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
CVI signs (oedema): ankle circumference reduction (in mm) 
2/60 (of 261) 2 RCTs (in 
syst. Review) 
1-2 mo: mean difference: 2.38;  
CI:-1.47, 6.23; p=N.S. 
Serious limitations (-1)138 Important inconsistency (-1)163 Direct Imprecise data (-1)159 Very low 
CVI signs (oedema): calf circumference reduction(in mm) 
1/30 (of 261) RCT (in syst. 
Review) 
2 mo: mean difference: 6.8; CI: 4.26,9.34; 
p= S.S., in favour of 50 mg aescin 
Serious limitations138 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
CVI signs (ulcer): no evidence 
CVI symptoms (general): no evidence 
CVI symptoms (pain): change from baseline (score n/a) 
1/30 (of 261) RCT (in syst. 
Review) 
2 mo: mean difference: 0.65; CI: -1.74,3.04; 
p=N.S. 
Serious limitations138 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
                                                             
158
 Unclear blinding of outcome assessor and allocation concealment. 
159
 Low incidence, study/studies not powered to detect difference. 
160
 Study consisted of 3 groups: two groups received oxerutin-containing agents in two different dosages, results of these two groups were summarised in this table. 
161
 Reduction was statistically significant for group that receive 2 x 500 mg oxerutin-containing agents vs. the group that received 50 mg aescin-containing agents. 
162
 Unclear blinding of outcome assessor and random sequence generation in study. 
163
 Systematic review summarised outcomes of studies from different times (e.g., after 0.5, 1, 3 or 4 months) and on different scales. 
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No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI symptoms (cramps): no evidence 
CVI symptoms (restless legs): no evidence 
CVI symptoms (itching): change from baseline (score 0-10) 
1/137160 RCT 1 mo: -0.9 to -0.1 vs. +0.2; p=n/a  
2 mo: -0.9 to -0.1 vs.±0; p=n/a 
3 mo: -0.9 to -0.7 vs.+0.1; p=n/a 
4.5 mo: -1.1 to -0.7 vs. +0.8; p=n/a 
Serious limitations (-1)140 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
CVI symptoms (heaviness): change from baseline (score 0-10) 
1/137160 RCT 1 mo: -1 to -0.5 vs. +0.8; p=n/a  
2mo: -1.2 to -0.5 vs.. ±0; p=n/a 
3 mo: -1.4 to -1.3 vs. -0.3; p=n/a 
4.5 mo: -1.5 to -1 vs. -0.2; p=n/a 
Serious limitations (-1)140 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
CVI symptoms (swelling): change from baseline (score 0-10) 
1/137160 RCT 1 mo: -0.7 to -0.5 vs. +0.5; p=n/a  
2mo: -0.7 to -0.5 vs. +0.3; p=n/a 
3 mo: -1.4 to -1 vs. -0.3; p=n/a 
4.5 mo: -1.7 to -1.3 vs. -0.1; p=n/a 
Serious limitations (-1)140 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
CVI symptoms (paraesthesias): no evidence 
Quality of life: no evidence 
Efficacy: oxerutin-containing agents (+ compression stockings) versus flavonoid fraction-containing agents (+ compression stockings) 
Change of CVI stage: no evidence 
CVI signs (general): no evidence 
CVI signs (trophic alternations): no evidence 
CVI signs (oedema): no evidence 
CVI signs (ulcer): no evidence 
CVI symptoms (general): change from baseline (score 0-10) 
1/90 RCT 2mo: -6.5 vs. -0.6; p=n/a Serious limitations (-1)164 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
CVI symptoms (pain): no evidence 
                                                             
164
 Study is likely to be open. 
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No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency 
Indirect-
ness 
Other  
modifying factors 
Strength  
of evidence 
CVI symptoms (cramps): no evidence 
CVI symptoms (restless legs): no evidence 
CVI symptoms (itching): no evidence 
CVI symptoms (heaviness): no evidence 
CVI symptoms (swelling): no evidence 
CVI symptoms (paraesthesias): no evidence 
Quality of life: no evidence 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
Table 3.1-25: Evidence profile: Safety of capillary stabilising agents versus other capillary stabilising agents for treatment of CVI 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Safety: oxerutin-containing agents (+ compression stockings) versus 50 mg aescin-containing agents (+ compression stockings) 
Adverse events (general): no evidence 
Adverse events (treatment-related): in % 
1/137  RCT 5 to 16 vs. 3; p=n/a Serious limitations (-1)140 n/a (only 1 trial) Direct Imprecise data (-1)159 Low 
Safety: oxerutin-containing agents (+ compression stockings) versus flavonoid fraction-containing agents (+ compression stockings) 
Adverse events (general): no evidence 
Adverse events (treatment-related): in % 
1/90 
1/122 
RCT 
Non-RCT 
0 vs. o; p=N.S. 
0 vs. o; p=N.S. 
Serious limitations (-1)165 
Serious limitations (-1)166 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct Imprecise data (-1)159 Low 
Very low 
Abbreviations: n/a = data not available; Non-RCT = non-randomised controlled trial; N.S. = not statistically significant; RCT = randomised controlled trial;  
S.S. = statistically significant; vs. = versus 
 
                                                             
165
 Study is likely to be open. 
166
 No blinding. 
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3.2 Treatment of haemorrhoidal diseases 
Overall, 17 randomised controlled trials (RCTs), 1 non-randomised controlled 
trial (non-RCT) and 1 uncontrolled trial (single-arm study), were identified 
to assess either the efficacy or safety or both of capillary stabilising agents 
for the treatment of haemorrhoidal diseases (HD). 
 
3.2.1 Oxerutin-containing agents 
Study characteristics 
For evaluating the efficacy and safety of capillary stabilising agents contain-
ing oxerutin (0-beta-hydroxyethyl-rutoside, HR), we identified 1 RCT [68] 
that met our inclusion criteria. The study is comparing oxerutin-containing 
agents with placebo for a treatment of HD. The dosage of oxerutin was 500 
mg two times a day [68].The study characteristics and results are summa-
rised in Table 3.2-1.  
There were no studies identified comparing oxerutin-containing agents with 
other interventions, such as lifestyle changes or further medical, office-based 
(or local) and surgical treatment, mentioned in Chapter 1.1.3. 
Table 3.2-1: Efficacy and safety-related outcomes of a randomised controlled trial of oxerutin-containing agents vs. 
placebo for HD 
Author, year,  
reference number Wijayanegara 1992 [68] 
Country Indonesia 
Study design RCT 
Sponsor n/a 
Intervention/product 2x 500 mg HR tablets (Venoruton®) per day 
Comparator Placebo 
Number of pts. 48 vs. 49 
Age of patients (yrs.)  29 vs. 30 
Sex (% female) 100 
Clinical classification Grade 1-3167 
Primary endpoint n/a 
Inclusion criteria Women with severe haemorrhoids (grade 1-3), between gestation weeks 12-34; 
uncomplicated pregnancy and with no other treatment 
Duration of Treatment (weeks) 4 
Follow-up (weeks) 0 
Drop-outs, n (%) 3 (3)168 
 
                                                             
167
 It was not stated on which grading the stage of HD was based. 
168
 A total of 100 patients were included in the study and 3 of them withdrew. 
insgesamt 17 RCTs,  
1 non-RCT und  
1 Ein-Arm-Studie 
eingeschlossen 
1 RCT mit 97 
PatientInnen 
eingeschlossen 
 
Dosis: 500 mg  
2 x täglich vs. Placebo 
keine Studien  
mit anderen 
Vergleichsgruppen 
Vasoprotectives 
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Author, year,  
reference number Wijayanegara 1992 [68] 
Efficacy-related outcomes 
Change of HD stage n/a 
HD signs (general) Improved pts. (%)169: 
Baseline: - 
After <1; 1 week: n/a 
After 2 weeks: 21 vs. 0; p=n/a 
After 4 weeks: 67 vs. 0; p=n/a 
After 8, 12; 24, 50 weeks: n/a 
Prolapse (or swelling) n/a 
Discharge (or leakage) n/a 
Incontinence n/a 
HD symptoms (general) Improved pts. (%)170: 
Baseline: - 
After <1 week: n/a 
After 1 week: n/a 
After 2 weeks: 84 vs. 12; p=n/a 
After 4 weeks: 94 vs. 14; p=n/a 
After 8, 12; 24, 50 weeks: n/a 
Pain n/a 
Bleeding n/a 
Itching (or pruritus) n/a 
QoL n/a 
Recurrence rate n/a 
Safety-related outcomes 
Adverse events, general in % (n) pts. n/a 
Major adverse events n/a 
Minor adverse events n/a 
Adverse events, treatment-related  
in % (n) pts. 
63 (3) vs. n/a; p=n/a 
(abdominal discomfort, dizziness vs. n/a)  
Major adverse events n/a 
Minor adverse events n/a 
Abbreviations: HD = haemorrhoidal diseases; HR = 0(beta-hydroxyethyl)-rutosides (also called oxerutin);  
n = number (of patients); n/a = data not available; N.S. = not statistically significant; pts. = patients; QoL = quality of life; 
RCT = randomised controlled trial; vs. = versus; yrs. = years 
 
  
                                                             
169
 Assessment of objective signs was given in percentage of patients with improvement 
(in %), based on bleeding, inflammation and vein dilatation. 
170
 Assessment of subjective symptoms was given in percentage of patients with im-
provement (in %), based on pain, bleeding, exudation, pruritus. 
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Efficacy 
For evaluating the efficacy of capillary stabilising agents containing oxerutin 
(0-beta-hydroxyethyl-rutoside, HR), we identified 1 RCT that met our inclu-
sion criteria [68]. 
There were 97 patients in the study, of whom 48 were treated with 500 mg 
oxerutin tablets (treatment group) and 49 received placebo (control group). 
The patients were on average 29 years in the treatment and 30 years in the 
control group. All patients were females. Furthermore, the patients had HD 
grade 1 to 3, yet, it was not stated on which grading the reported stage was 
based. In addition, the duration of treatment was 4 weeks. There was no fol-
low-up without treatment. The drop-out rate was 3% [68]. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.2-2. 
 
Oxerutin-containing agents versus placebo 
The identified study did not assess the change of the HD stage, the HD signs 
prolapse, discharge and incontinence, the symptoms pain, bleeding and itch-
ing, quality of life and recurrence rate of a treatment of HD with oxerutin 
versus placebo. 
After 2 and 4 weeks of treatment the general signs of HD were more improved 
in the treatment than in the control group (improved patients, after 2 weeks: 
21 vs 0%, after 4 weeks: 67 vs. 0%). It was not stated whether the difference 
between the study groups was statistically significant or not [68]. 
General symptoms of HD improved in more patients in the treatment than 
in the control group after 2 and 4 weeks of treatment respectively (improved 
patients after 2 weeks: 84 vs. 12%, after 4 weeks: 94 vs. 14%) [68]. Whether 
the difference between the study groups was statistically significant or not was 
not mentioned.  
 
Safety 
For evaluating the safety of capillary stabilising agents containing oxerutin 
(0-beta-hydroxyethyl-rutoside, HR), we identified no other study beside the 
previously mentioned RCT [68] that met our inclusion criteria. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.2-2. 
 
Oxerutin-containing agents versus placebo 
There was no available evidence to assess general adverse events. Treatment-
related adverse events occurred in 63% of the patients treated with oxerutin-
containing agents [68]. Treatment-related adverse events in the control group 
were not stated. 
 
  
für Wirksamkeit:  
1 RCT 
insgesamt  
97 PatientInnen,  
im Durchschnitt  
ca. 30 Jahre alt,  
100 % Frauen 
Zusammenfassung in 
GRADE-Tabelle 
zahlreiche nicht 
erhobende Endpunkte 
generelle Anzeichen  
von Hämorrhoiden in 
Behandlungsgruppe 
verbessert 
generelle Symptome in 
Behandlungsgruppe 
stärker verbessert 
für Bewertung 
Sicherheit keine 
weiteren Studien  
Zusammenfassung in 
GRADE-Tabelle 
Nebenwirkungen bei  
63 % der PatientInnen 
in Oxerutin-Gruppe 
Vasoprotectives 
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Risk of bias 
The identified RCT for a treatment of HD with oxerutin-containing agents 
shows an unclear risk of bias for several types of biases (see Figure 3.2-1). In 
addition there is a high risk of reporting bias due to missing description of 
outcomes (only percentage of improved patients for efficacy-related outcomes 
stated). In summary, the risk of bias is mostly unclear. 
 
Figure 3.2-1: Risk of bias of RCTs for treatment of HD with oxerutin-containing agents 
 
Strength of evidence 
Overall, the strength of evidence of the efficacy and safety of a treatment of 
HD with oxerutin-containing agents is low. Although the only identified study 
was a RCT, due to several study limitations and a low number of patients in 
the study the strength of evidence was downgraded. The strength of evidence 
is summarised in the Table 3.2-2. 
There was no evidence available to compare a treatment of HD with oxerutin-
containing agents with other interventions, such as lifestyle changes or further 
office-based and surgical treatment, mentioned in Chapter 1.1.3. 
 
0% 25% 50% 75% 100%
Random sequence generation (selection bias)
Allocation conealment (selection bias)
Blinding (performance and detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Low risk of bias Unclear risk of bias High risk of bias
Bias-Risiko  
insgesamt unklar 
Evidenzstärke  
insgesamt niedrig 
keine Evidenz zu 
Vergleich mit anderen 
Behandlungen 
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Table 3.2-2: Evidence profile: Efficacy and safety of oxerutin-containing agents for treatment of HD compared to placebo 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: oxerutin-containing agents versus placebo  
Change of HD stage: no evidence 
HD signs (general): improved patients (in %) 
1/97 RCT 2 we: 21 vs. 0; p=n/a 
4 we: 67 vs. 0; p=n/a 
Serious limitations (-1)171 n/a (only 1 trial) Direct Imprecise data (-1)172 Low 
CVI signs (prolapse): no evidence 
CVI signs (discharge): no evidence 
CVI signs (incontinence): no evidence 
CVI symptoms (general): improved patients (in %) 
1/97 RCT 2 we: 84 vs. 12; p=n/a 
4 we: 94 vs. 14; p=n/a 
Serious limitations (-1)171 n/a (only 1 trial) Direct Imprecise data (-1)172 Low 
CVI symptoms (pain): no evidence 
CVI symptoms (bleeding): no evidence 
CVI symptoms (itching): no evidence 
Quality of life: no evidence 
Safety: oxerutin-containing agents versus placebo 
Adverse events (general): no evidence 
Adverse events (treatment-related): in % 
1/97 RCT 63 vs. n/a; p=n/a Serious limitations (-1)173 n/a (only 1 trial) Direct Imprecise data (-1)174 Low 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
                                                             
171
 Unclear random sequence generation, allocation concealment and blinding of outcome assessors. 
172
 Low incidence, study/studies not powered to detect difference. 
173
 Unclear random sequence generation, allocation concealment and blinding of outcome assessors. 
174
 Low incidence, study/studies not powered to detect difference. 
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3.2.2 Flavonoid fraction-containing agents 
Study characteristics 
For evaluating the efficacy and safety of flavonoid fraction-containing capil-
lary stabilising agents for a treatment of HD, we identified 13 RCTs [23, 69-
80] and 1 single-arm study (study with no control group) [81] that met our 
inclusion criteria. In addition, we included another publication that was de-
scribed as a non-randomised controlled trial [82]; however, this study consist-
ed of the same patient population as another study [70] (conducted as RCT). 
Therefore, we added the non-RCT to the RCT, due to the fact that adverse 
events were not reported in the RCT. 
Overall, 6 studies compared flavonoid fraction-containing agents with placebo 
[69-72, 74, 75], 3 studies gave the drug after surgery and compared to no treat-
ment after surgery [73, 79, 80], in 3 studies the control groups received an of-
fice-based treatment [23, 76, 77], in 1 study, the control group was treated 
with anti-inflammatory medication [78] and in another study a second con-
trol group did not receive a treatment (except fibre supplements) [77]. 
The dosage of flavonoid fraction-containing agents in the treatment groups 
was 500 mg two to six times a day [23, 69-82]. 
The study characteristics and results are summarised in Table 3.2-3 for RCTs 
and in Table 3.2-4 for the single-arm study.  
There were no studies identified comparing flavonoid fraction-containing 
agents with further lifestyle changing or further medical, office-based and 
surgical treatment options, mentioned in Chapter 1.1.3. 
 
 
13 RCTs +  
1 Ein-Arm-Studie 
eingeschlossen 
Vergleichsgruppen: 
Placebo, keine 
Behandlung, ambulante 
Maßnahmen, Gabe von 
Entzündungshemmern 
Dosis: 500 mg  
2-6x täglich 
Studiencharakteristika 
in Tabelle 
keine Studien  
mit anderen 
Vergleichsgruppen 
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Table 3.2-3: Efficacy and safety-related outcomes of randomised controlled trials of flavonoid fraction-containing agents vs. placebo, no treatment, infrared photocoagulation, 
sclerotherapy, fibre supplements, rubber band ligation or anti-inflammatory medication for HD 
Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
Country Thailand Italy France Singapore Singapore India Turkey Italy Greece Slovenia China Turkey Thailand 
Study design RCT RCT RCT175 RCT RCT RCT RCT RCT RCT RCT RCT RCT RCT176 
Sponsor n/a n/a Servier n/a n/a Serdia Phar-
maceuticals 
n/a  n/a n/a n/a Servier n/a National Re-
search Coun-
cil Thailand 
Intervention/ 
product 
2-3x 500 mg 
MPFF tablets 
(Daflon®) per 
day177 
4-6x 500 mg 
MPFF tablets 
(Daflon®) per 
day178 
2x 500 mg 
MPFF tablets 
(Daflon®) per 
day 
3-6x 500 mg 
MPFF tablets 
(Daflon®) per 
day179, after 
haemor-
rhoidectomy 
4-6x 500 mg 
MPFF tablets 
(Daflon®) per 
day180 + fi-
bre supple-
ments 
2-6x 500 mg 
MPFF tablets 
(Daflon®) per 
day181 
4-6x 500 mg 
MPFF tablets 
(Daflon®) per 
day182, after 
haemor-
rhoidectomy 
2-4x 500 mg 
MPFF tablets 
(Daflon®) per 
day183 
6x 500 mg 
MPFF tablets 
(Daflon®) per 
day alone | 
6x500 mg 
MPFF tablets 
(Daflon®) per 
day + infrared 
photocoagu-
lation alone 
6x 500 mg 
MPFF tablets 
(Detralex®) 
per day, after 
haemor-
rhoidopexy 
4-6x 500 mg 
MPFF tablets 
(Daflon®) per 
day184 
2x 500 mg 
MPFF tablets 
(Daflon®) per 
day 
2-6x 500 mg 
MPFF tablets 
(Daflon®) per 
day185 
Comparator Placebo Placebo Placebo No treat-
ment, after 
haemor-
rhoidectomy 
Not treat-
ment + fibre 
supplements | 
rubber band 
ligation 
Placebo No treat-
ment, after 
haemor-
rhoidectomy 
Anti-
inflammatory 
medication 
Infrared pho-
tocoagulation 
alone 
No treat-
ment, after 
haemor-
rhoidopexy 
Placebo Sclerotherapy Placebo 
Number of pts. 50 vs. 50 50 vs. 50 60 vs. 60 114 vs. 114 39 vs. 66 | 57 50 vs. 50 56 vs. 56 25 vs. 25 117 | 117 vs. 117 30 vs. 33 49 vs. 41 64 vs. 62 189 vs. 190 
                                                             
175
 Additionally, the results for adverse events of Godeberge 1992 [82] were extracted since no safety-related outcomes in Godeberge 1994 [70] were reported. Both articles reported 
the results of the same study.  
176
 This study consisted of three study groups, whereas one group received Cissus quadrangularis L. that did not met our inclusion criteria. 
177
 In the first 4 days of treatment patients received 3 x 500 mg MPFF followed by 2 x 500 gm MPFF per day for the rest of the treatment phase. 
178
 In the first 4 days of treatment patients received 6 x 500 mg MPFF followed by 4 x 500 gm MPFF per day for the rest of the treatment phase. 
179
 In the first 3 days of treatment patients received 6 x 500 mg MPFF followed by 3 x 500 mg MPFF per day for the rest of the treatment phase. 
180
 In the first 5 days of treatment patients received 6 x 500 mg MPFF followed by 4 x 500 mg MPFF per day for the rest of the treatment phase. 
181
 In the first 4 days of treatment patients received 6 x 500 mg MPFF followed by 4 x 500 gm MPFF per day for 3 days. In a second period, patients with stopped bleeding received 
2 x 500 mg MPFF per day for the rest of the treatment phase. 
182
 In the first 3 days of treatment patients received 6 x 500 mg MPFF followed by 4 x 500 mg MPFF per day for the rest of the treatment phase. 
183
 In the first 10 days of treatment patients received 4 x 500 mg MPFF followed by 2 x 500 mg MPFF per day for the rest of the treatment phase. 
184
 In the first 4 days of treatment patients received 6 x 500 mg MPFF followed by 4 x 500 gm MPFF per day for the rest of the treatment phase. 
185
 In the first 4 days of treatment patients received 6 x 500 mg MPFF followed by 4 x 500 gm MPFF per day for 3 days. In a second period, patients with stopped bleeding received 
2 x 500 mg MPFF per day for the rest of the treatment phase. 
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Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
Age of  
patients (yrs.)  
Ø 32 vs. 32 Ø 45 vs. 43 Ø 46 vs. 48 Ø 40 Ø 41 vs. 44 | 
45 
Ø 35 vs. 33 Ø 41 vs. 45 Ø 57 vs. 56 Ø 49 | 48 vs. 
50 
Ø 49 Ø 44 vs. 42 Ø 44 vs. 44 n/a186 
Sex  
(% female) 
56 vs. 62 46 vs. 56 60 vs. 50 46 28 vs. 29 | 32 24 vs. 18 43 vs. 39 36 vs. 36 50 | 52 vs. 52 70 45 vs. 46 48 vs. 48 55 vs. 54 
Clinical  
classification 
Grade 1-2 acc. 
to Goligher 
Grade 1-3187 n/a n/a Grade 1-2188 Grade 1-2188 Grade 3-4188 Grade 2-4188 Grade 1-3188 Grade 3-4188 n/a Grade 1-2 acc. 
to Goligher 
Grade 1-3188 
Primary  
endpoint 
n/a n/a n/a n/a n/a Number of 
patients with 
no bleeding 
after 3 days 
n/a n/a Rate of bleed-
ing cessation 
within 5 days 
after inter-
vention 
n/a Assessment 
of signs and 
symptoms of 
HD 
n/a n/a 
Inclusion  
criteria 
Pts. with 
acute symp-
toms due to 
grade 1-2 of 
internal 
haemorrhoids 
(Goligher) 
Adult pts., 
regardless of 
age and sex, 
with history 
of HD, suffer-
ing from un-
complicated 
+ untreted 
haemorrhoi-
dal attack + 
with/without 
proctorrha-
gia, lasting <3 
days,  
Ambulatory 
pts., aged >18 
yrs., with 
symptomatic 
haemorrhoids 
+ acute epi-
sode in pre-
ceding 2 
months, indi-
cated for 
medical 
treatment 
n/a Pts. with 
bleeding 
nonprolapsed 
haemorrhoids 
Pts. of both 
sexes, aged 
>18 yrs., with 
a history of 
haemorrhoids 
in the last 18 
months + 
acute rectal 
bleeding in 
the last 3 
days + visible 
distended or 
displaced anal 
cushions, 
conforming 
to grade 1 or 
2 internal 
haemorrhoids 
n/a Pts. aged >18 
yrs., with in-
dication for 
haemor-
rhoidectomy, 
past history 
of haemor-
rhoids longer 
than 6 
months, 
symptomatic 
irreducible 
prolapsed 
haemorrhoids 
Ambulatory 
pts of both 
sexes, aged 18 
yrs. or older, 
presenting 
with rectal 
bleeding due 
to grade I-III 
acute internal 
haemorrhoids, 
with no pre-
vious treat-
ment for 
haemorrhoids 
within 6 
months and 
without coex-
isting colon 
diseases 
n/a Pts. of both 
sexes, aged 
>18 yrs., pre-
senting acute 
haemorrhoi-
dal episode 
for first time 
Pts. who suf-
fered from 
symptomatic 
haemorrhoids 
grade 1-2 
(acc. to 
Goligher) 
Acute rectal 
bleeding 
within 5 days  
Duration of 
Treatment 
(weeks) 
2 1 8 1 4 12 1 4 <1189 <1189 1 12 1 
Follow-up 
(weeks) 
0 0 0 Ø 62 24 0 0 8 12 4 0 96 0 
Drop-outs,  
n (%) 
0 (0) vs. 2 (4) 1 (2) vs. 5 (10) 5 (8) vs. 2 (3) n/a 0 vs. 0 | 0 13 (26) vs.  
22 (44) 
n/a n/a 49 (42) | 34 
(29) vs. 52 
(44) 
0 vs. 0 0 13 (10) 41 (7)190 
                                                             
186
 Mean age was not stated, but all patients were younger than 50 years. 
187
 It was not stated on which grading the stage of HD was based. 
188
 It was not stated on which type of grading the stage of HD was based. 
189
 Duration of treatment with MPFF was 5 days. 
190
 From 570 patients a total of 41 patients withdraw from study. 
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Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
Efficacy-related outcomes 
Change of  
HD stage 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
HD signs 
(general) 
Improved pts. 
(%)191: 
Baseline: - 
After <1 
week: 52 vs. 
22; p=n/a 
After 1 week:: 
n/a 
After 2 
weeks: 72 vs. 
67; p=N.S. 
After 4; 8; 12; 
24; 50weeks: 
n/a  
n/a Score 
(n/a)192: 
Baseline: 4.9 
vs. 4.5; 
p=N.S. 
After<1; 1; 2; 
4 weeks: n/a 
After 8weeks: 
0.9 vs. 2.9; 
p<0.01 
After 12; 24; 
50 weeks: n/a  
n/a n/a n/a n/a n/a n/a n/a n/a193 n/a n/a 
Prolapse 
(or  
swelling) 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a Score (0-3): 
Baseline: 1.3 
vs. 1.5; p=N.S. 
After <1 
week: 1.2 vs. 
1.3; p<0.05 
After 1 week: 
1.1 vs. 1.3; 
p<0.05 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Patients (%): 
Baseline: 12 
vs. 12; p=n/a 
After <1 
week: 2 vs. 5; 
p=n/a 
After 1 week: 
0 vs. 5; p=n/a 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
n/a Improved pts. 
(%): 
Baseline: - 
After <1 
week: n/a 
After 1 week: 
3.5 vs. 6.2; 
p=n/a  
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
                                                             
191
 Signs were measured for swelling, congestion, bleeding, exudation and prolapse, but only given as percentage (in %) of improvements. 
192
 Signs were measured on a scale of 0-3 (nil to severe), whereas the score for general signs was not clear. 
193
 Signs were measured for prolapse and discharge on a 4-point grading scale (0-3) and additionally given as percentage of patients (in %) with this sign. 
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Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
Discharge 
(or leakage) 
n/a Score  
(0-3)194: 
Baseline: n/a 
After <1 
week: n/a 
After 1 week: 
0.03 vs. 0.91; 
p<0.001 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Improved pts. 
(%): 
Baseline: - 
After <1; 1; 2; 
4 weeks: n/a 
After 8 
weeks: 97 vs. 
54; p<0.01 
After 12; 24; 
50 weeks: n/a 
n/a n/a n/a n/a n/a n/a n/a Score (0-3): 
Baseline: 1.3 
vs. 1; p=N.S. 
After <1 week: 
1.2 vs. 1.2; 
p=N.S. 
After 1 week: 
1.1 vs. 1.2; 
p=N.S. 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Patients (%): 
Baseline: 2 vs. 
7; p=n/a 
After <1 week: 
2 vs. 2; p=n/a 
After 1 week: 
0 vs. 2; p=n/a 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
n/a Improved pts. 
(%): 
Baseline: - 
After <1 
week: n/a 
After 1 week: 
5.2 vs. 6.2; 
p=n/a  
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Inconti-
nence 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
HD symptoms 
(general) 
Improved pts. 
(%)195: 
Baseline: - 
After <1 week: 
74 vs. 60; p=n/a 
After 1 week: 
n/a 
After 2 weeks: 
97 vs. 94; 
p=N.S. 
Score 
(n/a)196: 
Baseline: n/a 
After <1 
week197: 1.06 
vs. 0.42; 
p<0.001 
After 1 week: 
2.56 vs. 1.2; 
p<0.001 
Score  
(0-3)198: 
Baseline: 6.6 
vs. 6.0; 
p=N.S. 
After <1; 1; 2; 
4 weeks: n/a 
After 8 
weeks: 1.1 vs. 
4.0; p<0.01 
n/a n/a n/a n/a n/a199 n/a n/a n/a200 Score  
(0-2)201: 
Baseline: 1.57 
vs. 1.87; 
p=N.S. 
After <1; 1 
week: n/a 
After 2 weeks: 
1.38 vs. 1.45; 
p=n/a 
n/a 
                                                             
194
 Measured on a scale of 0-3 (nil to severe). 
195
 Symptoms were measured for swelling, congestion, bleeding, exudation and prolapse, but only given as percentage (in %) of improvements. 
196
 Measurement of individual symptoms (pain etc.) were measured on a scale of 0-3 (nil to severe) for the severity of symptoms, whereas the score for general symptoms was not clear. 
197
 Results after 3 days are reported. 
198
 Symptoms were measured on a scale of 0-3, whereas the score at baseline for overall symptoms was >3. 
199
 Symptoms were measured on a score of 0-3 for pain, tenesmus, pruritus and bleeding. Assessment for <0.25 months was done after 3 days. P-Values were calculated for a global score. 
200
 Symptoms were measured for pain, bleeding and itching on a 4-point grading scale and additionally given as percentage of patients (in %) with this symptom. 
201
 Symptoms were measured on a score of 0-2 points for bleeding, pain, heaviness, pruritis and discharge. 
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Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
After 4; 8; 12; 
24; 50 weeks: 
n/a  
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
After 12; 24; 
50 weeks: n/a 
After 4 
weeks: 0.8 
vs. 1.12; 
p<0.05, in 
favour of 
MPFF 
After 8; 12 
weeks: n/a 
After 24 
weeks: 0.08 
vs. 0.24; 
p=n/a 
After 50 
weeks: 0.9 
vs. 0.42; 
p<0.001, in 
favour of SCL 
After 100 
weeks: 1.32 
vs. 0.68; 
p<0.001, in 
favour of SCL 
Pain n/a Score (0-3): 
Baseline: n/a 
After <1 
week: n/a 
After 1 week: 
0.24 vs. 1.26; 
p=n/a 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Improved pts. 
(%): 
Baseline: - 
After <1; 1; 2; 
4 weeks: n/a 
After 8 
weeks: 98 vs. 
47; p<0.01 
After 12; 24; 
50 weeks: n/a 
n/a n/a n/a Score  
(0-10) 202: 
Baseline: 7 vs. 
6; p=N.S. 
After <1 
week: 3.5 vs. 
5; p=0.011 
After 1 week: 
2 vs. 3.5; 
p=0.001 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Score (0-3): 
Baseline: 1.56 
vs. 2.24; p=n/a 
After <1 
week: 0.72 
vs. 1.76; 
p<0.001 
After 1 week: 
0.24 vs. 1.36; 
p= n/a 
After 2 
weeks: 0.16 
vs. 0.6; p=n/a 
After 4 
weeks: 0 vs. 
0.2; p=n/a 
After 8 
weeks: 0 vs. 0 
After 12; 24; 
50 weeks: n/a 
n/a Score  
(0-10)202: 
Baseline: n/a 
After <1 
week: n/a 
After 1 week: 
3.48 vs. 3.40; 
p=N.S. 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Score (0-3): 
Baseline: 3.2 
vs. 3.1; p=N.S. 
After <1 
week: 2.0 vs. 
2.1; p=N.S. 
After 1 week: 
1.4 vs. 1.8; 
p=0.001 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Patients (%): 
Baseline: 73 
vs. 85; p=n/a 
After <1 
week: 18 vs. 
20; p=n/a 
After 1 week: 
6 vs. 15; p=n/a 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
n/a Improved pts. 
(%): 
Baseline: - 
After <1 
week: n/a 
After 1 week: 
33 vs. 33; 
p=n/a  
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
                                                             
202
 Pain was measured on a 10 cm visual analogue scale. 
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Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
Bleeding n/a Score (0-3): 
Baseline: n/a 
After <1 
week: n/a 
After 1 week: 
0.05 vs. 0.83; 
p=n/a 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Improved pts. 
(%): 
Baseline: - 
After <1; 1; 2; 
4 weeks: n/a 
After 8 
weeks: 91 vs. 
59; p<0.01 
After 12; 24; 
50 weeks n/a 
n/a203 Days of 
bleeding: 
3.9 vs. 10.6 | 
5.6; p=0.043 
in favour of 
MPFF com-
pared with 
not treat-
ment; p=N.S. 
comparing 
MPFF with 
rubber band 
ligation; 
p=N.S. com-
paring no 
treatment + 
fibre supple-
ments with 
rubber band 
ligation 
Days of 
bleeding: 
4.9 vs. 7.0, 
p<0.01 
n/a Score (0-3): 
Baseline: 1.04 
vs. 1.8; p=n/a 
After <1 
week: 0.24 
vs. 1.08; 
p<0.001 
After 1 week: 
0 vs. 0.52; 
p=n/a 
After 2 
weeks: 0 vs. 
0.52; p=n/a 
After 4 weeks: 
0 vs. 0 
After 8 weeks: 
0 vs. 0 
After 12; 24; 
50 weeks: n/a 
Pts. with 
stopped 
bleeding (%): 
Baseline: – 
After <1 
week: 59.6 | 
74.8 vs. 55.6; 
p=N.S. be-
tween MPFF 
alone and IRP 
alone| p=S.S. 
between 
MPFF + IRP 
and MPFF 
and IRP 
After 1; 2; 4; 
8; 12; 24; 50 
weeks: n/a 
Days of 
bleeding: 
3.6 | 3.2 vs. 
3.5; p=N.S. 
Days of 
bleeding: 
2.30 vs. 1.97, 
p=N.S. 
Score (0-3): 
Baseline: 2.1 
vs. 2.1; p=N.S. 
After <1 
week: 1.3 vs. 
1.5; p<0.05 
After 1 week: 
1.2 vs. 1.4; 
p<0.05 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Patients (%): 
Baseline: 37 
vs. 39; p=n/a 
After <1 
week: 4 vs. 5; 
p=n/a 
After 1 week: 
2 vs. 7; p=n/a 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Pts with 
bleeding (%): 
Baseline: 79 
vs. 87; p=n/a 
After <1; 1 
week: n/a 
After 2 
weeks: 60 vs. 
88; p=n/a 
After 4 
weeks: 40 vs. 
80; p=n/a 
After 8; 12 
weeks: n/a 
After 24 
weeks: 20 vs. 
24; p=n/a 
After 50 
weeks: 48 vs. 
28; p=n/a 
After 100 
weeks: 68 vs. 
29; p=n/a 
Improved pts. 
(%)204: 
Baseline: - 
After <1 
week: n/a 
After 1 week: 
67.8/16.1 vs. 
74.2/14.0; 
p=n/a  
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Itching (or 
pruritus) 
n/a n/a Improved pts. 
(%): 
Baseline: - 
After <1; 1; 2; 
4 weeks: n/a 
After 8 
weeks: 86 vs. 
58; p<0.01 
After 12; 24; 
50 weeks: n/a 
n/a n/a n/a n/a Score (0-3): 
Baseline: 
0.88 vs. 1.68; 
p=n/a 
After <1 week: 
0.24 vs. 0.92; 
p<0.001 
After 1 week: 
0.12 vs. 0.64; 
p=n/a 
After 2 weeks: 
0 vs. 0.2; 
p=n/a 
After 4 weeks: 
0 vs. 0.16; 
p=n/a 
After 8 
weeks: 0 vs. 0 
After 12; 24; 
50 weeks: n/a 
n/a n/a Score (0-3): 
Baseline: 1.4 
vs. 1.6; p=N.S. 
After <1 week: 
1.2 vs. 1.3; 
p=N.S. 
After 1 week: 
1.1 vs. 1.3; 
p=n/a 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
Patients (%): 
Baseline: 10 
vs. 12; p=n/a 
After <1 week: 
2 vs. 5; p=n/a 
After 1 week: 
0 vs. 5; n/a 
n/a Improved pts. 
(%): 
Baseline: - 
After <1 
week: n/a 
After 1 week: 
6.9 vs. 9.6; 
p=n/a  
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
                                                             
203
 There was some information regarding to bleeding, but the information was not clear and was therefore not extracted. 
204
 Assessed by patients/investigators. 
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Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
QoL n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a Score  
(0-10)205: 
Baseline: n/a 
After <1, 1; 2; 
4; 8; 12; 24; 
50 weeks: n/a 
After 100 
weeks: 4.25 
vs. 6.87; 
p=n/a 
Increase of 
QoL (%): 
Baseline: - 
After 2; 4; 8; 
12; 24; 50 
weeks: n/a 
After 100 
weeks: 36 vs. 
68; p=n/a 
n/a 
Recurrence 
rate 
n/a n/a 0.6 vs. 2.1; 
p<0.01206 
1 vs. 6, 
p=0.03 (dur-
ing follow-
up) 208 
5 | 12 vs. 21; 
p=N.S. (after 
24 weeks) 
208 
Days until 
next epi-
sode207: 
53.1 vs. 34.2; 
p=N.S. 
n/a n/a 13.2 | 4.8 vs. 
13.8; p=N.S. 
(after 12 
weeks)208 
n/a n/a n/a, p<0.05 
in favour of 
sclerothera-
py.209 
n/a 
                                                             
205
 QoL was measured on a visual analogue scale (0-10). 
206
 Number of haemorrhoidal episodes after start of treatment. 
207
 Patients with stopped bleeding (30 vs. 47) were eligible for preventive HD treatment and for those the days until the next episode of HD were reported. 
208
 Recurrence rate was given for relapse in bleeding. 
209
 It was stated that the recurrence rate (relapse in bleeding) was statistically significantly higher in the treatment group. 
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Author, year,  
reference 
number 
Thana-
pongsathorn 
1992 [72] 
Cospite  
1994 [71] 
Godeberge 
1994 [70] 
(Godeberge 
1992 [82]) 
Ho  
1995 [79] 
Ho  
2000 [77] 
Misra  
2000 [74] 
Colak  
2003 [80] 
La Torre 
2004 [78] 
Dimitrou-
lopoulos 
2005 [23] 
Mlakar  
2005 [73] 
Jiang  
2006 [69] 
Yuksel  
2008 [76] 
Panpi-
manmas 2010 
[75] 
Safety-related outcomes 
Adverse 
events,  
general in % 
(n) pts. 
0 vs. 0 8 (4) vs. 6 
(3); p=n/a 
(gastralgia, 
diarrhoea, 
abdominal 
pain, head-
ache vs.  
gastralgia, 
dyspepsia, 
nausea) 
3 (2) vs. 5 (3); 
p=n/a 
(no infor-
mation about 
events) 
5 (6) vs. 6 
(8); p=n/a 
(faecal im-
paction vs. 
faecal impac-
tion and anal 
stricuters) 
n/a 2 (1) vs. 4 (2); 
p=n/a 
(gastritis vs. 
gastritis) 
11 (6) vs. 20 
(8); p=N.S. 
(acute urine 
retention in 
both groups) 
n/a 2 (2) | 3 (4) 
vs. 2 (2)210; 
p=n/a 
(nausea, epi-
gastric dis-
comfort | 
pain, diar-
rhoea, gastro-
intestinal ad-
verse events 
vs. gastroin-
testinal ad-
verse events) 
n/a 2 (1) vs. 0; 
p=n/a 
(abdominal 
discomfort) 
0 vs. 3 (2); 
p=N.S. 
(pain) 
0 (0) vs. 1 
(2)211; p=n/a 
(headache, 
drowsiness, 
gastritis vs. 
headache, 
drowsiness, 
gastritis) 
Major  
adverse 
events 
0 vs. 0 0 vs. 0 n/a n/a n/a n/a n/a n/a 0 | 0 vs. 0 0 vs. 0 n/a n/a n/a 
Minor  
adverse 
events 
0 vs.0 8 (4) vs. (6) 
3; p=n/a 
(gastralgia, 
diarrhoea, 
abdominal 
pain, head-
ache vs.  
gastralgia, 
dyspepsia, 
nausea) 
n/a n/a n/a n/a n/a n/a 2 (2) | 3 (4) 
vs. 2 (2); 
p=n/a210 
(nausea, epi-
gastric dis-
comfort | 
pain, diar-
rhoea, gastro-
intestinal ad-
verse events 
vs. gastroin-
testinal ad-
verse events) 
n/a n/a n/a n/a 
Adverse 
events, treat-
ment-related 
in % (n) pts. 
0 vs.0 n/a n/a 0 vs. n/a 0 vs. 0 | 0 n/a 0 vs. n/a n/a n/a 0 vs. n/a n/a 0 vs. 3 (2); 
p=N.S. 
(pain) 
n/a 
Major ad-
verse events 
0 vs.0 n/a n/a 0 vs. n/a 0 vs. 0 | 0 n/a 0 vs. n/a n/a n/a n/a n/a n/a n/a 
Minor ad-
verse events 
0 vs.0 n/a n/a 0 vs. n/a 0 vs. 0 | 0 n/a 0 vs. n/a n/a n/a n/a n/a n/a n/a 
Abbreviations: acc. = according; HD = haemorrhoidal diseases; MPFF = micronised purified flavonoid fraction); n = number (of patients); n/a = data not available;  
N.S. = not statistically significant; pts. = patients; QoL = quality of life; RCT = randomised controlled trial; SCL = sclerotherapy; vs. = versus; yrs. = years 
 
                                                             
210
 Furthermore, it was stated that a total of 111 patients that received IRP reported pain, whereas the rates for the individual groups were not stated.  
211
 It was not stated whether adverse events were related to treatment or not, but it was stated that these events were the only ones. 
Results 
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Table 3.2-4: Safety-related outcomes of non-randomised trials for flavonoid fraction-containing agents vs.  
placebo for treatment of HD 
Author, year, reference number Buckshee 1997 [81] 
Country India 
Study design Single-arm study 
Sponsor n/a 
Intervention/product 2-6x 500 mg MPFF tablet (Daflon®) per day212 
Comparator None 
Number of pts. 50 
Age of patients (yrs.)  Ø 27 
Sex (% female) 100 
Clinical classification Grade 1-2213 
Primary endpoint n/a 
Inclusion criteria Pts. with amenorrhea >28 weeks, with a history of haemorrhoids, aged >18 yrs. 
and visibly distended or displaced anal cushion on proctoscopy in association 
with at least on symptom of bleeding, pain, exudation or discomfort 
Duration of Treatment (weeks) 5-12214 
Follow-up (weeks) 0 
Drop-outs, n (%) 9 (18) 
Safety-related outcomes 
Adverse events, general in % (n) pts. 18 (9) 
(nausea, diarrhoea) 
Major adverse events n/a 
Minor adverse events n/a 
Adverse events, treatment-related  
in % (n) pts. 
n/a 
Major adverse events n/a 
Minor adverse events n/a 
 
 
Efficacy 
For evaluating the efficacy of flavonoid fraction-containing capillary stabilis-
ing agents for a treatment of HD, we identified 13 RCTs [23, 69-80] that met 
our inclusion criteria.  
Overall, there were 1,981 patients in the studies, of whom patients in the treat-
ment groups received agents containing 500 mg of flavonoid fraction (Daflon
®
) 
two to six times per day. Patients in the control groups received either pla-
cebo, were treated with office-based procedures or did not receive a treatment. 
Furthermore, three studies were conducted after surgery. 
                                                             
212
 In the first 4 days of treatment patients (pregnant women) received 6 x 500 mg 
MPFF followed by 4 x 500 mg MPFF per day for 3 days. In a second phase patients 
received 2 x 500 mg MPFF per day the rest of the study duration. 
213
 It was not stated on which type of grading the stage of HD was based. 
214
 The treatment in this study started with a one week high-dosage phase (all patients 
were pregnant women), followed by a phase that lasted for the rest of the pregnancy 
(median 8 weeks) and a phase of 4 weeks after delivery. 
13 RCTs eingeschlossen 
insgesamt  
1.981 PatientInnen 
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The patients were on average between 32 and 57 years in the treatment groups 
and between 32 and 56 years in the control groups respectively. There were 
around 24 to 60% females in the treatment and 18 to 62% females in the con-
trol groups. If stated, the HD grade was 1 to 4 either according to Goligher 
(see Chapter 1.1.3) or it was not stated which grading was used. The dura-
tion of treatment was from less than one week up to 12 weeks. Half of the 
studies had a follow-up without treatment of 4-96 weeks and half of the stud-
ies had no follow-up. The drop-out rate differed between 0 and 42% in the 
treatment groups and between 0 and 44% in the control groups. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.2-5. 
 
Flavonoid fraction-containing agents versus placebo  
None of the identified studies assessed the change of the HD stage, inconti-
nence and the quality of life of a treatment with flavonoid fraction-containing 
agents versus placebo. 
The general HD signs improved slightly, but not statistically significant, more 
in the flavonoid fraction group than in the placebo group during 2 weeks of 
treatment (72 vs. 67% improved patients) [72]. In addition, the score for 
general HD signs could be statistically significantly more reduced in the fla-
vonoid fraction group than in the control group after 8 weeks of treatment in 
one study (-4 vs. -1.6, however, the scale used was not stated) [70]. 
Prolapses (also described as swellings) improved during 1 week of treatment 
in less patients in the flavonoid fraction group than in the placebo group 
(3.5 vs. 6.2%) [75]. Furthermore, prolapses, measured on a scale (0-10) were 
reduced likewise in both study groups during one week of treatment (-0.67 vs. 
-0.67) [69]. In addition, the percentage of patients with prolapses were more 
reduced in the flavonoid fraction group than in the placebo group during one 
week of treatment (-100% vs. -58%) [69]. Whether the difference between the 
groups was statistically significant was not stated. 
There were statistically significantly more improved patients regarding dis-
charge (or leakage) in the flavonoid fraction group than in the placebo group 
after 8 weeks of treatment (97 vs. 54%) [70]. Likewise, the percentage of pa-
tients with discharge were more reduced in the flavonoid fraction group than 
in the placebo group during one week of treatment (-100% vs. -71%), howev-
er, if the difference between the groups was statistically significant or not 
was not stated. 
The general symptoms improved in more patients in the treatment group 
compared to the control group after 2 weeks of treatment (97 vs. 94%), yet 
the difference was not statistically significant [72]. In contrast, measured by a 
score (scaling was not stated), the general symptoms were reduced more in the 
flavonoid group than in the placebo group after 8 weeks of treatment (-5.5 
vs. -2.0). The group difference was statistically significant [70]. 
Pain improved in statistically significantly more patients in the flavonoid frac-
tion group during 8 weeks of treatment than in the placebo group (98 vs. 47%) 
[70].  
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Furthermore, the score for pain (0-10) was more reduced in the treatment 
group compared to placebo (-6.0 vs. -4.33) during 1 week of treatment. The 
difference between the study groups was statistically significant [69]. In ad-
dition, the percentage of patients with pain were more reduced in the flavo-
noid fraction group than in the placebo group during one week of treatment 
(-92% vs. -82%) [69]. 
Bleeding was measured with several parameters: there was a statistically sig-
nificant difference in favour of flavonoid-containing agents compared to pla-
cebo regarding the percentage of improved patients after 8 weeks of treatment 
(91 vs. 59%) [70]. Measured on a score (0-10), after 1 week of treatment the 
results were also statistically significant in favour of the treatment group (-0.9 
vs. -0.7) [69]. The average days of bleeding were 5 and 7 in the treatment and 
control group respectively [74]. In addition, the percentage of patients with 
bleeding was more (not stated if statistically significantly) reduced in the 
treatment than in the placebo group after 1 week of treatment [69]. 
After 8 weeks of treatment, itching improved in statistically significantly more 
patients in the flavonoid fraction group than in the placebo group (86 vs. 58%) 
[70]. The number of patients with itching was more (not stated if statistically 
significantly) reduced in the treatment group (-100% vs. -58%) and the score 
(0-10) for itching was reduced by the same value in both study groups (-0.3 
vs. -0.3) after 1 week of treatment [69]. 
The recurrence rate was lower in the flavonoid fraction group (0.6 vs. 2.1) in 
one study. The group difference was statistically significant [70]. However, 
the difference of days until the next haemorrhoidal episode was not statisti-
cally significant between the groups in another study (53 vs. 34) [74]. 
 
Flavonoid fraction-containing agents after surgery versus  
no treatment after haemorrhoidectomy 
None of the identified studies assessed the change of the HD stage, any of the 
HD signs, HD symptoms in general, itching (a typical HD symptom) and the 
quality of life resulting from treatment with flavonoid fraction-containing 
agents versus no treatment after previous surgery. 
The score for pain (0-10) was more reduced during 1 week of treatment after 
haemorrhoidal surgery in the group that received flavonoid fraction-contain-
ing agents than the group that did not receive a treatment (-5 vs. -2.5). The 
difference between the study groups was statistically significant [80]. 
One RCT reported no statistically significant difference between the study 
groups regarding the days of bleeding after surgery (2.3 vs. 2 days) [73]. 
The recurrence rate (relapse in bleeding) was lower in the flavonoid fraction 
group than in the group that did not receive a treatment during the follow-
up (Ø 62 weeks) (1 vs. 6%). The difference between the study groups was sta-
tistically significant [79]. 
 
Flavonoid fraction-containing agents versus anti-inflammatory medication 
There was no evidence available assessing the change of the HD stage, any of 
the HD signs, the HD symptoms in general, the quality of life and recurrence 
rate of a treatment with flavonoid fraction-containing agents versus anti-in-
flammatory medication. 
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After 4 weeks without treatment, the scores (0-10) for pain, bleeding and itch-
ing were reduced slightly, but not statistically significant, less in the group 
that had received flavonoid fraction-containing agents compared to the con-
trol group that had received anti-inflammatory medications (pain: -5.3 vs. -7.3, 
bleeding: -3.3 vs. -6.0, itching: -3.0 vs. -5.67) [78].  
 
Flavonoid fraction-containing agents (+ fibre supplements) versus  
office-based treatment (+ fibre supplements) 
There was no evidence available assessing the change of the HD stage, any of 
the HD signs, the HD symptoms pain and itching after treatment with fla-
vonoid fraction-containing agents (partly supplemented by fibre supplements) 
versus office-based treatments (also partly supplemented by fibre supple-
ments). 
The scores (0-10) for general HD symptoms were likewise reduced in the 
flavonoid fraction and in the control group during the treatment phase (after 
4 weeks: -4 vs. -4) and also 38 weeks after the treatment has stopped (after 50 
weeks: -7.5 vs. -7.5). However, after 88 weeks without treatment the score re-
duction was statistically significantly lower in the flavonoid fraction group 
(-1.5 vs. -6.0) [76]. 
During the treatment phase, there were more patients with stopped bleeding 
in the flavonoid fraction group than in the group that received an office-based 
treatment (after 4 weeks: 60 vs. 20%), whereas 88 weeks after the treatment 
phase there were fewer patients with stopped bleeding in the treatment group 
(after 100 weeks: 32 vs. 71%) [23, 76]. Whether the differences are statistical-
ly significant is unknown. Furthermore, two studies reported differences be-
tween the study groups regarding days of bleeding (3.6 to 3.9 vs. 3.5 to 5.6 
days). However, the differences were not statistically significant [23, 77]. 
After 100 weeks – 88 weeks after the treatment phase – patients in the flavo-
noid fraction group had a lower increase in quality of life than patients in the 
control group (36 vs. 68%) [76]. 
Finally, the differences of the recurrence rate between the study groups were 
not statistically significant in two studies [23, 77] and statistically significant 
in one study in favour of the office-based treatment [76] (5 to 13 vs. 21 to 14%). 
 
Flavonoid fraction-containing agents (+ fibre supplements) versus  
no treatment (+ fibre supplements) 
The identified study did not assess the change of the HD stage, any of the HD 
signs, HD symptoms in general, pain plus itching and the quality of life of a 
treatment with flavonoid fraction-containing agents (and additional fibre sup-
plements) versus no treatment (and additional fibre supplements). 
The number of days of bleeding was lower in the flavonoid fraction group 
than in the group that did not receive a treatment (3.9 vs. 10.6 days). Howev-
er, the difference was not statistically significant [77].  
In addition, the recurrence rate was lower in the treatment group compared 
to the control group (5 vs. 12%). The difference was not statistically signifi-
cant [77]. 
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Safety 
For evaluating the safety of flavonoid fraction-containing agents for treatment 
of HD, we identified, beside the previous mentioned RCTs [23, 69-80], an 
additional single-arm study with 50 patients. All of them were females, aged 
27 years on average, with HD grade 1-2 (based on unknown grading) [81]. 
Furthermore, we added another publication [82] to an already included study 
[70], since safety-related outcomes were only reported in the additional one. 
A summary of the effect sizes for the individual outcome indicators is present-
ed in Table 3.2-6. 
 
Flavonoid fraction-containing agents versus placebo  
General adverse events differed between 0 and 8% in the flavonoid fraction 
groups and between 0 and 6% in the control groups. It was not stated wheth-
er the difference was statistically significant or not. The most common adverse 
events in both groups were abdominal discomfort, nausea, headache, pain and 
drowsiness [69, 71, 72, 74, 75, 82]. 
The meta-analysis of the general adverse events is displayed in Figure 3.2-2. 
The risk ratio was 0.84 for the probability of general adverse events with fla-
vonoid fraction-containing agents compared to placebo. The results show that 
there is no statistically significant difference between occurred adverse events 
in the treatment and in the placebo group.  
 
Study name Statistics for each study Sample size Risk ratio, 95% CI 
 
Risk 
ratio 
Lower 
limit 
Upper 
limit 
Flavonoid 
fraction 
No 
treatment 
 
Cospite 1994 1.33 0.31 5.65 4/50 3/50 
Godeberge 1994/1992 0.67 0.12 3.85 2/60 3/60 
Misra 2000 0.50 0.05 5.34 1/50 2/50 
Jiang 2006 2.52 0.11 60.25 1/49 0/41 
Panpimanmas 2010 0.20 0.32 2.71 0/189 2/190 
Total (95% CI) 0.84 0.34 2.11 8/398 10/391 
  
Random effects meta-analysis; I²: 0.0%; p=0.72 Favours MPFF   Favours placebo 
Figure 3.2-2: General adverse events (dichotomous) for flavonoid fraction-containing agents vs. placebo 
There were no treatment-related adverse events in any of the study groups 
[72]. 
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Flavonoid fraction-containing agents after haemorrhoidectomy versus  
no treatment after haemorrhoidectomy 
General adverse events occurred in 5 to 11% of the patients in the flavonoid 
fraction groups and in 6-20% of the patients in the control groups after haem-
orrhoidectomy [79, 80]. The difference between the groups was not statisti-
cally significant in one study [80]. The most common adverse events were 
faecal impaction and acute urine retention in both groups [79, 80]. 
In addition, all 3 identified studies mentioned that there were no treatment-
related adverse events in the flavonoid fraction group [73, 79, 80] 
 
Flavonoid fraction-containing agents versus anti-inflammatory medication 
There was no evidence available to assess the safety of a treatment with fla-
vonoid fraction-containing agents versus anti-inflammatory medication.  
 
Flavonoid fraction-containing agents (+ fibre supplements) versus  
office-based treatment (+ fibre supplements) 
A total of 2 RCTs reported general adverse events in 0-2% of the patients in 
the treatment and in 2-3% of the patients in the control groups [23, 76]. The 
difference between the study groups was not statistically significant in one 
study [76]. 
Treatment-related adverse events did not occur in the flavonoid fraction 
groups, though, in up to 3% of the patients in the groups that received an of-
fice-based treatment [76, 77]. The difference between the study groups was 
not statistically significant in both studies [76, 77]. 
 
Flavonoid fraction-containing agents (+ fibre supplements) versus  
no treatment(+ fibre supplements) 
There was no evidence available to assess general adverse events of a treatment 
of flavonoid fraction-containing agents versus no treatment. 
On the other hand, treatment-related adverse events did not occur in any of 
the study groups [77]. 
 
Flavonoid fraction-containing agents 
In addition, the included single-arm study reported general adverse events in 
18% of the patients with treatment of HD with flavonoid fraction-containing 
agents [81]. 
Treatment-related adverse events were not stated in the study. 
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Risk of bias 
The majority of the identified RCTs for a treatment of HD with flavonoid 
fraction-containing agents show a low or unclear risk of bias for several types 
of biases (see Figure 3.2-3). Around 15% of the studies show a high risk of 
attrition bias due to high drop-out rates and no intention to treat analysis. 
Furthermore, 38% of the studies show a high risk of reporting bias due to 
reporting incomplete data for several outcomes. In summary, the risk of bias 
is low to unclear. 
 
Figure 3.2-3: Risk of bias of RCTs for treatment of HD with flavonoid fraction-containing agents 
In the uncontrolled studies, the risk of the performance and detection bias is 
high, due to no blinding of the outcome assessor and more than half of the 
indicators show a high risk of reporting bias due to no confounder adjustment 
(see Figure 3.2-4). In summary, the risk of bias is high, due to the uncontrolled 
study design. 
 
Figure 3.2-4: Risk of bias of (un)controlled trials for treatment of HD with flavonoid fraction-containing agents 
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Strength of evidence 
Overall, the strength of evidence of the efficacy and safety of flavonoid frac-
tion-containing agents for a treatment of HD is low to moderate. Although the 
majority of studies were RCTs, due to several study limitations and a low 
number of patients in the studies, the strength of evidence was downgraded. 
The strength of evidence is summarised in Tables 3.2-5 for efficacy and 3.2-6 
for safety. 
There was no evidence available to compare a treatment of HD with flavonoid 
fraction-containing agents with other interventions, such as further lifestyle 
changes or further medical, office-based and surgical treatment, mentioned in 
Chapter 1.1.3. 
 
 
Evidenzstärke insgesamt 
niedrig bis moderat 
keine Evidenz zu 
Vergleich mit anderen 
Behandlungen 
  
R
esu
lts 
LB
I-H
T
A
 | 20
14
 
14
9
 
Table 3.2-5: Evidence profile: Efficacy of flavonoid fraction-containing agents for treatment of HD 
No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: flavonoid fraction-containing agents versus placebo  
Change of HD stage: no evidence 
HD signs (general): improved patients (in %) 
1/100 RCT <1 we: 52 vs. 22; p=n/a 
2 we: 72 vs. 67; p=N.S. 
Serious limitations (-1)215 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD signs (general): change from baseline (score, not stated) 
1/120 RCT 8 we: -4 vs. -1.6; p=S.S. Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD signs (prolapse): improved patients (in %) 
1/379 RCT 1 we: 3.5 vs. 6.2; p=n/a Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD signs (prolapse): patients change from baseline (in %) 
1/90 RCT <1 we: -83 vs. -58; p=n/a 
1 we: -100 vs. -58; p=n/a 
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD signs (prolapse): change from baseline (score 0-10) 
1/90 RCT <1 we: -0.33 vs. -0.67; p=n/a 
1 we: -0.67 vs. -0.67; p=n/a 
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD signs (discharge): improved patients (in %) 
1/379 
1/120 
RCT 
RCT 
1 we: 5.2 vs. 6.2; p=n/a 
8 we: 97 vs. 54; p=S.S. 
Serious limitations (-1)217 
Serious limitations (-1)217 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Imprecise data (-1)216 
Imprecise data (-1)216 
Low 
Low  
HD signs (discharge): patients change from baseline (in %) 
1/90 RCT <1 we: ±0 vs. -71; p=n/a 
1 we: -100 vs. -71; p=n/a 
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD signs (incontinence): no evidence 
HD symptoms (general): improved patients (in %) 
1/100 RCT <1 we: 74 vs. 60; p=n/a 
2 we: 97 vs. 94; p=N.S. 
Serious limitations (-1)215 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD symptoms (general): change from baseline (score, not stated) 
1/120 RCT 8 we: -5.5 vs. -2.0; p=S.S. Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
                                                             
215
 Unclear allocation concealment and blinding of outcome assessor. 
216
 Low incidence, study/studies not powered to detect difference. 
217
 Unclear random sequence generation, allocation concealment and blinding of outcome assessor. 
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No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
HD symptoms (pain): improved patients (in %) 
1/379 
1/120 
RCT 
RCT 
1 we: 33 vs. 33; p=n/a 
8 we: 98 vs. 47; p=S.S. 
Serious limitations (-1)217 
Serious limitations (-1)217 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct Imprecise data (-1)216 
Imprecise data (-1)216 
Low 
Low 
HD symptoms (pain): patients change from baseline (in %) 
1/90 RCT <1 we: -75 vs. -76; p=n/a 
1 we: -92 vs. -82; p=n/a 
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD symptoms (pain): change from baseline (score 0-10) 
1/90 RCT <1 we: -4.0 vs. -3.33; p=N.S. 
1 we: -6.0 vs. -4.33; p=S.S.  
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD symptoms (bleeding): improved patients (in %) 
1/379 
1/120 
RCT 
RCT 
1 we: 16 to 68 vs. 14 to 74; p=n/a 
8 we: 91 vs. 59; p=S.S. 
Serious limitations (-1)217 
Serious limitations (-1)217 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct Imprecise data (-1)216 
Imprecise data (-1)216 
Low 
Low 
HD symptoms (bleeding): patients change from baseline (in %) 
1/90 RCT <1 we: -89 vs. -87; p=n/a 
1 we: -95 vs. -82; p=n/a 
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD symptoms (bleeding): change from baseline (score 0-10) 
1/90 RCT <1 we: -0.8 vs. -0.6; p=S.S. 
1 we: -0.9 vs. -0.7; p=S.S. 
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD symptoms (bleeding): days of bleeding 
1/100 RCT 5 vs. 7; p=S.S. Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD symptoms (itching): improved patients (in %) 
1/379 
1/120 
RCT 
RCT 
1 we: 7 vs. 10; p=n/a 
8 we: 86 vs. 58; p=S.S. 
Serious limitations (-1)217 
Serious limitations (-1)217 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct Imprecise data (-1)216 
Imprecise data (-1)216 
Low 
Low 
HD symptoms (itching): patients change from baseline (in %) 
1/90 RCT <1 we: -80 vs. -58; p=n/a 
1 we: -100 vs. -58; p=n/a 
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD symptoms (itching): change from baseline (score 0-10) 
1/90 RCT <1 we: -0.2 vs. -0.3; p=N.S. 
1 we: -0.3 vs. -0.3; p=n/a  
No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
Quality of life: no evidence 
Recurrence rate: in % 
1/120 RCT 0.6 vs. 2.1; p=S.S.  Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
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No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Recurrence rate: days until next episode 
1/100 RCT 53 vs. 34; p=N.S.  Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
Efficacy: flavonoid fraction-containing agents after haemorrhoidectomy versus no treatment after haemorrhoidectomy 
Change of HD stage: no evidence 
HD signs: no evidence 
HD symptoms (general): no evidence 
HD symptoms (pain): change from baseline (score 0-10) 
1/112 RCT <1 we: -3.5 vs. -1; p=S.S. 
1 we: -5 vs. – 2.5; p=S.S. 
No serious limitations218 n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
HD symptoms (bleeding): days of bleeding 
1/63 RCT 2.3 vs.. 2; p=N.S. Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD symptoms (itching): no evidence 
Quality of life: no evidence 
Recurrence rate: in % 
1/128 RCT 1 vs. 6; p=S.S.  No serious limitations218 n/a (only 1 trial) Direct Imprecise data (-1)216 Moderate 
Efficacy: flavonoid fraction-containing agents versus anti-inflammatory medication 
Change of HD stage: no evidence 
HD signs: no evidence 
HD symptoms (general): no evidence 
HD symptoms (pain): change from baseline (score 0-10) 
1/50 RCT <1 we: -3.0 vs. -1.67; p=S.S. 
1 we: -4.4 vs. -3.0; p=n/a 
2 we: -4.67 vs. -5.33; p=n/a 
4 we: -5.33 vs. -6.67; p=n/a 
8 we: -5.33 vs. -7.33; p=N.S. 
Serious limitations (-1)219 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
                                                             
218
 Only unclear allocation concealment and blinding of personnel and participants, but random sequence generation and blinded outcome assessor. 
219
 High risk of bias due to non-blinded study design. 
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No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
HD symptoms (bleeding): change from baseline (score 0-10) 
1/50 RCT <1 we: -2.67 vs. -2.33; p=n/a 
1 we: -3.33 vs. -4.33; p=n/a 
2 we: -3.33 vs. -4.33; p=n/a 
4 we: -3.33 vs. -6.0; p=N.S. 
8 we: -3.33 vs. -6.0; p=N.S. 
Serious limitations (-1)219 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD symptoms (itching): change from baseline (score 0-10) 
1/50 RCT <1 we: -2.0 vs. -2.67; p=n/a 
1 we: -2.67 vs. -3.33; p=n/a 
2 we: -3.0 vs. -5.0; p=n/a 
4 we: -3.0 vs. -5.0; p=n/a. 
8 we: -3.0 vs. -5.67; p=N.S. 
Serious limitations (-1)219 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
Quality of life: no evidence 
Recurrence rate: no evidence 
Efficacy: flavonoid fraction-containing agents (+ fibre supplements) versus office-based treatment (+ fibre supplements) 
Change of HD stage: no evidence 
HD signs: no evidence 
HD symptoms (general): change from baseline (score 0-10) 
1/126 RCT 2 we: -1.0 vs. -2.0; p=n/a 
4 we: -4.0 vs. -4.0; p=n/a 
24 we: -7.5 vs. -8.0; p=n/a 
50 we: -7.5 vs. -7.5; p=n/a 
100 we: -1.5 vs. -6.0; p=S.S. 
Serious limitations (-1)220 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD symptoms (pain): no evidence 
HD symptoms (bleeding): patients with stopped bleeding (in %) 
1/234221 
1/126 
1/126 
1/126 
1/126 
1/126 
RCT 
RCT 
RCT 
RCT 
RCT 
RCT 
<1 we: 59.6 vs.55.6; p=N.S. 
2 we: 40 vs. 12; p=n/a 
4 we: 60 vs. 20; p=n/a 
24 we: 80 vs. 76; p=n/a 
50 we: 52 vs. 72; p=n/a 
100 we: 32 vs. 71; p=n/a 
Serious limitations (-1)222 
Serious limitations (-1)220 
Serious limitations (-1)220 
Serious limitations (-1)220 
Serious limitations (-1)220 
Serious limitations (-1)220 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
n/a (only 1 trial) 
Direct 
Direct 
Direct 
Direct 
Direct 
Direct 
Direct 
Imprecise data (-1)216 
Imprecise data (-1)216 
Imprecise data (-1)216 
Imprecise data (-1)216 
Imprecise data (-1)216 
Imprecise data (-1)216 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
                                                             
220
 High risk of bias due to random sequence generation by hospital registration number. Furthermore, blinding of participants not possible and blinding of outcome assessor unclear. 
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No of studies/ 
patients 
Study 
Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
HD symptoms (bleeding): days of bleeding 
2/330223 RCT 3.6 to 3.9 vs. 3.5 to 5.6; p=N.S. in both studies Serious limitations (-1)224 No important 
inconsistency 
Direct Imprecise data (-1)216 Low 
HD symptoms (itching): no evidence 
Quality of life: increase (in %) 
1/126 RCT 100 we: 36 vs. 68; p=n/a Serious limitations (-1)220 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
Recurrence rate: in % 
3/456225 RCTs 5 to 13 vs. 21 to 14; p=N.S. in two studies; p=S.S. 
in one study in favour of sclerotherapy 
Serious limitations (-1)226 No important 
inconsistency 
Direct None Moderate 
Efficacy: flavonoid fraction-containing agents (+ fibre supplements) versus no treatment (+ fibre supplements) 
Change of HD stage: no evidence 
HD signs: no evidence 
HD symptoms (general): no evidence 
HD symptoms (pain): no evidence 
HD symptoms (bleeding): days of bleeding 
1/105227 RCT 3.9 vs. 10.6; p=N.S. Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
HD symptoms (itching): no evidence 
Quality of life: no evidence 
Recurrence rate: in % 
1/105227 RCT 5 vs. 12; p=N.S. Serious limitations (-1)217 n/a (only 1 trial) Direct Imprecise data (-1)216 Low 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
                                                                                                                                                                                                                                                                                   
221
 This study consisted of three groups, whereas one group received flavonoid fraction-containing agents and an office-based treatment and was therefore excluded from this analysis. 
222
 Unclear random sequence generation and allocation concealment and unclear blinding of outcome assessor. 
223
 Two studies contained of three groups, whereas in one study a group received fibre supplements alone and in the other study a group received flavonoid fraction-containing 
agents and an office-based treatment. Therefore, both groups were excluded from this analysis. 
224
 Unclear random sequence generation, allocation concealment and blinding of outcome assessor in both studies. 
225
 Both studies contained of three groups, whereas in one study a group received fibre supplements alone and in the other study a group received flavonoid fraction-containing 
agents and an office-based treatment. Therefore, both groups were excluded from this analysis. 
226
 Unclear random sequence generation in two studies, high risk of bias due to randomisation generation by hospital registration number, unclear allocation concealment and 
blinding of outcome assessor in all studies. 
227
 This study consisted of three groups, whereas one group received an office-based treatment and was therefore excluded from this analysis. 
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Table 3.2-6: Evidence profile: Safety of flavonoid fraction-containing agents for treatment of HD 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Safety: flavonoid fraction-containing agents versus placebo  
Adverse events (general): in % 
6/889 RCTs 0 to 8 vs. 0 to 6; p=N.S. Serious limitations (-1)228 No important inconsistency  Direct none Moderate 
Adverse events (treatment-related): in % 
1/100 RCT 0 vs. 0; p=N.S. No serious limitations n/a (only 1 trial) Direct Imprecise data (-1)229 Moderate 
Safety: flavonoid fraction-containing agents after haemorrhoidectomy versus no treatment after haemorrhoidectomy 
Adverse events (general): no evidence 
2/340 RCTs 5 to 11 vs. 6 to 20; p=N.S. in one study No serious limitations Important inconsistency (-
1)230 
Direct Imprecise data (-1)229 Low 
Adverse events (treatment-related): in % 
3/403 RCTs 0 vs. n/a; p=n/a Serious limitations (-1)231 No important inconsistency Direct Imprecise data (-1)229 Low 
Safety: flavonoid fraction-containing agents (+ fibre supplements) versus office-based treatment (+ fibre supplements) 
Adverse events (general): in % 
2/360232 RCTs 0 to 2 vs. 2 to 3; p=N.S. in one study Serious limitations (-1)233 No important inconsistency Direct Imprecise data (-1)229 Low 
Adverse events (treatment-related): in % 
2/222234 RCTs 0 vs. 0-3; p=N.S. in both studies Serious limitations (-1)233 No important inconsistency Direct Imprecise data (-1)229 Low 
Safety: flavonoid fraction-containing agents versus anti-inflammatory medication 
no evidence 
                                                             
228
 Unclear random sequence generation in 4 studies and unclear allocation concealment and blinding of outcome assessor in 5 studies. 
229
 Low incidence, study/studies not powered to detect difference. 
230
 Rates in control groups differed more than 10%. 
231
 Unclear random sequence generation, allocation concealment and blinding of outcome assessor in one study. 
232
 One study consisted of three groups, whereas one group received flavonoid fraction-containing agents and an office-based treatment and was therefore excluded from this analysis. 
233
 High risk of bias in one study due to random sequence generation by hospital registration number. Furthermore, unclear random sequence generation in second study und un-
clear blinding of outcome assessor unclear in both studies. 
234
 One study consisted of three groups, whereas one group received fibre supplements alone and was therefore excluded from this analysis. 
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No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Safety: flavonoid fraction-containing agents (+ fibre supplements) versus no treatment (+ fibre supplements) 
Adverse events (general): no evidence 
Adverse events (treatment-related): in % 
1/105235 RCT 0 vs. 0; p=N.S. Serious limitations (-1)236 n/a (only 1 trial) Direct Imprecise data (-1)229 Low 
Safety: flavonoid fraction-containing agents 
Adverse events (general): in % 
1/50 Single-arm study 18 Serious limitations (-1)237 n/a (only 1 trial) Direct Imprecise data (-1)229 Low 
Adverse events (treatment-related): no evidence 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
 
                                                             
235
 This study consisted of three groups, whereas one group received an office-based treatment and was therefore excluded from this analysis. 
236
 Unclear random sequence generation, allocation concealment and blinding of outcome assessor. 
237
 Unclear random sequence generation, allocation concealment and blinding of outcome assessor. 
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3.2.3 20 mg aescin-containing agents 
We could not identify any studies evaluating agents containing 20 mg of aes-
cin for the treatment of HD. It is essential to consider that Reparil
®
 20 mg 
dragées (the only agent containing 20 mg of aescin listed in the Austrian EKO 
[1]) are not explicitly indicated for HD (see also Chapter 1.2.2) [24, 25]. 
Nevertheless, there was a study (received from the manufacturer) that seemed 
to be relevant, yet, the administered dosage was not stated and therefore the 
study was excluded. 
 
3.2.4 50 mg aescin-containing agents 
We could not identify any studies evaluating capsules containing 50 mg of 
aescin for the treatment of HD. It is essential to consider that Venosin retard
®
 
50 mg capsules (the only agent containing 50 mg of aescin listed in the Aus-
trian EKO [1]) are mainly indicated for a treatment of CVI and not explicit-
ly for HD (see also Chapter 1.2.2) [26]. 
 
3.2.5 Calcium dobesilate-containing agents 
Doxium
® 
500 mg capsules (the only calcium dobesilate containing agent listed 
in the Austrian EKO [1]) are not explicitly indicated for a treatment of HD 
(see also Chapter 1.2.2), according to the package insert [27]. We did not iden-
tify any studies evaluating 500 mg calcium dobesilate-containing capsules for 
the treatment of HD. 
 
3.2.6 Comparison between capillary stabilising agents 
Study characteristics 
For evaluating the efficacy and safety of capillary stabilising agents in com-
parison with each other for a treatment of HD, we identified 1 RCT that met 
our inclusion criteria. 
The study compares the treatment of HD by using calcium dobesilate-contain-
ing agents or flavonoid fraction (MPFF)-containing, agents [83]. The study 
characteristics and results are summarised in Table 3.2-7. 
There were no studies identified comparing other capillary stabilising agents 
with each other. 
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aber keine Angabe  
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keine Studien 
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Table 3.2-7: Efficacy and safety-related outcomes of a randomised controlled trial of capillary stabilising agents versus 
other capillary stabilising agents for HD 
Author, year,  
reference number Sarabia 2001 [83] 
Country Venezuela 
Study design RCT 
Sponsor Laboratories Leti SAV 
Intervention/product 3x 500 mg calcium dobesilate capsules (Doxium®) per day238 
Comparator 6x 500 mg MPFF tablets (Daflon®) per day 
Number of pts. 25 vs. 26 
Age of patients (yrs.)  n/a 
Sex (% female) n/a 
Clinical classification n/a 
Primary endpoint n/a 
Inclusion criteria Pts. of both sexes, ages 18-75 yrs. with acute haemorrhoidal episode 
Duration of Treatment (weeks) 4239 
Follow-up (weeks) 0 
Drop-outs, n (%) n/a 
Efficacy-related outcomes 
Change of HD stage n/a 
HD signs (general) n/a 
Prolapse (or swelling) n/a 
Discharge (or leakage) n/a 
Incontinence n/a 
HD symptoms (general) Score (0-21)240: 
Baseline: 8.94 vs. 7.81; p=N.S. 
After <1 week: 3.16 vs. 3.26; p=n/a 
After 1 week 1.81 vs. 1.21; p=n/a 
After 2 weeks: n/a 
After 4 weeks: 0.74 vs. 0.61; p=N.S. 
After 8, 12; 24, 50weeks: n/a 
Pain Score (0-3): 
Baseline: 1.52 vs. 1.31; p=N.S. 
After <1 weeks: 0.67 vs. 0.66; p=n/a 
After 1 week: 0.53 vs. 0.25; p=n/a 
After 2 weeks: n/a 
After 4 weeks: 0.09 vs. 0.14; p=N.S. 
After 8, 12; 24, 50weeks: n/a 
 
                                                             
238
 Patients received 3 x 500 mg per day in the first 7 days, followed by 2 x 500 mg 
per day for the rest of the treatment phase. 
239
 Study started with a placebo run-in phase of 10 days. 
240
 Subjective symptoms were measured on a scale of 0-3 for pain, discharge, bleeding, 
edema, inflammation, pruritus and anal pressure. The score for general symptoms 
was 0-21. 
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Author, year,  
reference number Sarabia 2001 [83] 
Bleeding Score (0-3): 
Baseline: 1.72 vs. 1.09; p=N.S. 
After <1 week: 0.59 vs. 0.39; p=n/a 
After 1 week: 0.28 vs. 0.13; p=n/a 
After 2 weeks: n/a 
After 4 weeks: 0.14 vs. 0.05; p=N.S. 
After 8, 12; 24, 50weeks: n/a 
Itching (or pruritus) Score (0-3): 
Baseline: 1.09 vs. 0.88; p=N.S. 
After <1 week: 0.38 vs. 0.46; p=n/a 
After 1 week: 0.28 vs. 0.28; p=n/a 
After 2 weeks: n/a 
After 4 weeks: 0.14 vs. 0.18; p=N.S. 
After 8, 12; 24, 50weeks: n/a 
QoL n/a 
Recurrence rate in % 12 vs. 12; p=N.S. 
Safety-related outcomes 
Adverse events, general in % (n) pts. 12 (3) vs. 8 (2); p=n/a 
(cephalgia, vertigo, colic pain vs. vertigo, severe anal pressure) 
Major adverse events n/a 
Minor adverse events n/a 
Adverse events, treatment-related  
in % (n) pts. 
n/a  
Major adverse events n/a 
Minor adverse events n/a 
Abbreviations: HD = haemorrhoidal diseases; n = number (of patients); n/a = data not available; N.S. = not statistically 
significant; pts. = patients; QoL = quality of life; RCT = randomised controlled trial; vs. = versus; yrs. = years 
 
Efficacy 
A summary of the effect sizes for the individual outcome indicators is pre-
sented in Table 3.2-8. 
 
Calcium dobesilate-containing agents versus  
flavonoid fraction-containing agents 
For evaluating the efficacy of calcium dobesilate, 25 patients in the calcium 
dobesilate group received 500 mg capsules three times per day and the 26 
patients in the flavonoid fraction group received a 500 mg tablet six times a 
day [83]. 
There was no information about the age, the sex and the clinical classifica-
tion of the patients. The duration of treatment was 4 weeks, whereby there 
was no follow-up without treatment [83]. The drop-out rate was not report-
ed. 
The identified study did not assess the change of the HD stage, any of the HD 
signs (general, prolapse, discharge and incontinence), and quality of life. 
Zusammenfassung  
in GRADE-Tabelle 
3x 500 mg 
Calciumdobesilat vs.  
6x 500 mg Flavonoid-
fraktion am Tag 
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The scores (0-10) for general symptoms of CVI (pain, bleeding and itching) 
were reduced slightly more in the calcium dobesilate group during 4 weeks 
of treatment than in the flavonoid fraction group (general symptoms: -4.0 vs. 
-3.3, pain: -4.7 vs. -4.0, bleeding: -5.3 vs. -3.3, itching: -3.3 vs. -2.3). However, 
the difference between the groups was not statistically significant for any of 
the outcomes [83]. 
Furthermore, the difference of the recurrence rate between the study groups 
was also not statistically significant (12 vs. 12%) [83]. 
 
Safety 
Calcium dobesilate-containing agents versus  
flavonoid fraction-containing agents 
General adverse events occurred in 12% of the patients in the calcium dobesi-
late group and in 8% in the flavonoid fraction group. It was not stated whether 
the difference between the study groups was statistically significant or not. 
The most common adverse events in the calcium dobesilate group were head-
ache (cephalgia), dizziness (vertigo) and pain. Dizziness and severe anal pres-
sure were the most common adverse events in the flavonoid fraction group 
[83].  
However, there was no available evidence to assess treatment-related adverse 
events.  
A summary of the effect sizes for the individual outcome indicators is pre-
sented in Table 3.2-8. 
 
Risk of bias 
The identified RCT comparing capillary stabilising agent with each other for 
a treatment of HD shows an unclear risk of bias for the majority of types of 
biases (see Figure 3.2-5). In addition there is a high risk of performance and 
detection bias due the discontinued double-blind design after 10 days. In 
summary, the risk of bias is unclear. 
 
Figure 3.2-5: Risk of bias of RCTs for treatment of HD comparing capillary stabilising agents 
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Strength of evidence 
Overall, the strength of evidence of the efficacy and safety for a treatment of 
HD by comparing capillary stabilising agents with each other is low. Alt-
hough the study was a RCT, due to several study limitations and a low num-
ber of patients, the strength of evidence was downgraded. The strength of ev-
idence is summarised in the Table 3.2-8. 
There was no evidence available to compare other capillary stabilising agents 
mentioned in Chapter 1.2 (e.g., oxerutin- or aescin-containing agents), with 
each other,  
 
Evidenzstärke gering 
keine Evidenz zu 
Vergleich mit anderen 
kapillarstabilisierenden 
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Table 3.2-8: Evidence profile: Efficacy and safety of capillary stabilising agents versus other capillary stabilising agents for treatment of HD 
No of studies/ 
patients Study Design Estimate of effect Study Limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy: calcium dobesilate-containing agents versus flavonoid-containing agents 
Change of HD stage: no evidence 
HD signs: no evidence 
HD symptoms (general): change from baseline (score 0-10)241 
1/51 RCT <1 we: -2.67 vs. -2.33; p=n/a 
1 we: -3.33 vs. -3.0; p=n/a 
4 we: -4.0 vs. -3.33; p=N.S. 
Serious limitations (-1)242 n/a (only 1 trial) Direct Imprecise data (-1)243 Low 
HD symptoms (pain): change from baseline (score 0-10) 
1/51 RCT <1 we: -3.0 vs. -2.33; p=n/a 
1 we: -3.33 vs. -3.67; p=n/a 
4 we: -4.67 vs. -4.0; p=N.S. 
Serious limitations (-1)242 n/a (only 1 trial) Direct Imprecise data (-1)243 Low 
HD symptoms (bleeding): change from baseline (score 0-10) 
1/51 RCT <1 we: -3.67 vs. -2.33; p=n/a 
1 we: -4.67 vs. -3.33; p=n/a 
4 we: -5.33 vs. -3.33; p=N.S. 
Serious limitations (-1)242 n/a (only 1 trial) Direct Imprecise data (-1)243 Low 
HD symptoms (itching): change from baseline (score 0-10) 
1/51 RCT <1 we: -2.33 vs. -1.33; p=n/a 
1 we: -2.67 vs. -2.0; p=n/a 
4 we: -3.33 vs. -2.33; p=N.S. 
Serious limitations (-1)242 n/a (only 1 trial) Direct Imprecise data (-1)243 Low 
Quality of life: no evidence 
Recurrence rate: in % 
1/51 RCT 12 vs. 12; p=N.S. Serious limitations (-1)242 n/a (only 1 trial) Direct Imprecise data (-1)243 Low 
Safety: calcium dobesilate-containing agents versus flavonoid-containing agents 
Adverse events (general): in % 
1/51 RCT 12 vs. 8; p=n/a Serious limitations (-1)244 n/a (only 1 trial) Direct Imprecise data (-1)245 Low 
Adverse events (treatment-related): no evidence 
Abbreviations: n/a = data not available; N.S. = not statistically significant; RCT = randomised controlled trial; S.S. = statistically significant; vs. = versus 
                                                             
241
 The stated score in study was 0-21. To make the values comparable, the results were divided by 7 to adopt them to a score of 0-3. 
242
 Unclear random sequence generation and allocation concealment and high risk of bias due to discontinued blinded drug provision after 10 days. 
243
 Low incidence, study/studies not powered to detect difference. 
244
 Unclear random sequence generation and allocation concealment and high risk of bias due to discontinued blinded drug provision after 10 days. 
245
 Low incidence, study / studies not powered to detect difference. 
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4 Summary and discussion 
Chronic venous insufficiency (CVI) and haemorrhoidal diseases (HD) are very 
common, affecting about 20 to 40% of the Austrian population. Since these 
diseases occur mainly in females and older people, the prevalence in these 
populations is much higher [9]. Even if CVI and HD are not directly associ-
ated with mortality, both diseases severely affect the quality of life, e.g., due 
to pain and discomfort. Besides, HD is often tabooed in our society.  
The aim of this systematic review was to assess the efficacy and safety of a 
treatment of CVI and HD with capillary stabilising agents. We focused on five 
different agents and seven drugs that are listed in the Austrian Code of Re-
imbursement (EKO) [1]:  
 oxerutin-containing agents  
(Venoruton
®
 300 mg dragées, 500 mg tablets and 1,000 mg granulate), 
 flavonoid fraction-containing agents (Daflon® 500 mg tablets), 
 20 mg aescin-containing agents (Reparil® 20 mg dragées), 
 50 mg aescin-containing agents (Venosin retard® 50 mg capsules) and  
 calcium dobesilate-containing agents (Doxium® 500 mg capsules). 
 
 
4.1 Strength of evidence and clinical relevance of outcomes 
In total, we selected 56 studies with 21,606 patients for evaluating either ef-
ficacy and safety or safety only of capillary stabilising agents for CVI or HD. 
The majority of studies compared capillary stabilising agents with placebo, 
in much fewer cases other interventions (e.g., compression stockings for CVI 
and surgery for HD) were used as comparators. We could not identify any evi-
dence where a CVI treatment with capillary stabilising agents was compared 
with lifestyle changes, medical or surgical treatment. In addition, there was 
no evidence available to assess capillary stabilising agents for a treatment of 
HD compared to lifestyle changes and surgical treatment options. 
Overall, the strength of evidence is low. This is due to a number of reasons: 
On one hand, it has to be mentioned as positive that many of the studies start-
ed with a wash-out or placebo period before the treatment to exclude any ef-
fects of previous treatments. On the other hand, however, there were many 
studies that allowed patients with CVI to wear compression stockings and pa-
tients with HD had an additional diet in several cases. Thus, we do not know 
who received additional interventions. Consequently, it is also unknown wheth-
er positive effects in the treatment groups were caused by capillary stabilis-
ing agents or by the additional interventions.  
A major quality issue of the studies is related to their age (the oldest study is 
from 1987 [32]). Because today’s standards of study designs and transparen-
cy in reporting research results did not exist 30 years ago, it is challenging to 
assess the risk of bias and the strength of evidence with today’s criteria. Most 
of the studies did not mention the randomisation process, the allocation con-
cealment or the blinding of personnel and participants in detail. Furthermore, 
we were able to identify a study protocol for only a few studies. This intro-
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duces a high risk of bias. Interestingly, the RCT with the lowest risk of bias 
[62] has shown no benefit of a treatment of CVI with capillary stabilising 
agents. Hence, it seems most likely that the study results are biased in favour 
of the treatment.  
Moreover, some of the outcome indicators that have been used in the studies 
do not match today’s standards. Leg volume, for example, which has often 
been used as an indicator for oedema in the studies, can be regarded as obso-
lete according to clinical experts. This is also true for scores that use a scaling 
from 1-3, which have often been used as indicators for CVI or HD symptoms 
(e.g., pain). 
Further weaknesses of the identified studies are the small number of patients, 
the relatively short treatment durations (especially for CVI) and, particular-
ly, hardly any follow-up after treatment. This is a severe limitation, since the 
few studies with a follow-up without treatment have shown that differences 
between study groups (thus, the benefit of treatment over the comparator) de-
creased dramatically, if there was a benefit at all. 
Moreover, the identified systematic reviews [10, 58] summarised outcomes 
across different time periods; as a result, treatment effects after, e.g., 1, 2 or 3 
months of treatment cannot be distinguished between. Furthermore, several 
outcomes, e.g., leg circumference, were reported without presenting the change 
of the leg volume from baseline in one of the systematic reviews [10]. There-
fore, the results do not allow any conclusion on the efficacy. 
Overall, the clinical relevance of any improvement presented in the previous 
chapters is marginal and in many cases even negligible (see Chapter 2.7.3). 
For example, in terms of score changes for pain, itching, etc., changes below 
5 on a scale from 0-10 have been judged by two experts (both are angiologists) 
as clinically irrelevant. Hence, for many of the outcomes measured on a scale, 
neither the changes from baseline in the individual study groups, nor the dif-
ferences between the study groups fulfil the criterion of clinical relevance. 
Hence, despite statistically significant changes or differences between the study 
groups in many cases, the improvements are too marginal to be regarded as 
clinically relevant. 
In addition, four meta-analyses for a treatment of CVI have shown a high 
heterogeneity (with I²>80%). The high heterogeneity occurred only in stud-
ies where patients were allowed to wear additional compression stockings. 
Therefore, it seems likely that some studies measured a different effect of the 
capillary stabilising agents compared to placebo when additional compres-
sion stockings were worn. 
The pathophysiology of the diseases is mostly unclear. As a result, the major-
ity of treatment options focus on the reduction of signs and symptoms of CVI 
and HD. Not surprising, in the case of capillary stabilising agents, the bene-
fit from medication (if there was one at all) decreased or disappeared as soon 
as treatment was stopped. Therefore, a benefit can only be expected during 
medication. 
The majority of studies compared capillary stabilising agents with placebo. 
Hence, we know little about the efficacy of the drugs compared to interven-
tions that are relevant in daily practice. 
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Furthermore, because of the selective study population and a strongly proto-
col-driven treatment, the results from a clinical trial cannot automatically be 
transferred to routine clinical practice where patient characteristics and treat-
ment processes may be different. In this case, however, the characteristics of 
the study populations seem to be similar to a routine population in terms of 
age, gender and severity of disease. Moreover, compliance and adherence may 
also be similar in routine care because the drugs do not have severe side ef-
fects.  
Taking these limitations into account, the results on efficacy and safety of 
capillary stabilising agents can be summarised in the following chapter. 
 
 
4.2 Summary of evidence 
This chapter will summarise the results from the third chapter for each in-
dication. 
Although the strength of evidence for safety was mostly low, a treatment of 
CVI and HD with capillary stabilising agents does not seem to be associated 
with severe adverse events or side effects.  
The efficacy results of comparing the treatment of CVI and HD with capillary 
stabilising to other treatment options (defined in Chapter 1.1) or with each 
other are presented in the Tables 4.2-1 and 4.2-2 (one for each indication). 
The conclusions in the tables are based on the summarised estimates of ef-
fect from the studies, considering, however, study limitations and associated 
potential risks of bias as well as further limiting issues as presented in the 
GRADE tables in Chapter 3. Additionally, the clinical relevance of the effect 
estimates as described in Chapter 2.7.3 has been taken into account. 
Overall, from the study results and their individual strength of evidence, we 
are not able to draw any robust conclusions. 
From the studies on oxerutin-containing agents (Venoruton
® 
300 mg dragées, 
500 mg tablets and 1,000 mg granulate) we can conclude that compression stock-
ings could probably reduce oedema – measured as change in leg volume in 
ml – more than oxerutin-containing agents. However, leg volume is an out-
dated surrogate parameter and, therefore, a very weak outcome to draw a con-
clusion for assessing the overall efficacy.  
Furthermore, if patients take oxerutin-containing agents in addition to wear-
ing compression stockings, they may probably experience a slight improve-
ment of CVI signs (oedema, yet measured with an obsolete indicator) and 
some patients may have fewer single symptoms (heaviness) compared to com-
pression stockings in combination with placebo. In addition, oxerutin-con-
taining agents reduced the severity of signs and symptoms of HD, yet whether 
this improvement is statistically significant is unknown. 
Flavonoid fraction-containing agents (Daflon
®
 500 mg tablets) in addition to 
wearing compression stockings could probably improve CVI signs slightly 
(especially ulcer) compared to wearing compression stockings only or to com-
pression stockings combined with placebo. However, we are unable to draw a 
conclusion on whether patients benefit from taking flavonoid fraction-con-
taining agents after surgery compared to no treatment after surgery. 
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Treating HD with flavonoid fraction-containing agents does not seem more 
effective (regarding symptoms reduction) than with anti-inflammatory med-
ication. Compared to office-based treatment, flavonoid fraction-containing 
agents could probably be more effective during medication. Yet, after medi-
cation is stopped, office-based treatments could eventually be more effective. 
Compared to placebo, a treatment of HD with flavonoid fraction-containing 
agents seems to improve the signs and symptoms in some patients. After sur-
gery, flavonoid fraction-containing agents seem to reduce the severity of pain 
and the recurrence rate slightly better than no treatment. We are unable to 
draw a conclusion on whether flavonoid fraction-containing agents have an 
additional benefit when combined with fibre supplements, compared to no 
treatment (and fibre supplements). 
We could not draw any conclusion regarding the efficacy of 20 mg aescin-con-
taining agents (Reparil
®
 20 mg dragées) for the treatment of CVI and HD, since 
we could not identify any randomised controlled trials.  
A treatment with 50 mg aescin-containing agents (Venosin
®
 retard 50 mg cap-
sules), in addition to compression stockings, could probably improve some 
signs (oedema) and some single symptoms of CVI (pain) in some patients, 
compared to compression stockings with placebo. However, we are unable to 
draw a conclusion regarding a treatment of HD with 50 mg aescin. 
When added to compression stockings, calcium dobesilate (Doxium
® 
500 mg 
capsules) seems to slightly improve the symptoms of CVI, compared to place-
bo (and compression therapy). However, we are unable to draw a conclusion 
on the efficacy of for HD, since the drug is not explicitly indicated for HD. 
The comparison of capillary stabilising agents has shown that oxerutin-con-
taining agents for the treatment of CVI are probably not more effective than 
50 mg aescin- or flavonoid fraction-containing agents. Moreover, the reduc-
tion of HD symptoms and the recurrence rate seems to be equal with either 
calcium dobesilate- or flavonoid fraction-containing agents. We do not know 
whether one agent is generally superior to others. 
Overall, an effective medical treatment of CVI or HD with capillary stabilis-
ing agents would be an attractive alternative, since all further treatment op-
tions show several weaknesses. For example, compression stockings may be 
effective for the treatment of CVI, but they may be inappropriate in several 
situations, such as application difficulty (due to frailty or arthritis), physical 
constraints (e.g., limb obesity or contact dermatitis), and coexisting arterial 
insufficiency. Many patients who are eligible for wearing stockings abandon 
them due to complaints about tightness and warmth. In the case of HD, sur-
gical and office-based treatments are associated with a higher risk of adverse 
events. In addition, a long-term application of topical agents and antibiotics 
should be also discouraged because they may induce erythema from local al-
lergic reactions due to compromise of the dermal barrier. 
However, the identified evidence is not strong enough to conclude that a treat-
ment of HD and CVI with any of the mentioned capillary stabilising agents 
without additional therapy (e.g., compression therapy for CVI or diet for HD) 
is effective. 
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Table 4.2-1: Summary of the efficacy of capillary stabilising agents for treatment of CVI 
Agent Comparator 
Strength of 
evidence Conclusion 
Oxerutin  
(Venoruton®) 
Lifestyle changes  No evidence - 
Local treatment Low Compression stockings could probably reduce oedema 
(leg volume in ml) more than oxerutin-containing 
agents. However, leg volume is an obsolete surrogate 
parameter and, therefore, a very weak outcome to 
draw a conclusion for efficacy as a whole. 
Medical treatment No evidence - 
Surgical treatment No evidence - 
Placebo/ 
no treatment 
Low Added to compression stockings, oxerutin-containing 
agents could probably be of additional benefit by slightly 
reducing signs (oedema) and symptoms (heaviness) of 
CVI compared to placebo and compression stockings. 
Flavonoid 
fraction 
(Daflon®) 
Lifestyle changes  No evidence - 
Local treatment Low Added to compression stockings, flavonoid fraction-
containing agents could probably support a slight 
improvement of CVI signs (especially ulcer) compared 
to compression stockings only. 
Medical treatment No evidence - 
Surgical treatment No evidence - 
Placebo/ 
no treatment 
Low Added to compression stockings, flavonoid fraction-
containing agents could probably improve CVI signs 
(especially ulcer healing) slightly, compared to placebo 
and compression stockings. 
We are unable to draw a conclusion on whether 
flavonoid fraction-containing agents after surgery have 
an additional benefit on CVI signs and symptoms, 
compared to no treatment after surgery. 
20 mg aescin 
(Reparil®) 
All  No evidence We are unable to draw a conclusion, since we could not 
identify any RCT. 
50 mg aescin 
(Venosin 
retard®) 
Lifestyle changes  No evidence - 
Local treatment Low When compared to compression stockings only, 50 mg 
aescin with additional compression stockings could be 
similar (in)effective. 
Medical treatment No evidence - 
Surgical treatment No evidence - 
Placebo/no 
treatment 
Low When supported by compression stockings, 50 mg aescin 
could have an additional benefit on signs (oedema) and 
symptoms of CVI, especially with respect to pain reduction, 
compared to placebo (with compression therapy).  
Calcium 
dobesilate 
(Doxium®) 
Lifestyle changes  No evidence - 
Local treatment No evidence - 
Medical treatment No evidence - 
Surgical treatment No evidence - 
Placebo/no 
treatment 
Moderate If added to compression stockings, calcium dobesilate 
seems to slightly improve some symptoms of CVI (e.g., 
pain and cramps), when compared to placebo (with 
compression therapy). 
Capillary 
stabilising 
agents 
Capillary 
stabilising agents 
Low Oxerutin-containing agents for the treatment of CVI are 
probably not much more effective than 50 mg aescin. 
We are unable to draw a conclusion on whether 
another agent is superior to others. 
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Table 4.2-2: Summary of the efficacy of capillary stabilising agents for treatment of HD 
Agent Comparator 
Strength of 
evidence Conclusion 
Oxerutin  
(Venoruton®) 
Lifestyle changes  No evidence - 
Medical treatment No evidence - 
Local/office-based 
treatment 
No evidence - 
Surgical treatment No evidence - 
Placebo/ 
no treatment 
Low Oxerutin-containing agents could probably  
reduce the severity of signs and symptoms of HD 
compared to placebo, yet whether the differences 
are statistically significant is unknown. 
Flavonoid fraction 
(Daflon®) 
Lifestyle changes  No evidence - 
Medical treatment Low The treatment of HD with flavonoid fraction-
containing agents does not seem more effective 
(regarding symptoms reduction) than treatment 
with anti-inflammatory medication. 
Local/office-based 
treatment 
Low During medication, flavonoid fraction-containing 
agents could probably equally effective than 
office-based treatment, yet after medication is 
stopped, office-based treatments could eventually 
be more effective. 
Surgical treatment No evidence - 
Placebo/ 
no treatment 
Low-
moderate 
A treatment of HD with flavonoid fraction-
containing agents seems to improve the signs and 
symptoms of the disease, compared to placebo. 
However, the conclusion is limited. 
After surgery, flavonoid fraction-containing agents 
may slightly more reduce the severity of pain and 
the recurrence rate than no treatment. 
We are unable to draw a conclusion on whether 
flavonoid-containing agents have an additional 
benefit when combined with fibre supplements, 
compared to no treatment (and fibre supplements). 
20 mg aescin 
(Reparil®) 
All No evidence We are unable to draw a conclusion.  
However, Reparil®20 mg Dragées (the only 20 mg 
aescin-containing agent listed in the Austrian EKO) 
are not explicitly indicated for HD. 
50 mg aescin 
(Venosin retard®) 
All No evidence We are unable to draw a conclusion.  
However, Venosin® retard 50 mg capsules (the 
only 50 mg aescin-containing agent listed in the 
Austrian EKO) are not explicitly indicated for HD. 
Calcium dobesilate 
(Doxium®) 
All No evidence We are unable to draw a conclusion.  
However, Doxium® 500 mg capsules (the only 
calcium dobesilate-containing agent listed in the 
Austrian EKO) are not explicitly indicated for HD 
Capillary 
stabilising agents 
Capillary stabilising 
agents 
Low The reduction of HD symptoms and the recurrence 
rate will probably be similar with calcium dobesilate 
and flavonoid fraction-containing agents. We do 
not know whether another agent is superior to 
others 
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4.3 Limitations 
Naturally, our systematic review has several weaknesses: 
First of all, we accepted surrogate parameters like leg volume or ankle and calf 
circumferences as indicators for oedema, since the measurement of oedema 
is clinically relevant, yet it cannot be measured directly. Although these pa-
rameters have been measured frequently in the studies, their value for draw-
ing conclusions on the drugs’ efficacy is marginal.  
Besides, the majority of studies measured the signs and symptoms of CVI and 
HD by a score on a scale of 0-3 or 0-100. However, as stated earlier (Chapter 
2.7), a measurement on a scale of, e.g., 0-3 is often associated with imprecise 
results. Where possible, we adapted the scores to a scale of 0-10 to make the 
results comparable, yet it is uncertain whether the results from a primary da-
ta collection on a 0-10 score would be identical.  
We excluded many studies due to missing information on dosage forms or due 
to dose deliveries that did not meet our inclusion criteria (e.g., tablets instead 
of capsules). Additionally, we excluded studies in which patients received the 
oxerutin-containing agents as an aqueous solution and not as granulate. The 
reason was to assess only those capillary stabilising agents that are listed in 
the Austrian EKO. Hence, the results cannot be transferred to other products.  
Another restriction of our systematic review is that for oxerutin-containing 
agents we did not present the results for each available dosage form separately. 
However, since the quality of evidence of the individual studies is low, we 
would not be able to draw a meaningful conclusion with respect to individu-
al dosages. 
Regarding the meta-analyses, it was not possible to perform a sensitivity anal-
ysis to verify the results for their robustness, since there were not enough stud-
ies with strong evidence (minimum moderate strength of evidence) for one 
individual outcome. 
In addition, we were not able to identify the most effective capillary stabilis-
ing agent for a treatment of CVI or HD, since no evidence was available for 
some agents and indications. Moreover, the quality of evidence did not allow 
any quantitative comparative efficacy analysis (such as a network meta-analy-
sis).  
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5 Conclusion 
Since the strength of the evidence of nearly all identified studies is low, we 
cannot draw a final conclusion on the efficacy of capillary stabilising agents 
for the treatment of CVI and HD. 
For Doxium
®
 500 mg capsules (for CVI only), Venoruton
®
 (for CVI only), Daflon
®
 
500 mg tablets (for CVI and HD) and Venosin retard
®
 50 mg capsules (for CVI 
only) the evidence shows a tendency for a benefit, yet the results are very un-
certain. 
For Reparil
®
 20 mg dragées we could not identify any efficacy-assessing evi-
dence. Therefore, it is unclear whether the drug is more effective than other 
alternatives.  
In any case, there does not seem to be any sustaining benefit for CVI after 
treatment has been stopped, since the drugs do not treat the causes of CVI, 
but only the symptoms and signs. That means treatment will have to last for 
very long time periods in the individual patients. 
Even though the quality of evidence of safety-related outcomes is low as well, 
it is very likely that the drugs do not cause any major adverse events or side 
effects. 
It is debatable whether studies from the 1980s can be sensibly assessed with 
today’s quality criteria. However, it is also questionable to continue to pub-
licly spend 20 million Euros annually for capillary stabilising agents based on 
this relatively weak and uncertain evidence. 
Future reimbursement of the drugs should be conditional on the generation 
of robust evidence concerning patients’ benefits. This needs to be provided 
by the manufacturers. Cooperation with public payers in terms of study design 
(particularly concerning the selection of outcome parameters) is recommend-
ed. The studies need to have a sufficient number of participants and they need 
to comply with today’s standards in study design and transparency.  
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7 Appendix 
Search strategy for Cochrane 
171 Hits 
ID Search 
#1 MeSH descriptor: [Venous Insufficiency] explode all trees 
#2 venous near insufficienc* (Word variations have been searched) 
#3 MeSH descriptor: [Hemorrhoids] explode all trees 
#4 H*emorrhoid* (Word variations have been searched) 
#5 piles (Word variations have been searched) 
#6 #1 or #2 or #3 or #4 or #5  
#7 Vasoprotect* (Word variations have been searched) 
#8 Oxerutin* (Word variations have been searched) 
#9 troxerutin* (Word variations have been searched) 
#10 monoxerutin* (Word variations have been searched) 
#11 Venoruton* (Word variations have been searched) 
#12 Flavonoidf* (Word variations have been searched) 
#13 flavonoid fraction* (Word variations have been searched) 
#14 Daflon* (Word variations have been searched) 
#15 Aescin* (Word variations have been searched) 
#16 MeSH descriptor: [Escin] explode all trees 
#17 Escin* (Word variations have been searched) 
#18 Reparil* (Word variations have been searched) 
#19 Venosin* (Word variations have been searched) 
#20 Calciumdobesilat* (Word variations have been searched) 
#21 MeSH descriptor: [Calcium Dobesilate] explode all trees 
#22 calcium dobesilat* (Word variations have been searched) 
#23 dobesilate calcium* (Word variations have been searched) 
#24 Doxium* (Word variations have been searched) 
#25 #7 or #8 or #9 or #10 or #11 or #13 or #14 or #15 or #16 or #17 or #18 or #20 or #21 or #22 or #23 or #24  
#26 #6 and #25  
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Search strategy for CRD (Centre for Research and Dissemination) 
13 Hits 
1 (Vasoprotect*) 
2 (Oxerutin*) 
3 (troxerutin*) 
4 (monoxerutin*) 
5 (Venoruton*) 
6 (Flavonoidf*) 
7 (flavonoid fraction*) 
8 (Daflon*) 
9 (Aescin*) 
10 MeSH DESCRIPTOR Escin EXPLODE ALL TREES 
11 (Escin*) 
12 (Reparil*) 
13 (Venosin*) 
14 (Calciumdobesilat*) 
15 MeSH DESCRIPTOR Calcium Dobesilate EXPLODE ALL TREES 
16 (calcium dobesilat*) 
17 (dobesilate calcium*) 
18 (Doxium*) 
19 #2 OR #3 OR #7 OR #8 OR #10 OR #11 OR #15 OR #16 
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Search strategy for Embase  
No. Query Results Results Date 
#39 ‘clinical article’/de OR ‘clinical study’/de OR ‘clinical trial’/de OR ‘comparative 
study’/de OR ‘controlled clinical trial’/de OR ‘controlled study’/de OR ‘double 
blind procedure’/de OR ‘evidence based medicine’/de OR ‘major clinical study’/ 
de OR ‘meta analysis’/de OR ‘multicenter study’/de OR ‘practice guideline’/de 
OR ‘prospective study’/de OR ‘randomized controlled trial’/de OR ‘randomized 
controlled trial (topic)’/de AND (‘vein insufficiency’/exp OR ‘venous 
insufficiency’ OR ‘venous insufficiencies’ OR ‘hemorrhoid’/exp OR hemorrhoid* 
OR haemorrhoid* OR piles) AND (vasoprotect* OR oxerutin* OR ‘troxerutin’/ 
exp OR troxerutin* OR ‘monoxerutin’/exp OR monoxerutin* OR venoruton* 
OR flavonoidf* OR ‘flavonoid fraction’ OR ‘flavonoid fractions’ OR ‘daflon’/ 
exp OR daflon* OR ‘escin’/exp OR aescin* OR escin* OR reparil* OR venosin* 
OR ‘dobesilate calcium’/exp OR calciumdobesilat* OR ‘calcium dobesilate’ OR 
‘dobesilate calcium’ OR doxium*) AND ‘human’/de OR (‘vein insufficiency’/exp 
OR ‘venous insufficiency’ OR ‘venous insufficiencies’ OR ‘hemorrhoid’/exp 
OR hemorrhoid* OR haemorrhoid* OR piles AND (vasoprotect* OR oxerutin* 
OR ‘troxerutin’/exp OR troxerutin* OR ‘monoxerutin’/exp OR monoxerutin* 
OR venoruton* OR flavonoidf* OR ‘flavonoid fraction’ OR ‘flavonoid fractions’ 
OR ‘daflon’/exp OR daflon* OR ‘escin’/exp OR aescin* OR escin* OR reparil* 
OR venosin* OR ‘dobesilate calcium’/exp OR calciumdobesilat* OR ‘calcium 
dobesilate’ OR ‘dobesilate calcium’ OR doxium*) AND ([cochrane review]/ 
lim OR [systematic review]/lim OR [controlled clinical trial]/lim OR 
[randomized controlled trial]/lim OR [meta analysis]/lim)) 
365 20 May 2014 
#38 ‘vein insufficiency’/exp OR ‘venous insufficiency’ OR ‘venous insufficiencies’ 
OR ‘hemorrhoid’/exp OR hemorrhoid* OR haemorrhoid* OR piles AND 
(vasoprotect* OR oxerutin* OR ‘troxerutin’/exp OR troxerutin* OR 
‘monoxerutin’/exp OR monoxerutin* OR venoruton* OR flavonoidf* OR 
‘flavonoid fraction’ OR ‘flavonoid fractions’ OR ‘daflon’/exp OR daflon* OR 
‘escin’/exp OR aescin* OR escin* OR reparil* OR venosin* OR ‘dobesilate 
calcium’/exp OR calciumdobesilat* OR ‘calcium dobesilate’ OR ‘dobesilate 
calcium’ OR doxium*) AND ([cochrane review]/lim OR [systematic review]/ 
lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim OR 
[meta analysis]/lim) 
161 20 May 2014 
#37 ‘clinical article’/de OR ‘clinical study’/de OR ‘clinical trial’/de OR ‘comparative 
study’/de OR ‘controlled clinical trial’/de OR ‘controlled study’/de OR ‘double 
blind procedure’/de OR ‘evidence based medicine’/de OR ‘major clinical study’/ 
de OR ‘meta analysis’/de OR ‘multicenter study’/de OR ‘practice guideline’/de 
OR ‘prospective study’/de OR ‘randomized controlled trial’/de OR ‘randomized 
controlled trial (topic)’/de AND (‘vein insufficiency’/exp OR ‘venous 
insufficiency’ OR ‘venous insufficiencies’ OR ‘hemorrhoid’/exp OR hemorrhoid* 
OR haemorrhoid* OR piles) AND (vasoprotect* OR oxerutin* OR ‘troxerutin’/ 
exp OR troxerutin* OR ‘monoxerutin’/exp OR monoxerutin* OR venoruton* 
OR flavonoidf* OR ‘flavonoid fraction’ OR ‘flavonoid fractions’ OR ‘daflon’/ 
exp OR daflon* OR ‘escin’/exp OR aescin* OR escin* OR reparil* OR venosin* 
OR ‘dobesilate calcium’/exp OR calciumdobesilat* OR ‘calcium dobesilate’ OR 
‘dobesilate calcium’ OR doxium*) AND ‘human’/de 
364 20 May 2014 
#36 ‘vein insufficiency’/exp OR ‘venous insufficiency’ OR ‘venous insufficiencies’ 
OR ‘hemorrhoid’/exp OR hemorrhoid* OR haemorrhoid* OR piles AND 
(vasoprotect* OR oxerutin* OR ‘troxerutin’/exp OR troxerutin* OR 
‘monoxerutin’/exp OR monoxerutin* OR venoruton* OR flavonoidf* OR 
‘flavonoid fraction’ OR ‘flavonoid fractions’ OR ‘daflon’/exp OR daflon* OR 
‘escin’/exp OR aescin* OR escin* OR reparil* OR venosin* OR ‘dobesilate 
calcium’/exp OR calciumdobesilat* OR ‘calcium dobesilate’ OR ‘dobesilate 
calcium’ OR doxium*) AND ‘human’/de 
543 20 May 2014 
#35 ‘vein insufficiency’/exp OR ‘venous insufficiency’ OR ‘venous insufficiencies’ 
OR ‘hemorrhoid’/exp OR hemorrhoid* OR haemorrhoid* OR piles AND 
(vasoprotect* OR oxerutin* OR ‘troxerutin’/exp OR troxerutin* OR 
‘monoxerutin’/exp OR monoxerutin* OR venoruton* OR flavonoidf* OR 
‘flavonoid fraction’ OR ‘flavonoid fractions’ OR ‘daflon’/exp OR daflon* OR 
‘escin’/exp OR aescin* OR escin* OR reparil* OR venosin* OR ‘dobesilate 
calcium’/exp OR calciumdobesilat* OR ‘calcium dobesilate’ OR ‘dobesilate 
calcium’ OR doxium*) AND (‘clinical article’/de OR ‘clinical study’/de OR 
‘clinical trial’/de OR ‘comparative study’/de OR ‘controlled clinical trial’/de 
432 20 May 2014 
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OR ‘controlled study’/de OR ‘double blind procedure’/de OR ‘evidence based 
medicine’/de OR ‘major clinical study’/de OR ‘meta analysis’/de OR ‘multicenter 
study’/de OR ‘practice guideline’/de OR ‘prospective study’/de OR ‘randomized 
controlled trial’/de OR ‘randomized controlled trial (topic)’/de) 
#34 ‘vein insufficiency’/exp OR ‘venous insufficiency’ OR ‘venous insufficiencies’ 
OR ‘hemorrhoid’/exp OR hemorrhoid* OR haemorrhoid* OR piles AND 
(vasoprotect* OR oxerutin* OR ‘troxerutin’/exp OR troxerutin* OR 
‘monoxerutin’/exp OR monoxerutin* OR venoruton* OR flavonoidf* OR 
‘flavonoid fraction’ OR ‘flavonoid fractions’ OR ‘daflon’/exp OR daflon* OR 
‘escin’/exp OR aescin* OR escin* OR reparil* OR venosin* OR ‘dobesilate 
calcium’/exp OR calciumdobesilat* OR ‘calcium dobesilate’ OR 
675 20 May 2014 
#33 vasoprotect* OR oxerutin* OR ‘troxerutin’/exp OR troxerutin* OR 
‘monoxerutin’/exp OR monoxerutin* OR venoruton* OR flavonoidf* OR 
‘flavonoid fraction’ OR ‘flavonoid fractions’ OR ‘daflon’/exp OR daflon* OR 
‘escin’/exp OR aescin* OR escin* OR reparil* OR venosin* OR ‘dobesilate 
calcium’/exp OR calciumdobesilat* OR ‘calcium dobesilate’ OR ‘dobesilate 
calcium’ OR doxium* 
4,516 20 May 2014 
#32 doxium*  177 20 May 2014 
#31 ‘dobesilate calciums’   20 May 2014 
#30 ‘dobesilate calcium’  562 20 May 2014 
#29 ‘calcium dobesilates’   20 May 2014 
#28 ‘calcium dobesilate’ 295 20 May 2014 
#27 calciumdobesilat*  30 20 May 2014 
#26 ‘dobesilate calcium’/exp  560 20 May 2014 
#25 venosin* 5 20 May 2014 
#24 reparil*  181 20 May 2014 
#23 escin* 1,305 20 May 2014 
#22 aescin* 329 20 May 2014 
#21 ‘escin’/exp  877 20 May 2014 
#20 daflon*  509 20 May 2014 
#19 ‘daflon’/exp  440 20 May 2014 
#18 ‘flavonoid fractions’ 46 20 May 2014 
#17 ‘flavonoid fraction’  316 20 May 2014 
#16 flavonoidf* 4 20 May 2014 
#15 venoruton* 326 20 May 2014 
#14 monoxerutin* 599 20 May 2014 
#13 ‘monoxerutin’/exp  596 20 May 2014 
#12 troxerutin*  603 20 May 2014 
#11 ‘troxerutin’/exp  586 20 May 2014 
#10 oxerutin*  44 20 May 2014 
#9 vasoprotect*  919 20 May 2014 
#8 ‘vein insufficiency’/exp OR ‘venous insufficiency’ OR ‘venous insufficiencies’ 
OR ‘hemorrhoid’/exp OR hemorrhoid* OR haemorrhoid* OR piles 
20,202 20 May 2014 
#7 piles  1,336 20 May 2014 
#6 haemorrhoid* 2,094 20 May 2014 
#5 hemorrhoid* 8,935 20 May 2014 
#4 ‘hemorrhoid’/exp 7,413 20 May 2014 
#3 ‘venous insufficiencies’ 16 20 May 2014 
#2 ‘venous insufficiency’ 5,789 20 May 2014 
#1 ‘vein insufficiency’/exp  8,298 20 May 2014 
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Search strategy for Medline 
1 exp Venous Insufficiency/(5885) 
2 venous insufficienc*.mp. (6785) 
3 exp Hemorrhoids/(4595) 
4 H?emorrhoid*.mp. (6005) 
5 piles.mp. (885) 
6 1 or 2 or 3 or 4 or 5 (14047) 
7 Vasoprotect*.mp. (637) 
8 Oxerutin*.mp. (23) 
9 troxerutin*.mp. (210) 
10 monoxerutin*.mp. (0) 
11 Venoruton*.mp. (109) 
12 Flavonoidf*.mp. (1) 
13 flavonoid fraction*.mp. (224) 
14 Daflon*.mp. (130) 
15 Aescin*.mp. (204) 
16 exp Escin/(416) 
17 Escin*.mp. (641) 
18 Reparil*.mp. (51) 
19 Venosin*.mp. (3) 
20 Calciumdobesilat*.mp. (13) 
21 exp Calcium Dobesilate/(210) 
22 calcium dobesilat*.mp. (246) 
23 dobesilate calcium*.mp. (4) 
24 Doxium*.mp. (44) 
25 7 or 8 or 9 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 (2208) 
26 6 and 25 (268) 
27 remove duplicates from 26 (267) 
 
